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 BPGAP1 (BNIP-2 and Cdc42GAP Homology [BCH] domain-containing, 
Proline-rich and Cdc42GAP-like protein 1) is a multi-domain GTPase-activating 
protein (GAP) that exerts catalytic activity specifically towards RhoA. By 
coordinating induction of morphological changes via BCH and GAP domains, and 
translocation of cortactin to cell periphery through the proline-rich region, BPGAP1 
functions to promote cell migration. Interaction of this RhoGAP protein with 
EEN/endophilin II through also its proline-rich region further enhances EGF receptor 
endocytosis upon EGF stimulation, thereby activating ERK1/2 signaling.  
Apart from mediating cellular functions, association of BPGAP1 with other 
interacting partners could also serve regulatory purposes. For instance, release of 
auto-inhibition within BPGAP1 by active MEK2 that targets the proline-rich region 
allows Pin1 to suppress BPGAP1-induced acute ERK activation, and promote 
attenuation of Rho signaling. On-going research on BPGAP1 interacting partners 
identified in proteomics pull-down further reveal that both SmgGDS and human 
LanCL1 negatively regulate the effect of BPGAP1 on Ras activation. In earlier work, 
BNIP-2 (Bcl-2 and E1B Nineteen kDa Interacting Protein-2) has been shown to 
interact with BPGAP1. However, the significance of their interaction has yet to be 
uncovered.  
To elucidate the functional significance of BNIP-2-BPGAP1 interaction, 
BNIP-2 was first confirmed as a bona fide interacting partner of BPGAP1 through 
semi-endogenous immunoprecipitation study. Intriguingly, BNIP-2 BCH domain not 
only forms heterophilic interaction with the corresponding BCH domain of BPGAP1 
but associates also with its GAP module, probably to stabilize the structure of 
BPGAP1 for its catalytic function. Furthermore, both BNIP-2 and BPGAP1 harbor 
 x 
Rho binding motifs within their BCH domains that are capable of binding RhoA. 
Despite both RhoA and BPGAP1 share overlapping interaction sites on BNIP-2 BCH 
domain, these three proteins could possibly form a triple complex from 
immunofluorescence study. Interestingly, a greater degree of active RhoA 
downregulation by BPGAP1 was observed in the presence of BNIP-2, an effect that 
was no longer evident once the RhoGAP activity of BPGAP1 was abolished with a 
catalytic inactive mutant. Consistently, this synergistic effect on RhoA inactivation 
also led to a further loss of stress fiber, an increase in GAP-induced cell rounding, and 
an overall decrease in cellular proliferation.  
Our present study hereby establishes the role of BNIP-2 as a regulator of 
BPGAP1 that serves to synergistically enhance the RhoGAP activity of BPGAP1 
towards RhoA. This effect could possibly be achieved by the relieve of auto-
inhibition within BPGAP1 by BNIP-2 through heterophilic interactions of their BCH 
domains and possible stabilization of the altered conformation via binding to the GAP 
module to bring about more efficient catalysis of RhoA GTP hydrolysis. These results 
further substantiate earlier findings of BCH domain as a regulatory module for Rho 
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1.1 The Ras superfamily of small GTPases – Master regulators of cellular 
dynamics  
The Ras (Ras sarcoma) superfamily of monomeric small (20-25 kDa) 
guanosine triphosphatases (GTPases) are guanosine diphosphate/guanosine 
triphosphate (GDP/GTP)-regulated proteins (Vetter and Wittinghofer, 2001) that 
coordinate a diverse array of fundamental cellular processes. These proteins, with a 
human repertoire of 154 members, are evolutionarily conversed with orthologs 
present in insects (Drosophila), nematodes (Caenorhabditis elegans), fungi 
(Saccharomyces cerevisiae; Schizosaccharomyces pombe), amoeba (Dictyostelium 
discoideum) and plants (Colicelli, 2004; Wennerberg et al., 2005). 
Based on sequence identity, structure and functional similarities (Wennerberg 
et al., 2005), members of the Ras superfamily have typically been classified into five 
major subfamilies comprising of Ras, Rho (Ras homologous), Rab (Ras-like proteins 
in brain), Ran (Ras-like nuclear protein) and Arf (ADP-ribosylation factor). However, 
this classification is less than definitive due to the lack of functional data especially 
for the less-studied proteins, thereby leaving some of them unclassified (Wennerberg 
et al., 2005). In addition, the atypical GTPases Miro (Mitochondria Rho), previously 
marginally classified under Rho subfamily, are redefined as a distinct subgroup due to 
the lack of a characteristic Rho insert domain and their distinct phylogenetic origin 
(Figure 1.1) (Boureux et al., 2007; Wennerberg et al., 2005).  
  
 




Figure 1.1 The human Ras superfamily of small GTPases. The five major 
subfamilies are indicated by the coloured branches: Ras (green), Rho (pink), Rab 
(blue), Ran (blue) and Arf (yellow).  Atypical GTPases – Miro (orange), is presented 
as a separate subgroup from Rho. [Adapted from Colicelli, 2004]. 
 
 
GTPases of the Ras superfamily serve as nucleotide-regulated binary 
molecular switches through their basic biochemical activity of GTP binding and 
hydrolysis (Colicelli, 2004; Vetter and Wittinghofer, 2001). This activity is mediated 
by the conserved ~20 kDa core G domain comprising of five G-box GDP/GTP-
binding motifs: G1 [GXXXXGKS/T], G2 [T], G3 [DXXGQ/H/T], G4 [T/NKXD] and 
G5 [C/SAK/L/T], that bind phosphate and Mg2+ or guanine (Bourne et al., 1991; 
Wennerberg et al., 2005). Within the G domain are two loop regions, Switch I and II, 
that re-orientate during the GDP/GTP-cycling process. These changes in 
conformation allow the effectors to bind preferentially to GTP-bound GTPase via the 
core effector domain (Figure 1.2) (Vigil et al., 2010).  
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Besides the basic biochemical activity, majority of the small GTPases are also 
subjected to post-translational modifications by lipids at either the amino-terminal (N-
terminal) (for example Arf) or carboxyl-terminal (C-terminal) hypervariable regions 
of different terminating Cysteine-containing motifs (Ras, Rho, Rab) (Figure 1.2) 
(Vigil et al., 2010). These modifications are essential for their targeting to distinct 
membrane compartments and subcellular localizations for interactions with different 
regulators and effectors (Wennerberg et al., 2005).  Together, these properties confer 
small GTPases the ability to modulate diverse cellular processes such as proliferation 
(Ras), differentiation (Ras), gene expression (Ras and Rho), cytoskeletal 
reorganization (Rho), polarity (Rho), nucleocytopasmic transport (Ran) and 






















Figure 1.2 Domain architecture of Ras superfamily GTPases. The conserved ~20 
kDa core G domain consists of five guanine nucleotide consensus sequence motifs (G 
boxes). These G boxes bind to phosphate and Mg2+ (PM) or guanine (G) as indicated. 
Switch I (SI; Ras residues 30-38) and switch II (SII; Ras residues 59-76) in the two 
loop regions undergo conformation changes during the nucleotide cycling process. 
These re-orientations allow preferential binding of the effectors to the core effector 
domain in the GTP-bound state (E; Ras residues 32-40). Post-translational lipid 
modifications (farnesylation or geranylgeranylation and/or palmitoylation of cysteine 
residues) occur at the C termini hypervariable (HV) regions of Ras, Rho and Ran 
GTPases. Arf GTPases, on the other hand, have an N-terminal extension that is also 
myristoylated for some members. These lipid modifications and extensions are 
essential for membrane targeting and for mediating associations. While Ran GTPases 
are not lipid modified, they too harbor a C-terminal extension that is required for its 
function. The ‘Rho Insert’ sequence of Rho GTPases lies between Ras residues 122 
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1.2 The Rho family GTPase – Intermediaries of signaling networks 
1.2.1 The Rho family GTPases 
The Rho gene was first identified from the sea-slug Aplysia in 1985 (Madaule 
and Axel, 1985) with Rac proposed as the evolutionary founder of the Rho family 
(Boureux et al., 2007). All members of the Rho family are characterized by a 13-
amino acid helical insertion (Rho insert) positioned between G4 and G5 boxes of the 
canonical G domain (Boureux et al., 2007).  
To date, the human Rho GTPase family comprises 20 members and is 
redefined into eight subfamilies based on primary amino acid sequence identity, 
structural motifs and biological functions. These subfamilies include Rho-like [RhoA-
C], Rac (Ras-related C3 botulinum toxin substrate)-like [Rac1-3; RhoG], Cdc42 (Cell 
division cycle 42)-like [Cdc42; TC10; TCL], RhoD/RhoF [RhoD; Rif], RhoH, 
RhoUV [Wrch-1 (Wnt1-responsive cdc42 homologue-1); Chp], Rnd (Round) [Rnd1-
3] and RhoBTB (Broad complex, Tramtrack and Bric-a-brac) [RhoBTB1-2] (Boureux 
et al., 2007; Heasman and Ridley, 2008). In addition, splice isoforms of Rac1 and 
Cdc42 have been identified (Wennerberg and Der, 2004).  
While classical Rho GTPases are subjected to GDP/GTP-regulation, eight 
proteins within the Rho family exist predominantly in GTP-bound form and are 
termed atypical Rho GTPases (Figure 1.3) (Heasman and Ridley, 2008; Vega and 
Ridley, 2008). This exception arises due to either mutations at amino acid residues 
critical for GTP hydrolysis and GDP binding (for example Rnd proteins and RhoH) or 
increased nucleotide exchange in the case of Wrch-1 (Aspenstrom et al., 2007; 
Chardin, 2006; Heasman and Ridley, 2008).  




Figure 1.3 The mammalian Rho family GTPases. The 20 Rho GTPase members 
are categorized into eight subfamilies: Rho-like (RhoA-C), Rac-like (Rac1-3; RhoG); 
Cdc42-like (Cdc42; TC10; TCL), RhoD/RhoF (RhoD; Rif), RhoH, RhoUV (Chp, 
Wrch-1), Rnd (Rnd1-3) and RhoBTB (RhoBTB1-2). Classical Rho GTPases (pink) 
undergo GDP/GTP cycling while the atypical Rho GTPases (blue) are not subjected 
to this mode of regulation. Amino acid identities between proteins in the same 
subfamily are the highest for Rho-like and Rac-like subfamilies [Adapted from 
Heasman and Ridley, 2008].   
 
 
1.2.2 Rho GTPases function as binary molecular switches 
 To fulfill the fundamental role as signal transducers, Rho GTPases operate as 
molecular switches that can be turned on and off. This on/off mechanism is dependent 
on the nucleotide status of Rho GTPases such that they become active when in GTP-
bound state and are inactive when in GDP-bound form (Vetter and Wittinghofer, 
2001). The underlying basis of this universal mechanism lies in the conformation 
changes during GDP/GTP cycling that occur primarily in the two loop regions - 
Switch I and II (Hakoshima et al., 2003; Wennerberg and Der, 2004). During the 
exchange of GDP for GTP, hydrogen bonds formed between the γ-phosphate and 
conserved threonine and glycine residues (Thr37/Gly62 in RhoA) in Switch I and II, 
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respectively (Wei et al., 1997), stabilize the structure of GTPases and thus allows for 
high affinity binding to downstream effectors. Conversely, such interactions are 
abolished upon GTP-hydrolysis. Once in the relax state, the switch regions can 
assume variable structural forms and this reduces the affinity for effector proteins, 
leading to their rapid dissociations (Colicelli, 2004; Hakoshima et al., 2003).  
 Although classical Rho GTPases possess high binding affinity for GDP and 
GTP, they function ineffectively as molecular switches. This is attributed to their slow 
intrinsic GDP/GTP exchange and GTP hydrolysis activities (Wennerberg et al., 
2005). As such, the GDP/GTP cycling process is tightly regulated by three classes of 
regulatory proteins, namely, guanine nucleotide exchange factors (GEFs), GTPase-
activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs).  
 In the absence of stimuli, Rho GTPases in GDP-bound form are sequestered in 
the cytosol by GDIs, hence disallowing any association with the plasma membrane or 
interaction with regulators. Upon the arrival of a stimulus, this triggers the 
dissociation of GTPases from the inhibitory complexes. Following their release, these 
proteins translocate to the plasma membrane where the GEFs catalyze the dissociation 
of GDP. By virtue of the much higher intracellular GTP concentration, GTP is 
spontaneously incorporated into the GTPase. Binding of GTP to the GTPase promotes 
GTPase-effector interaction, thus activating the appropriate downstream signaling.  
Rho GTPase signaling is attenuated by the recruitment of GAPs that function to 
inactivate the GTPases by accelerating their intrinsic GTPase activity. Once in the 
GDP-bound form, these GTPases can no longer interact with the effectors and are 
sequestered by GDIs till the next activating stimulus (Tcherkezian and Lamarche-
Vane, 2007). This GDP/GTP-cycling process is summarized in Figure 1.4. 
 




Figure 1.4 The Rho GTPases cycling process.  Rho GTPases function as 
nucleotide-regulated binary switches that exist in either inactive GDP-bound or active 
GTP-bound state. Three main classes of regulators: GDIs, GEFs and GAPs, 
orchestrate this cycling process. GDIs serve to sequester and regulate the intracellular 
location of the GTPases, while GEFs and GAPs function to catalyze the activation 
(exchange of GDP for GTP) and inactivation (intrinsic GTP hydrolysis) of Rho 





1.2.3 Post-translational modification and subcellular targeting of Rho GTPases 
Apart from the highly conserved switch apparatus that govern the fundamental 
GTPase activity, majority of the Rho GTPases are subjected to a series of post-
translational modifications characterized by the covalent attachment of a prenyl group 
to the cysteine residue of the C-terminal CAAX tetrapeptide. The lipid modifications, 
together with immediate upstream hypervariable regions, mediate associations of Rho 
GTPases with the membrane and dictate their subcellular localization such as to the 
plasma membrane or endosomes (Roberts et al., 2008; Wennerberg et al., 2005). 
Variations in subcellular locations create microenvironments that facilitate 
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interactions of the Rho GTPases with distinct upstream activators and downstream 
effectors, thus allowing them to perform their divergent functions (Wennerberg and 
Der, 2004).  
 
1.2.3.1 Rho GTPase CAAX-dependent post-translational lipid modifications 
 Of the 20 members in the Rho GTPase family, 16 Rho proteins terminate with 
the canonical CAAX tetrapeptide motif (where C = cysteine, A = aliphatic amino acid 
and X = any amino acid) except Wrch-1, Chp/Wrch-2, RhoBTB1 and RhoBTB2 
(Roberts et al., 2008). CAAX-dependent post-translational modifications of the Rho 
GTPases occur in a three-step process beginning with covalent attachment of either a 
15-carbon (C15)-farnesyl or a C20-geranylgeranyl isoprenoid to the cysteine residue. 
Geranylgeranyl attachment predominates among the classical Rho GTPases, whereas 
majority of the atypical Rho proteins are modified by farnesylation (Roberts et al., 
2008).  
In general, the lipid moiety added is determined by the identity of the last 
amino acid residue in the tetrapeptide. Though not exclusive, knowledge derived from 
previous studies has proposed that Rho GTPase is subjected to farnesylation where X 
is hydrophobic (Met), polar (Gln) or small (Cys, Ser, Thr or Ala). On the other hand, 
geranylgeranylation occurs if X is Leu and less specifically for Met, Phe, Ile or Val 
(Roberts et al., 2008; ten Klooster and Hordijk, 2007). Although the more 
hydrophobic geranylgeranyl isoprenoid confers a stronger membrane association, 
there is no evidence of direct translation to any functional distinctions, probably with 
the exception of RhoB, which is either farnesylated or geranylgeranylated 
(Michaelson et al., 2001; Wennerberg and Der, 2004).    
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 In subsequent lipid modifications, AXX residues are cleaved from the 
carboxyl end of the protein, followed by addition of a methyl group to the prenylated 
cysteine residue. Together, these three modifications increase the overall 
hydrophobicity of the Rho GTPases and function as a lipid anchor to enable 
membrane association (Ellenbroek and Collard, 2007; Roberts et al., 2008).  
 
1.2.3.2 Rho GTPase targeting via hypervariable regions  Besides post-translational modifications, all Rho proteins exhibit diverse 
sequences mainly at their C-termini and this hypervariable region comprises 
approximately ten amino acid residues that precede the CAAX motif (ten Klooster 
and Hordijk, 2007). This region may include cysteine residue(s) immediately before 
the tetrapeptide or is rich in lysine and/or arginine residues (polybasic region) or have 
a combination of both features. The presence of extra cysteine residue(s) enables 
another type of lipid modification whereby a palmitate fatty acid is covalently 
attached to cysteine. This form of lipidation constitutes an additional targeting signal 
for some Rho family members, for example RhoB and TC10 (Roberts et al., 2008). 
Palmitoylation of Rho GTPases may also affect recognition and hence their 
interaction with RhoGDIs (Michaelson et al., 2001).  
 Apart from subcellular targeting, the hypervariable region may also play a role 
in enhancing membrane associations by facilitating interaction of the GTPases with 
acidic membrane-associated lipids through the net positively charged polybasic region 
(Roberts et al., 2008). In summary, these variations at the C-terminal region allow 
otherwise highly similar Rho GTPases (eg. Rho-related proteins) to be differentially 
targeted (ten Klooster and Hordijk, 2007) for interactions with their diverse effectors. 
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1.2.4 Rho GTPases and their effector proteins 
 Considering the diversity of cellular functions associated with merely 20 
members of the Rho family, it is not surprising that approximately 100 downstream 
targets have been identified thus far (Hall, 2009). While each Rho GTPase may 
exhibit binding affinity towards multiple effectors, some effector proteins are 
recognized by multiple Rho GTPases. Rho GTPase-effector interaction is mediated 
mainly through Switch I loop region, also known as the effector domain. Specificity 
in interaction is possible due to differences in amino acid residues at sites critical for 
interaction. For instance, PKN serine/threonine kinases act downstream of RhoA 
through interactions at Glu40, Ala44 and Asp49, but not Cdc42 with corresponding 
residues Asp38, Val42 and Asp47 (Maesaki et al., 1999). Besides Switch I loop region, 
α-helical Rho insert and sequences outside the effector domain can also contribute to 
effector binding (Bishop and Hall, 2000; Karnoub et al., 2004).   Most of the effectors of Rho GTPases are either scaffold proteins or kinases 
such as serine/threonine, tyrosine and lipid kinases (Ellenbroek and Collard, 2007; 
Jaffe and Hall, 2005). Common serine/threonine kinases include Rho-associated 
protein kinases (ROCK I and II) and p21-activated kinase (PAK), which activate their 
target proteins via phosphorylation to initiate the signaling cascades. On the other 
hand, non-kinase effector proteins such as neuronal Wiscott-Aldrich syndrome 
protein (N-WASP) function as scaffold proteins to mediate interactions with other 
proteins (Ellenbroek and Collard, 2007). Commonly, Rho GTPases activate their 
effectors by disrupting autoinhibition present within these proteins to free up the 
catalytic or functional domain, thus allowing activation of downstream signaling 
(Bishop and Hall, 2000; Jaffe and Hall, 2005).  
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1.2.5 Functions of Rho family GTPases 
 RhoA, Rac1 and Cdc42 are among all, the three best-characterized 
mammalian Rho GTPases. Early studies on Rho GTPases have established their 
fundamental yet major role in regulating actin cytoskeleton organization. Since 
cytoskeletal remodeling form the basis of many cellular events, Rho GTPases are 
hence involved in regulating many cytoskeleton-dependent events including changes 
in cell shape, cell adhesion, spreading events, motility, polarity, cytokinesis and 
vesicle trafficking (Wennerberg et al., 2005). In addition, they are implicated in a 
plethora of other functions such as cell cycle progression, gene transcription and cell 
survival (Burridge and Wennerberg, 2004; Ellenbroek and Collard, 2007; Etienne-
Manneville and Hall, 2002). Rho GTPases therefore function primarily as molecular 
switches at signaling nodes, where diverse extracellular stimuli converge, to control 
the transmission of signaling events to their extensive pool of downstream effectors 
(Karnoub et al., 2004) (Figure 1.5). A subset of their functions pertaining to actin 
cytoskeleton reorganization, cell motility and proliferation are further discussed in the 
following sections.  
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Figure 1.5 Functions of Rho GTPases. Rho GTPases function as intermediaries at 
signaling nodes to receive signals from various extracellular stimuli and elicit a 





1.2.5.1 Rho GTPases and actin cytoskeleton dynamics 
 First descriptions of the major function of Rho GTPases, mainly Rho, Rac and 
Cdc42, as key signal transducers linking cell surface receptors to the organization of 
actin cytoskeleton emerged in the early 1990s (Hall, 1998). It was described in 
quiescent Swiss3T3 fibroblast, in which serum starvation results in a very low level of 
organized F-actin structures, that Rho regulates the assembly of contractile actin-
myosin stress fiber and of associated focal adhesions (Ridley and Hall, 1992). This 
observed effect is induced by lysophosphatidic acid (LPA) and inhibited by 
exoenzyme C3 transferase. In the same system, Rac triggers the formation of a 
dynamic meshwork of actin filaments at the cell periphery known as lamellipodia and 
membrane ruffles (Ridley et al., 1992). Formation of these thin curtain-like extensions 
associated with integrin-based adhesion complexes is stimulated by growth factors 
such as platelet-derived growth factor (PDGF), insulin or epidermal growth factor 
(EGF). On the other hand, Cdc42 induces the formation of periphery microspikes or 
filopodia in bradykinin-treated fibroblast (Kozma et al., 1995; Nobes and Hall, 1995). 
Similarly, these actin-rich finger-like cytoplasmic protrusions are found to be in 
association with focal contacts. Together, these three morphologically distinct actin 
structures induce by the respective GTPases, constitute the actin component of the 
entire cytoskeletal network, alongside with intermediate filaments and microtubules. 
 Rho GTPases modulate the dynamics of actin organization by coordinating 
various signal transduction pathways that involve actin polymerization or 
depolymerization, and organization (filament bundling) of the actin filaments (Jaffe 
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and Hall, 2005). Formation of stress fibers is elicited by the concreted actions of two 
major effectors downstream of Rho signaling, namely mDia and ROCK. Mammalian 
Diaphanous protein (mDia) belongs to one of the seven formin subfamilies and is 
characterized by the presence two formin homology (FH) domains: FH2 domain and 
the variable-length profilin-binding FH1 domain. These two domains cooperatively 
mediate actin filament assembly such that upon the relief of autoinhibitory 
interactions through association with activated Rho, mDia continually associates with 
the barbed end of an actin filament via its FH2 domain, while the FH1 domain 
containing multiple proline-rich motifs interacts with the profilin/G-actin complex. 
These interactions facilitate filament elongation, which in turn provides the driving 
force for membrane extension (Bishop and Hall, 2000; Jaffe and Hall, 2005; Sit and 
Manser, 2011).  
 ROCK, another of the Rho effectors, is a serine/threonine kinase. It acts 
downstream of Rho by regulating the phosphorylation states of a variety of substrates 
(Riento and Ridley, 2003). Mainly, ROCK phosphorylates the myosin-binding 
subunit (MBS) of myosin light chain phosphatase and by doing so inhibits its 
phosphatase activity. ROCK is also able to directly phosphorylate myosin light chain 
(MLC) and contributes to an overall increase in the amount of phosphorylated MLC, 
either through its direct action on MLC or indirectly via the inhibition of MLC 
phosphatase activity. MLC, when phosphorylated mainly at Ser19, stimulates the 
actin-activated ATPase activity of myosin II to cross-link actin filaments and thus 
enhances actomyosin contractility (Bishop and Hall, 2000; Sit and Manser, 2011).  
 Besides the above-mentioned targets, ROCK can also phosphorylate LIM 
kinase (LIMK) and initiate another signaling cascade in which activated LIMK 
phosphorylates its substrate cofilin at Ser3, rendering it inactive (Schwartz, 2004; Sit 
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and Manser, 2011). Cofilin is an actin-depolymerizating molecule which has been 
suggested to act by promoting actin monomer dissociation from the pointed end of 
actin filament or by functioning as a severing factor for filamentous actin, thereby 
hindering barbed-end elongation. Thus, the Rho-ROCK-LIM pathway contributes to 
the stability of existing filamentous actin structures via negative regulation of cofilin 
(Sit and Manser, 2011). The concerted actions of both mDia and ROCK leading to 
stress fiber formation are depicted in Figure 1.6.  
 While the expression of constitutively active ROCK alone generates actin 
bundles that are disorganized due to random bundling and cell contraction, co-
expressing active forms of mDia abolishes this phenomenon, thereby producing 
thinner and less-bundled stress fibers. These results therefore suggest that mDia may 
serve to modulate the action of ROCK (Narumiya et al., 2009). Indeed, it is later 
revealed that Rac is activated downstream of Rho-mDia signaling through Src 
activation and subsequent phosphorylation-dependent formation of 
Cas/Crk/DOCK180 complex (Tsuji et al., 2002). Intriguingly, this Rho-dependent 
mDia-Rac pathway is inhibited by ROCK activity, which is in turn suppressed by 
active Rac. Therefore, distinct stress fiber pattern and cell shape may be achieved by 
establishing an equilibrium between the antagonistic Rho-mDia and Rho-ROCK 
signaling events (Narumiya et al., 2009). This form of modulation is clearly evident 
during the neurite-extension process in cultured cerebellular granule neurons such that 
in the presence of high level of active Rho, ROCK pathway is predominantly active, 
promoting enhanced actomyosin contraction and subsequently induces neurite 
retraction. Conversely, mDia is preferentially activated at low levels of active Rho to 
enhance neurite elongation (Figure 1.7) (Arakawa et al., 2003; Narumiya et al., 2009). 
 




Figure 1.6 RhoA-induced signal transduction pathways for stress fiber 
formation. Active Rho promotes contractile actin:myosin filament assembly through 
concerted actions of mDia and ROCK, the two major effectors downstream of Rho 




Figure 1.7 Antagonistic actions of RhoA-mDia and RhoA-ROCK signaling 
pathways in mediating neurite outgrowth. Local level of active RhoA determines 
the preferential activation of a particular Rho signaling pathway. In neuron cells, high 
level of active RhoA predominantly activates the RhoA-ROCK pathway, leading to 
enhanced actomyosin contractility and hence neurite retraction. Conversely, selective 
activation of RhoA-mDia signaling under low level of active RhoA results in Rac1 
activation that enhances growth cone motility and finally neurite elongation. A similar 
mechanism may function in other cell types under different contexts. [Adapted from 
Narumiya, 2009].  
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 Lamellipodia and filopodia are two types of protrusions often seen generated 
at the leading edge of a migrating cell. Rac1 and Cdc42 initiate their formation 
through several downstream effectors, some of which are common amongst the two. 
Both Rac1 and Cdc42 signal to nucleation actin-related protein 2/3 (Arp2/3) complex 
to initiate filamentous actin branching and increase the number of free barbed ends 
via the scaffold proteins, WASP-family Verprolin-homologous (WAVE) family 
proteins and WASP, respectively (Burridge and Wennerberg, 2004; Ellenbroek and 
Collard, 2007). Cdc42 initiates actin polymerization and formation of filopodia 
through the recruitment of N-WASP that functions primarily as a scaffold protein for 
the assembly of components required for actin polymerization, including actin 
monomers/profilin and Arp2/3 complex (Bishop and Hall, 2000). Although similar in 
structure to N-WASP, WAVE family proteins do not interact directly with active 
Rac1. Instead, their interactions occur through a heteropentameric WAVE complex 
containing WAVE protein, Rac1-binding protein PIR121, Nck-associated protein 1 
(Nap1), Abl-interacting protein (Abi) 1, 2 and 3, and HSPC300. However, both Rac1-
induced activation of WAVE complex via PIR121 and Cdc42-mediated WASP 
activation might occur through a similar mechanism (Sit and Manser, 2011).  
 PAK – a serine/threonine kinase, is another effector common to both Rac1 and 
Cdc42. Similar to ROCK, PAK acts along the same pathway via LIMK to negatively 
regulate cofilin, thereby maintaining the stability of actin filaments. In addition, it also 
participates in the regulation of MLC, leading to a corresponding reduction in 
actomyosin contractility by phosphorylating and inhibiting MLCK, a direct activator 
of MLC ATPase activity (Bishop and Hall, 2000). Filamin, another downstream 
target of PAK, is a major actin binding protein at the cell cortex. It is enriched in 
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membrane ruffles and serves to crosslink filamentous actin, hence stabilizing this 
meshwork of actin filaments (Burridge and Wennerberg, 2004).  
 Amongst the effectors of Rho GTPases are also lipid kinases, indicating the 
involvement of these GTPases in lipid signaling pathways that contribute to actin 
cytoskeleton dynamics. For instance, both Rho (via ROCK activity) and Rac signal to 
lipid kinase phosphatidylinositol-4-phosphate 5-kinase (PIP5K) that is involved in the 
production of phosphatidylinositol-4,5-bisphosphate (PIP2). PIP2 increases actin 
polymerization by stimulating the release of capping proteins such as gelsolin (Bishop 
and Hall, 2000). It also participates in the activation of erzin-radixin-moesin (ERM) 
family proteins through phosphorylation by ROCK for their function as linkers 
between actin and multiple transmembrane proteins to stabilize the cortical actin 
network (Schwartz, 2004; Sit and Manser, 2011).   
 Taken together, Rho GTPases coordinate a complex network of signaling 
events to regulate actin cytoskeleton dynamics, thereby forming the basis for many 
other cytoskeleton-dependent cellular events. 
 
1.2.5.2 Rho GTPases and cell motility 
 Cell migration is an orchestrated process in organisms that is essential for 
driving embryonic morphogenesis during development, tissue repair and regeneration, 
immune surveillance and also contributes to pathological processes such as cancer 
(Ridley et al., 2003). Directed migration of cells occur in response to extracellular 
cues including growth factors or chemokines gradients, extracellular matrix (ECM) 
proteins for instance collagen and fibronectin, as well as mechanical forces (Parsons 
et al., 2010). To initiate a migration cycle, the cell first polarizes and extends 
protrusions to form a leading edge towards the direction of migration. These 
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protrusions adopt distinct morphological features with large, broad lamellipodia and 
finger-like filopodia driven by actin polymerization. While newly formed nascent 
adhesions that link actin cytoskeleton to the underlying substratum aids in stabilizing 
these protrusions, the mature focal adhesions connected to the ends of actin stress 
fibers serve as traction sites for migration as the cell body contracts and moves over 
them. Finally, disassembly of focal adhesions at the cell rear follows to allow for 
detachment and forward movement of the cell. These iterative cycles of protrusion 
and retraction therefore enable the cell to migrate in a highly directed manner in 
response to environmental changes (Parsons et al., 2010; Ridley et al., 2003).  
 Cell migration, a well-coordinated multistep process, is mediated by a number 
of highly integrated signaling events regulated by the Rho GTPases. Dissecting the 
roles of Rho GTPases in cell migration has led to the understanding that Cdc42 
establishes cell polarity to ensure directed migration and Rac1 is localized to the 
leading edge to induce lamellipodia formation towards the stimulus; whereas RhoA 
activity is required for focal complex maturation into focal adhesions, cell body 
contraction to pull the cell body forward, rear end retraction (Raftopoulou and Hall, 
2004) and surprisingly at the leading edge, probably to promote actin polymerization 
via mDia. In spite of their distinct roles, crosstalks exist among the Rho GTPases. For 
instance, Cdc42 signals to activate Rac1 locally whereas Rac1 and RhoA act either in 
a cooperative or antagonistic manner to spatially define their activities and effects 
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1.2.5.2.1 Cdc42: A master regulator of cell polarity in cell migration 
 In general, migrating cells observed in tissue culture displayed a unique 
polarized morphology with a broad, flat lamellum extending in the direction of 
migration with a ruffling lamellipodium at the leading edge and a narrow retracting 
tail at the cell rear (Wittmann and Waterman-Storer, 2001). Cdc42 influences actin 
cytoskeleton polarity by defining the spatial region within the cell in which Rac1 is 
active and hence determine the location where lamellipodia are formed (Cau and Hall, 
2005; Ridley et al., 2003). Such signaling specificity is achieved through selective 
accumulation of an activating RacGEF βPIX at the leading edge of the migrating cell 
as induced by PAK, which acts downstream of Cdc42 (Cau and Hall, 2005). With 
Rac1 only activated at the leading edge, this ensures that the formation of 
lamellipodia is efficiently restricted towards the direction of migration.  
 Besides altering actin cytoskeleton polarity, microtubules in slower migrating 
cells are reorganized such that the microtubule-organizing center (MTOC) and golgi 
apparatus are positioned in front of the nucleus, oriented towards the direction of 
migration. Realignment of these organelles may serve to enhance directed migration 
by facilitating microtubule growth and hence the transport of golgi-derived vesicles to 
the leading edge to provide the membrane components and associated proteins 
essential for generating forward protrusions (Ridley et al., 2003). Cytoskeletal 
network polarization is mediated mainly by Cdc42, which is active towards the front 
of a migrating cell (two microns behind the leading edge) as observed with 
fluorescent resonance energy transfers (FRET)-based studies (Machacek et al., 2009). 
Since directed migration can be abolished with either inhibition or global activation of 
Cdc42, this further supports the role of Cdc42 as a master regulator of cell polarity 
(Etienne-Manneville and Hall, 2002).  
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1.2.5.2.2 Rac1: Driving the protrusive machinery in cell migration 
 Similar to Cdc42, Rac1 is activated at 2 microns behind the leading edge of a 
migrating cell (Machacek et al., 2009), in part due to the coupling of local Rac1 
activity to Cdc42 signaling. Localized Rac1 activity is crucial for the extension of a 
protrusive leading edge in the direction of migration by inducing lamellipodia 
formation via Arp2/3. In addition to Cdc42-induced Rac1 activation, this differential 
spatial localization of Rac1 is also mediated by an increase in concentration of 
phosphatidylinositiol 3,4,5 triphosphate (PIP3) at a similar region. PIP3 accumulation 
is positively regulated by PI3K that catalyzes its formation whereas PTEN, a PIP3 
phosphatase that inhibits PI3K activity, down-regulates this accumulation. Indeed, 
such tight regulation is achieved via mutually exclusive distribution of PI3K and 
PTEN, where PI3K is found only at the cell front and PTEN is restricted to regions 
where PI3K is absent (Hall, 2009; Raftopoulou and Hall, 2004; Ridley et al., 2003). 
Besides stimulating Rac1 activity through localization of PIP3-sensitive RacGEFs, 
PIP3 also function as signaling molecules to locally amplify even a very shallow 
gradient of difference in concentrations of chemoattractants, thus triggering 
directional migration (Raftopoulou and Hall, 2004; Ridley et al., 2003).  
  
1.2.5.2.3 RhoA: Multiple roles of RhoA in cell migration 
 Although it has previously been widely accepted that RhoA activity is not 
required at the cell front for protrusions as RhoA and Rac1 are mutually antagonistic, 
this notion has been challenged by experimental evidences that shown otherwise. In 
FRET-based analysis of Rho GTPase activities during cell protrusion, it was found 
that RhoA is activated at the leading edge synchronous with edge advancement 
whereas both Cdc42 and Rac1 are activated slightly behind with a delay of 
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approximately 40 s (Machacek et al., 2009; Pertz et al., 2006). The presence of RhoA 
at the migrating forefront is further supported by observations that RhoA co-localizes 
with mDia in this region (Goulimari et al., 2005). Multiple roles of RhoA at the 
leading edge pertaining to its signaling to mDia have been suggested.  
 First, it is proposed that RhoA initiates the iterative cycles of protrusion and 
retraction in migration. mDia, when activated at the cell front, promotes actin 
polymerization to generate the initial actin filaments that are required for Arp2/3-
mediated dendritic polymerization. It can also attach an actin barbed end to the 
membrane for subsequent polymerization (Machacek et al., 2009). Other studies have 
suggested that RhoA-mDia signaling contributes to migration via two separate 
pathways, either microtubule-dependent or actin-dependent (Narumiya et al., 2009). 
In the microtubule-dependent pathway, RhoA-mDia signaling promotes accumulation 
of Cdc42 and APC recruitment at the cell front for migration. This signaling pathway 
in turn induces actin-dependent translocation of Src to focal complexes to stimulate 
adhesion turnover, hence facilitating migration.  
 As the cell migrates, RhoA activity is also required for focal complex 
maturation, cell body contraction and rear end retraction. RhoA activation promotes 
the process of focal adhesion maturation through activation of myosin II, which 
brings about adhesion maturation and stability (Parsons et al., 2010). Contraction of 
actin-myosin bundles anchored at the adhesion sites then provides the traction force 
for cell body contraction and retraction of the lagging tail (Raftopoulou and Hall, 
2004; Ridley et al., 2003). This contractility is mediated by RhoA-ROCK signaling 
pathway that triggers subsequent downstream phosphorylation cascades, leading to 
eventual phosphorylation and hence inactivation of MLC phosphatase and cofilin. 
Through inactivation of these negative regulators, this sustains the level of actin 
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filaments cross-linked by phosphorylated myosin, thereby generating the contractile 
force required for forward movement and rear end retraction. RhoA-ROCK signaling 
is also essential for negatively regulating integrin adhesions in the tail region for 
retraction (Narumiya et al., 2009). In summary, RhoA functions as an initiator of 
protrusion (RhoA-mDia) and a mediator of contractility (RhoA-ROCK) by signaling 
through different pathways.  
 
1.2.5.3 Rho GTPases and cell proliferation 
 Uncontrolled cell proliferation is a hallmark of cancer. Proliferation of 
eukaryotic cells is an elegantly coordinated yet tightly regulated process in which 
cells undergo a round of cell division only when both extracellular and intracellular 
conditions are met (Villalonga and Ridley, 2006). Amongst environmental factors 
such as cell density, both availability of mitogenic growth factors and cell anchorage 
to extracellular matrix are critical determinants for entry into cell cycle (Welsh, 
2004). With the ability of Rho GTPases to function as signal transducers to transmit 
upstream signals from the plasma membrane receptors to other components within the 
cells, it is not surprising that they are involve in cell cycle regulation. Rho GTPases 
modulate the activity of cyclin-dependent kinases (Cdks) during G1 phase and 
subsequently the organization of microtubules and actin cytoskeleton during mitosis 
(Jaffe and Hall, 2005). 
 
1.2.5.3.1 Rho GTPases in G1 phase cell cycle regulation  
 The first evidence indicating the involvement of Rho GTPases in cell cycle 
came from an early study whereby exoenzyme C3 transferase blocks G1 progression 
in Swiss3T3 fibroblasts (Yamamoto et al., 1993). Subsequently, microinjection 
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studies using dominant negative or constitutive active mutants of RhoA, Rac1 and 
Cdc42 further proved their involvement in mitogen-stimulated G1 to S phase 
progression (Olson et al., 1995). However, the exact roles of Rho GTPases and the 
underlying mechanisms by which they coordinate the progression are complex and 
cell-type dependent (Jaffe and Hall, 2005), thus requiring further investigations. By 
far, Rho GTPases have been shown to modulate G1 to S phase progression primarily 
by regulating cyclin D expression and levels of p21 and p27 (Hall, 2009).  
 Mitogenic growth factors stimulate the expression of cyclin D via the 
canonical Ras-MEK-ERK pathway. However, ERK activation must be sustained in 
order to achieve both optimal timing and levels of cyclin D expression (Hall, 2009). 
In NIH3T3 fibroblasts, RhoA mediates prolonged ERK activation via integrin-
mediated adhesion and hence referred to as anchorage-dependent proliferation. RhoA 
activation leads to the formation of stress fibers that are required for the clustering of 
integrins. Here a positive feedback loop exists whereby these integrin focal 
complexes further promote RhoA activation by recruiting RhoGEFs to these sites. 
RhoA, when activated by integrins, signals through RhoA-ROCK-LIMK pathway to 
induce sustain ERK activation and thus maintain the expression of cyclin D for G1 
progression (Hall, 2009). Interestingly, inhibition of RhoA activity not only leads to 
an abolishment of prolonged ERK activity but also results in an earlier rapid increase 
in cyclin D level through a Rac-dependent mechanism that is normally suppressed by 
LIMK activity in the cell nucleus (Coleman et al., 2004; Roovers et al., 2003). As 
such, RhoA may function as an anchorage-dependent cell cycle checkpoint to regulate 
the timing and cytoskeletal dependence of cyclin D expression during G1 phase via 
RhoA-ROCK-LIMK pathway (Coleman et al., 2004; Villalonga and Ridley, 2006). In 
general, ectopic expression of Rho, Rac and Cdc42 can promote transcription of 
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cyclins D and E via various pathways including nuclear factor-κB (NFκB), reactive 
oxygen species (ROS), PAK, c-Jun N-terminal kinase (JNK) or p38, depending on the 
cell type (Hall, 2009; Villalonga and Ridley, 2006).  
 Rho and Ras GTPases function in synergism in the regulation of cell cycle. 
Apart from their combined effect in prolonging cyclin D expression through G1 phase, 
such synergism is also observed through their effect on CDK inhibitor p21. In a non-
transformed mitogen-stimulated cell, p21 expression increases in response to ERK 
activation, probably due to its function as an assembly factor for cyclinD/cdk4,6 
complex. This increase, however, is followed by a gradual decrease from the mid to 
late G1 phase that is adhesion-dependent but ERK-independent. RhoA may contribute 
to this decrease via p53-independent suppression of p21 transcription. Taken together, 
RhoA acts as an anchorage-dependent cell cycle checkpoint and mediates G1 
progression in non-transformed cells. Conversely, RhoA facilitates oncogenic Ras-
induced cell cycle progression in transformed cells through its inhibitory effect on 
p21 expression, thus accounting for the role of Rho GTPases in Ras-induced 
transformation (Coleman et al., 2004; Welsh, 2004). Activated Rac and Cdc42, 
induced by either mitogenic factors or by integrin-mediated cell attachment, may also 
decrease p21 through activation of its ubiquitin-independent proteosome-mediated 
degradation (Coleman et al., 2004).  
 
1.2.5.3.2 Rho GTPases in mitosis and cytokinesis 
 Besides G1 progression, Rho GTPases have also been implicated in G2 to M 
progression and mitosis (Villalonga and Ridley, 2006). During mitosis, the effect of 
Rho GTPases are observed mainly on cytoskeletal changes that accompanied this 
process; from the rounding of cell at the onset of mitosis driven by RhoA-ROCK 
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pathway (Maddox and Burridge, 2003), to the attachment of microtubules to 
kinetochores during metaphase for proper chromosome alignment regulated by mDia3 
downstream of Cdc42 (Yasuda et al., 2004) and the positioning of spindle mediated 
by Cdc42-induced assembly of Par6/αPKC polarity complex at the membrane (Hall, 
2009). Lastly, RhoA plays a crucial role in cytokinesis due mainly to its ability to 
promote actomyosin-based contractility (Villalonga and Ridley, 2006).  
 Cytokinesis is characterized by the formation of a cleavage furrow consisting 
of a ring of contractile actin-myosin II filaments at the cortex and subsequent 
ingression of the ring to constitute the midbody, resulting in the separation into two 
daughter cells (abscission) (Hall, 2009). During this process, active RhoA 
accumulates at a narrow zone in the cortex to initiate actomyosin contractile ring 
formation and subsequent ring ingression via stimulation of mDia, ROCK and citron 
kinase. ROCK promotes furrow ingression by phosphorylating MLC at Ser19 and 
inhibiting MLC phosphatase, while citron kinase that di-phosphorylate MLC at Thr18 
and Ser19 mediates the completion of cytokinesis (Piekny et al., 2005; Wadsworth, 
2005). RhoA activity is therefore crucial for cytokinesis and is regulated 
spatiotemporally specifically by RhoGEF Ect2 and RhoGAPs including MgcRacGAP 
(male germ cell RacGAP) and p190RhoGAP (D'Avino and Glover, 2009; 
Manchinelly et al., 2010; Su et al., 2009; Werner and Glotzer, 2008). Various roles of 
Rho GTPases in the cell cycle are depicted in Figure 1.8.  
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Figure 1.8 Roles of Rho family GTPases in the cell cycle. Rho GTPases play 
pivotal role in the regulation of cell cycle, particularly G1 phase and mitosis. In G1 
phase, Rho GTPases promote Cyclin D1 transcription or translation and inhibit the 
CDK inhibitors, p21 or p27. During mitosis, they are involved in various processes at 
different stages including cell rounding and centrosome positioning in prophase, 
kinetochore attachment and asymmetric spindle positioning in metaphase and lastly 





1.2.5.4 Rho GTPases and gene transcription 
 Of the many cellular effects associated with Rho GTPases, some are the result 
of alterations in gene transcription induced downstream of Rho GTPases signaling. 
Many transcription factors have been identified as targets of Rho GTPases signaling 
including SRF, NFκB, Stat3, Stat5, E2F and many more (Aznar and Lacal, 2001). 
Among them, serum response factor (SRF) is a well-known RhoA-induced 
transcription factor stimulated by mitogenic factors such as serum, LPA and PDGF. 
Activity of SRF can be modulated by changes in actin dynamics such that depletion 
of G-actin in response to RhoA-induced treadmilling and increase in actin 
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polymerization can induce gene transcription (Sotiropoulos et al., 1999). This actin-
dependent SRF activation requires nuclear translocation of its myocardin-related co-
activator MAL triggered downstream of RhoA (Miralles et al., 2003). Once activated, 
SRF binds to the serum response element (SRE) that is present in many gene 
promoters and induces transcription of distinct genes respective to the upstream 
stimuli. Although SRF activity has been associated with the transcription of diverse 
gene targets including those specific for embryonic development, proliferation and 
differentiation, it is an essential transcription factor in RhoA-induced morphological 
changes contributing to cell motility (Benitah et al., 2004; Merdek et al., 2008). 
Therefore, RhoA-dependent induction of SRF may confer the invasive phenotype of 
tumor cells since SRF activity is present only in tumor cells that have undergone 
epithelial to mesenchymal transition (EMT) in a mouse skin carcinogenesis model 
(Benitah et al., 2004).  
 Stat transcription factors constitute a family of latent cytoplasmic transcription 
factors (Benitah et al., 2003) and the activities of some of which are also modulated 
by Rho GTPases. For instance, RhoA and Rac1 can activate Stat3 in human cells by 
inducing its simultaneous dual tyrosine and serine phosphorylation, though via 
different mechanisms. Stat3 activity is necessary for RhoA-induced anchorage 
independent growth of human cells, as well as RhoA- and Rac1-induced 
transformation of murine fibrobasts. It is therefore possible that Rho GTPases 
promote transformation via transcriptional activity of Stat3, in particular through the 
regulation of cell cycle-related genes such as cyclin D1 or c-Myc (Benitah et al., 
2004). The requirement of Stat3 activity for RhoA-induced NFκB and cyclin D1 
transcription, cell proliferation, transformation, stress fiber formation and migration is 
further demonstrated in mouse embryonic fibroblasts (MEF) (Debidda et al., 2005), 
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thereby reinforcing the importance of Stat3 as a transcription factor functioning 
downstream of RhoA. Apart from Stat3, RhoA, Rac1, Cdc42 and RhoC can also 
signal to Stat5a, which has been demonstrated to be essential for both EMT and 
enhanced motility of RhoA-transformed MDCK cells, but suppresses proliferation in 
these cells (Benitah et al., 2003). Taken together, RhoA modulates activity of Stat3 
for cell proliferation and Stat5a for processes contributing to a motile phenotype 
including migration and EMT.   
 
1.2.6 Rho GTPases and cancer 
 Rho GTPases regulate a plethora of cellular functions and their deregulations 
contribute to most if not all stages of cancer development ranging from tumor 
initiation to cancer progression and metastasis (Figure 1.10). During initial tumor 
growth, cells acquire the ability for uncontrolled proliferation, accompanied by 
increased survival signals and evasion from apoptosis (Vega and Ridley, 2008). As 
evident from the requirement of Rho GTPases for oncogenic Ras transformation, 
RhoA and Rac1 contribute to carcinogenesis by promoting G1 phase progression 
through induction of cyclin D1 expression and also inhibition of cdk inhibitors p21 
and p27 by RhoA. Moreover, Rho GTPases can signal to transcription factors to alter 
the expression of genes for survival and prevention of apoptosis (Vega and Ridley, 
2008). For instance, RhoA promote Stat3 activity for proliferation, while Rac1 
suppresses Ras-induced apoptosis via NFκB (Ellenbroek and Collard, 2007).  
 EMT, a process which transformed cells transit into a more motile phenotype 
through disruption of adherens junctions, is a major event in cancer development. 
Multiple studies have linked RhoA signaling to reduced formation and destabilization 
of E-cadherin-mediated cell-cell adhesion, leading to EMT (Chang et al., 2009). 
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Conversely, E-cadherin can also negatively regulate active RhoA level via 
p190RhoGAP (Ellenbroek and Collard, 2007).  
 In malignant cancers, tumor cells that have acquired an invasive phenotype 
become more aggressive and can undergo metastasis. These invasive tumor cells can 
migrate in two different modes, either via proteolysis-guided mesenchymal movement 
or actomyosin-driven amoeboid movement (Narumiya et al., 2009). In mesenchymal 
migration, invasion of tumor cells into the surrounding tissues require degradation of 
ECM by enzymes matrix metalloproteinases (MMPs) and Rho GTPases have been 
shown to modulate the expression and secretion of these proteases (Bryan and 
D'Amore, 2007; Ellenbroek and Collard, 2007). Furthermore, Rho GTPases can 
regulate tissue inhibitors of metalloproteinases (TIMPs), thus enhancing the 
remodeling of ECM for invasion (Ellenbroek and Collard, 2007). On the other hand, 
tumor cells migrating via protease-independent amoeboid movement adopt a spherical 
form for squeezing through the fibrillar network and such movement is mediated 
primarily by the Rho-ROCK pathway (Narumiya et al., 2009). While availability of 
MMPs is a determining factor for utilization of different migratory mechanisms, Rho 
GTPases can also dictate the mode of migration through selective inhibition of either 
RhoA or Rac1 activity (Narumiya et al., 2009; Sanz-Moreno et al., 2008).  
 Lastly, angiogenesis is an essential step in supplying nutrients to support the 
growth of solid tumors. Rho GTPases participate in this process through regulation of 
proliferation, survival and migration of endothelial cells, as well as lumen formation 
and capillary branching (Bryan and D'Amore, 2007). RhoC, in addition, promotes this 
process by inducing the production of angiogenic factors in inflammatory breast 
cancer (Merajver and Usmani, 2005).  
 





Figure 1.9 Possible involvement of Rho family GTPases in various stages during 
cancer progression.  
  
 
 Given the wide implications that Rho GTPases have on multiple stages in 
tumorigenesis, it is surprising that genetic mutations that may result in gain- or loss- 
of-functions rarely exist in these proteins in human cancers. A few exceptions include 
Rac1, of which mutations have been found to affect the effector domain (Hwang et 
al., 2004), and RhoH that has been found to undergone gene rearrangement in non-
Hodgkin’s lymphomas and myeloma, with also reports of hypermutations in the non-
coding regions in diffuse large-cell lymphoma that may affect its expression 
(Karlsson et al., 2009). This rarity is in contrast with Ras GTPases that are mutated in 
about 30 % of human cancers of different origins (Ellenbroek and Collard, 2007). On 
the contrary, deregulations of Rho GTPase signaling in human cancers are often 
associated with perturbed expression of these proteins as shown in Table 1.1 or of 
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Table 1.1 Altered Rho GTPases (Rho, Rac and Cdc42) expression in human 
cancers. [Adapted from Karlsson et al., 2009]. 
 
Rho GTPase Alteration Malignancies 
RhoA Overexpression Invasion of hepatocellular carcinoma 
Metastasis of hepatocellular carcinoma 
Invasion and metastasis of bladder cancer 
Progression of esophageal squamous cell carcinoma 
Head and neck squamous cell carcinoma 
Progression of ovarian carcinoma  
Progression of gastric carcinoma  
Progression of testicular cancer 
Colon and lung cancer and progression of breast 
cancer 
RhoB Loss of expression Progression of lung cancer 
Reduced expression Head and neck squamous cell carcinoma 
Overexpression Presence and progression of breast cancer 
RhoC Overexpression Invasion of non-small cell lung carcinoma 
Inflammatory breast cancer 
Presence and progression of breast cancer 
Metastasis of breast cancer 
Invasion of breast carcinoma 
Metastasis of gastric cancer 
Progression and metastasis of hepatocellular 
carcinoma  
Progression of pancreatic ductal adenocarcinoma 
Metastasis of prostate cancer 
Metastasis of melanoma 
Head and neck squamous cell carcinoma 
Squamous cell carcinoma of skin 
Invasion and metastasis of bladder cancer 
Progression of esophageal squamous cell carcinoma 
Progression of ovarian carcinoma  
Rac1 Overexpression 
  
Progression and metastasis of breast tumors 
Oral squamous cell carcinoma 
Progression of prostate cancer 
Progression of gastric carcinoma 
Progression of testicular cancer 
Breast cancer 




Rac2 Overexpression Head and neck squamous cell carcinoma 
Squamous cell carcinoma and basal cell carcinoma of 
skin 
Hyperactivity  Chronic myelogenous leukemia 
Rac3 Hyperactivity or 
overexpression 
Breast cancer 
Cdc42 Overexpression Progression of testicular cancer 
Breast cancer 
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1.2.7 Regulators of Rho GTPase activity 
1.2.7.1 Rho family Guanine Nucleotide Dissociation Inhibitors (RhoGDIs) 
inhibits Rho GTPase signaling 
 Functions of Rho GTPases are dependent fundamentally on their cycling 
between active and inactive states, and their membrane associations at distinct 
subcellular compartments (Wennerberg and Der, 2004). Although RhoGDIs are not 
directly involved in the cycling process, they are pivotal regulators of Rho GTPases 
and function to maintain equilibrium between the cytosolic and membrane pools of 
Rho GTPases. In contrast to RhoGEFs and RhoGAPs, there are currently only three 
identified mammalian RhoGDIs, namely RhoGDIα (RhoGDI-1), RhoGDIβ (RhoGDI-
2 or Ly/D4GDI) and RhoGDIγ (RhoGDI-3). RhoGDIα is ubiquitously expressed 
whereas both RhoGDIβ and RhoGDIγ display tissue-specific expression. In addition, 
these three GDIs also have differential Rho-binding specificity, with RhoGDIα 
showing the widest substrate spectrum (DerMardirossian and Bokoch, 2005; Dovas 
and Couchman, 2005).  
 RhoGDIs are cytosolic proteins and form complexes with prenylated Rho 
proteins in a 1:1 stoichiometry (DerMardirossian and Bokoch, 2005). Binding of 
RhoGDI to the GTPase requires both its N-terminal flexible domain and C-terminal 
domain with an immunoglobulin-like fold through protein-protein and protein-lipid 
interactions, respectively, which are essential to the inhibitory function of RhoGDI 
(Dovas and Couchman, 2005). When in association with GDP-bound GTPase, 
RhoGDI prevents the dissociation of GDP and GEF-mediated GDP/GTP exchange. 
Alternatively, RhoGDI can also interact with GTP-bound GTPase to inhibit both the 
intrinsic and GAP-catalyzed GTP hydrolysis, and its interactions with downstream 
effectors. Taken together, RhoGDI functions to prevent the GDP/GTP cycle and 
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subsequent activation of Rho GTPase-mediated biological activities by inhibiting 
GDP dissociation and interactions with regulatory and effector molecules 
(DerMardirossian and Bokoch, 2005).   
 Apart from the above mentioned, RhoGDI also mediates the extraction of Rho 
GTPase from the membrane via a biphasic mechanism in which a rapid association of 
RhoGDI and Rho protein precedes a slow transfer of the lipid moiety from the 
membrane to RhoGDI (Nomanbhoy et al., 1999). Insertion of the isoprenyl moiety of 
Rho protein into the hydrophobic pocket of immunoglobulin-like β-sandwich of 
RhoGDI increases the solubility of GTPase. Therefore, through formation of 
RhoGDI-GTPase complexes, RhoGDIs replenish and maintain a cytosolic pool of 
soluble lipid-modified Rho GTPases by contributing to the recycling of Rho proteins 
(DerMardirossian and Bokoch, 2005). 
 Although the intracellular amount of RhoGDIs exceeds that of any single Rho 
GTPase, it is comparable to the total amount of Rho GTPases (Michaelson et al., 
2001). This stoichiometry strongly indicates that majority of the Rho proteins are in 
complex with RhoGDIs and maintained as inactive form in the cytosol. Formation of 
RhoGDI-GTPase complex therefore constitutes an important mechanism for the tight 
regulation of Rho GTPase signaling (Wennerberg and Der, 2004).  
 
1.2.7.2 Rho family Guanine Nucleotide Exchange Factors (RhoGEFs) activate   
Rho GTPase signaling  
 Function to accelerate GDP/GTP exchange, RhoGEFs constitute a large 
family of multi-domain proteins that confer not only speed but also specificity to the 
activation of Rho GTPases. Since the discovery of the first mammalian GEF – Dbl, 
isolated as a transforming gene in human diffuse B-cell lymphoma cells (Eva and 
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Aaronson, 1985), more than 70 human RhoGEFs have been identified (Garcia-Mata 
and Burridge, 2007). Based on the type of catalytic domain, RhoGEFs can be further 
classified into either Dbl or CZH/DOCK180 (CDM and Zizimin homology/Dedicator 
of cytokinesis 180) family. Canonical RhoGEFs in the former group contain a 
minimal module composed of the catalytic Dbl homology (DH) domain and a 
pleckstrin homology (PH) domain adjacent and C-terminal to the DH domain, 
whereas the newly defined members in the latter are characterized by the presence of 
two Dock homology regions (DHR) for mediating nucleotide exchange in replace of 
the DH-PH module (Ellenbroek and Collard, 2007; Garcia-Mata and Burridge, 2007). 
Beyond the basic structural requirement for nucleotide exchange activity, these 
otherwise highly diversified RhoGEFs may also contain additional functional 
domains including protein-protein or protein-lipid interaction domains such as Src 
homology 2 (SH2), SH3, PDZ (PSD95/Discs-large/ZO-1) and PH, or catalytic 
domains such as Ser/Thr or Tyr kinase, RasGEF and RhoGAP domains, which confer 
additional means for regulation (Schmidt and Hall, 2002). 
 Although structurally unrelated, both types of RhoGEF catalytic module 
function biochemically via a generalized mechanism in which interaction between 
RhoGEF and its target Rho GTPase deforms the nucleotide-binding site and results in 
a reduced affinity for GDP (Bos et al., 2007). In detail, conformation changes that 
occur within the GTPase upon binding of RhoGEF introduce a steric hindrance from 
either residues of the GEF itself or the repositioned alanine side chain of the 
conserved DTAG motif in switch II region of Rho GTPase. This steric occlusion of 
the magnesium-binding site, together with perturbation of the phosphate-binding 
surface, disrupt high-affinity binding of the nucleotide and promote its release from 
the Rho protein (Renault et al., 2003; Thomas et al., 2007). On the other hand, the 
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nucleotide base-binding region remains undisturbed and this allows the spontaneous 
binding of GTP, whose intracellular concentration is approximately ten times higher 
than that of GDP (Bos et al., 2007). This action re-orientates the essential threonine 
residue in the effector loop and displaces RhoGEF (ten Klooster and Hordijk, 2007), 
leaving the GTP-bound Rho GTPase ready to bind to its effectors.  
 Intriguingly, the number of RhoGEFs present in human far exceeds their 
cognate targets (Schmidt and Hall, 2002). No doubt this reflects specificity of some 
RhoGEFs for a single Rho GTPase such as p190RhoGEF for RhoA, Tiam1 for Rac1 
and Tuba for Cdc42, others including Vav can activate multiple Rho GTPases 
(Ellenbroek and Collard, 2007). Conversely, multiple RhoGEFs can act on the same 
Rho GTPase. Therefore, the large number of RhoGEFs provides a level of complexity 
and control to Rho GTPase signaling. Since majority of the RhoGEFs are 
ubiquitously expressed (Schmidt and Hall, 2002), additional means of regulation are 
required to modulate their activities to ensure precise control of Rho GTPase 
activation and subsequent downstream signaling. Indeed, this extra level of control is 
conferred by the multi-domain nature of RhoGEFs. For instance, PH domain though 
not required for RhoGEF catalytic activity, is essentially present in all Dbl family 
members with a few exceptions. This approximately 100-residue PH domain has been 
associated with both positive and negative regulatory roles pertaining to membrane 
targeting, interactions with phospholipids and proteins, and nucleotide exchange 
efficiency (Buchsbaum, 2007; Rossman et al., 2005).  
 Multiple combinations of different functional domains therefore provide the 
basis for modulation of RhoGEF activity via different modes including protein-
protein or protein-lipid interactions, binding of second messengers and post-
translation modifications (Bos et al., 2007). Apart from regulation, these characterized 
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modules also allow the RhoGEFs to serve an additional function of dictating Rho 
GTPase downstream signaling pathways, either by direct associations with immediate 
effectors or by functioning as a scaffold to integrate components of other signaling 
pathways (Buchsbaum, 2007; Ellenbroek and Collard, 2007).  
 
1.2.7.3 Rho family GTPase Activating Proteins (RhoGAPs) terminate Rho 
GTPase signaling  
 In the GDP/GTP cycle, RhoGAPs act in antagonism to RhoGEFs to accelerate 
deactivation of Rho GTPases by stimulating their weak intrinsic GTPase activity, 
thereby leading to enhanced GTP hydrolysis. Characterized by the presence of an 
approximately 150-residue RhoGAP domain, the human RhoGAP family is predicted 
to encompass up to 80 members from human genome analysis (Moon and Zheng, 
2003). Although members of the RhoGAP family may share as little as 20 % 
sequence identity in the RhoGAP domain, they form a distinct class of their own 
among other GAPs for the Ras superfamily (Moon and Zheng, 2003), similar to that 
observed for RhoGEFs. In addition to the RhoGAP domain, which constitutes a 
minimal module sufficient for binding GTP-bound Rho GTPase and catalyzing its 
GTPase activity, RhoGAPs are also multi-domain proteins that contain various 
combinations of additional functional modules. While some RhoGAPs may be 
specific to a single Rho GTPase, others display a broad substrate specificity and it 
remains to be determined how this variation is established (Tcherkezian and 
Lamarche-Vane, 2007).  
 Inherently low GTPase activity of Rho GTPases contributes to slow GTP 
hydrolysis and prolongs signal transductions. In the presence of RhoGAP, GTP 
hydrolysis rate is enhanced by several orders of magnitude and allows for rapid 
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termination of Rho GTPase signaling. Though diverse in sequence, the RhoGAP 
domain adopts a similar tertiary folding pattern and functions via a fundamental 
GTPase-activating mechanism as that of RasGAP (Zheng and Quilliam, 2003). In 
principle, RhoGAP facilitates the hydrolysis process by stabilizing the intrinsically 
mobile catalytic machinery of the GTPase and via the insertion of a catalytic residue 
in trans to stabilize the transition state (Bos et al., 2007). Indeed, structure analysis of 
p50RhoGAP shows that the GAP domain comprises nine α-helices and binds to both 
Switch I and II and P-loop of Rho GTPase to stabilize them (Hakoshima et al., 2003). 
Furthermore, a structural comparison of the transition state mimic, consisting of 
RhoGAP in complex with RhoA bound to GDP and aluminum fluoride, to that of 
RhoGAP-RhoA bound to GMPPNP which is a non-hydrolysable GTP analog, reveals 
a 20 o rotation between the two structures (Hakoshima et al., 2003; Moon and Zheng, 
2003; Nassar et al., 1998).  
 Taken together, binding of RhoGAP domain to Rho GTPase stabilizes the 
glutamine residue that coordinates the orientation of the attacking water molecule. In 
addition, insertion of a highly conserved catalytic residue known as the arginine 
finger by the RhoGAP in trans to interact directly with the glutamine residue 
neutralizes the negative charge at the γ-phosphate, thereby stabilizes the transition 
state. Through stabilization of this glutamine residue, the freedom of water molecule 
is restricted and this in turn may reduce the energy barrier for GTP hydrolysis (Bos et 
al., 2007; Rittinger et al., 1997; Scheffzek et al., 1997). While mutational analysis has 
confirmed the importance of this arginine finger in catalyzing Rho GTP hydrolysis, 
additional amino acids may also play secondary role in orientating the GTPase 
machinery for efficient hydrolysis (Moon and Zheng, 2003; Peck et al., 2002).  
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 Intriguingly, the presence of a large number of regulators that exceeds the Rho 
GTPases by two to three folds and the diverse multi-domain architecture of these 
regulators are two striking features common to both RhoGEFs and RhoGAPs - 
regulators of the GDP/GTP cycle. The vast number, coupled with multiple 
combinations of different functional domains, provides the basis for tight modulation 
of the activities of these regulators (Moon and Zheng, 2003; Tcherkezian and 
Lamarche-Vane, 2007). This is not surprising given the diverse spectrum of cellular 
activities under the control of Rho GTPases and dysfunctions of these proteins and 
their regulators have been implicated in various diseases. Similar to RhoGEFs, the 
multi-domain nature of many RhoGAPs allows the convergence of different signaling 
pathways through interactions with other molecules, as dictated by the domains 
present (Moon and Zheng, 2003). Alternatively, these domains may interact with 
different effectors of the Rho GTPases to specify activation of distinct pathways. 
Given the importance of the regulatory role that RhoGAPs have on switching off the 
Rho proteins, it is therefore imperative to understand how these regulators may in turn 
be modulated.  
 
1.2.8 Mechanisms of RhoGAP regulation 
 RhoGAP activity is subjected to stringent regulation via multiple mechanisms. 
These regulatory mechanisms include protein-protein interaction, lipid binding, 
phosphorylation and proteolytic degradation (Tcherkezian and Lamarche-Vane, 2007) 
that may serve to modulate the GAP activity, mediate translocation to specific 
intracellular location, relieve autoinhibition or bring about protein degradation (Bos et 
al., 2007).  
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 Firstly, the presence of different protein interaction domains such as SH2, 
SH3, PDZ and SAM (Sterile Alpha Motif) facilitates regulation via protein-protein 
interactions. For instance, interaction of CdGAP through probably its proline-rich 
motif with SH3 domain of intersectin, an endocytic scaffolding protein, may induce a 
conformation change in CdGAP that leads to the inhibition of its GAP activity (Jenna 
et al., 2002). Moreover, direct binding of PRC1 (protein regulating cytokinesis 1) to 
GAP domain of MgcRacGAP downregulates its GAP activity during metaphase (Ban 
et al., 2004). Interaction of Rap1 with RA (Ras association) domain of RA-RhoGAP, 
on the other hand, activates the RhoGAP via relief of intramolecular autoinhibition 
imposed by the RA domain (Yamada et al., 2005).  
 Besides protein interaction domains, some RhoGAPs may contain lipid 
binding domains such as BAR (Bin/amphiphysin/Rvs), DEP (Dishevelled/Egl-
10/pleckstrin), C1 (cysteine-rich phorbol ester) and C2 (calcium-dependent lipid 
binding) that may participate in membrane targeting and mediate subcellular 
localization (Kandpal, 2006). For example, binding of phorbol ester or diacylglycerol 
(DAG) to the cysteine-rich region of chimaerin, a Rac-specific GAP, stimulates its 
GAP activity and induces its translocation from the cytosol to perinuclear region and 
golgi (Moon and Zheng, 2003). In addition, there have been reports on the regulation 
of GAP activity of p190RhoGAPs (p190-A and p190-B) by phospholipids such that 
several phospholipids including phosphatidylserine (PS), PIP2 and phosphatidic acid 
inhibit their GAP activity in vitro, whereas PS and PIP2 can promote the GAP activity 
of p190RhoGAPs towards Rac1 (Ligeti et al., 2004).  
 Next, protein kinases can modulate RhoGAP activity via phosphorylation and 
p190RhoGAP is one such example that may be targeted by various kinases. Src-
induced phosphorylation of p190RhoGAP at two tyrosine residues near the RhoGAP 
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domain recruits p120RasGAP through a SH2 domain-phosphotyrosine interaction and 
this activates the GAP activity of p190RhoGAP (Moon and Zheng, 2003). 
Conversely, activation of low molecular weight protein-tyrosine phosphatase (LMW-
PTP) upon phosphorylation by c-Src in response to PDGF receptor signaling allows 
direct interaction of this protein with p190RhoGAP. This interaction facilitates the 
dephosphorylation of p190RhoGAP by LMW-PTP phosphatase activity, thus 
negatively regulate Src-induced activation of p190RhoGAP (Moon and Zheng, 2003). 
Furthermore, p190RhoGAP can be phosphorylated on Ser/Thr residues by PKC, 
which promotes the translocation of p190RhoGAP from the cytosol to membrane 
ruffles upon Src activation (Brouns et al., 2000).  
 Lastly, the protein level of RhoGAPs can be controlled intrinsically by 
targeting the protein for degradation. It is demonstrated that expression of 
p190ARhoGAP is transiently downregulated via ubiquitin-mediated degradation 
during late mitosis for successful completion of cytokinesis (Su et al., 2003). Given 
the modular complexity of RhoGAPs, it presents many possibilities on how these 
RhoGAPs can be modulated and are awaiting to be discovered. It is therefore through 
further characterization of members of the RhoGAP family that new insights can be 
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1.3 BCH (BNIP-2 and Cdc42GAP Homology) domain-containing, proline-
rich and Cdc42GAP-like protein 1 (BPGAP1) 
As discussed, the human RhoGAP family comprises many multi-domain 
proteins characterized by the presence of a conserved RhoGAP domain, coupled with 
additional functional signaling modules. Many RhoGAPs, termed as ARHGAP1-12, 
have been identified from the human genome.  BPGAP1 is a novel RhoGAP that was 
first discovered through bioinformatics analysis and it harbors an unique domain 
architecture similar to that of p50RhoGAP/ARHGAP1 (Shang et al., 2003). Together, 
p50RhoGAP and BPGAP1 constitute a distinct subgroup within the RhoGAP family 
(Johnstone et al., 2004) as defined by a N-terminal BCH (BNIP-2 and Cdc42GAP 
Homology)/Sec14p-like domain, followed by a proline-rich region and a C-terminal 




Figure 1.10 Domain architecture of BPGAP1. BPGAP1 harbors a N-terminal BCH 
domain followed by a proline-rich motif (P) and a C-terminal RhoGAP domain with a 
highly conserved arginine residue at position 232. [Adapted from Shang et al., 2003].  
 
 
 BPGAP1, also known as ARHGAP8, is encoded by 12 exons in the 
ARHGAP8 gene mapped to human chromosome 22q13.31 (Johnstone et al., 2004). 
Composed of 433 amino acids, BPGAP1 lacks a 31-amino acid insertion in the BCH 
domain due to the removal of exon 5 by alternative splicing (Johnstone et al., 2004; 
Shang et al., 2003). Thus far, transcripts of two other isoforms have been detected, 
with one encoded by all 13 exons of ARHGAP8 gene (BPGAP2) and the other has 
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five amino acids – YWDYR missing from the BCH domain as a consequence of a 
final 15 bp deletion from exon 5. However, both these transcripts are present at a 
much lower level as compared to BPGAP1 in normal breast and colon tissues tested 
(Johnstone et al., 2004). A mouse ortholog has also been detected and is encoded by 
the Arhgap8 gene located on mouse chromosome 15, region E2, in a region syntenic 
with human chromosome 22q13. Although mouse Arhgap8 gene shares an identical 
exon/intron organization to human ARHGAP8, it lacks an exon 5 equivalent and the 
541 bp CpG island in its 5’ region (Johnstone et al., 2004).  
 
1.3.1 BPGAP1 and p50RhoGAP 
 BPGAP1 and p50RhoGAP are amongst the smallest RhoGAP proteins in the 
family and are most closely related to each other (Johnstone et al., 2004; Peck et al., 
2002). With an identical domain organization, these two proteins share an overall 
approximate 54 % amino acid identity and 52 % identity within the RhoGAP domain 
itself. Conversely, BPGAP1 differs from p50RhoGAP such that it has a 44-amino 
acid extension C-terminal to the RhoGAP domain, whereas p50RhoGAP harbors 
extra 50 amino acids N-terminal to the BCH domain (Shang et al., 2003). While 
p50RhoGAP is ubiquitously expressed in the adult tissues tested including brain, 
colon, heart, kidney, liver, lung, placenta, small intestine, spleen, stomach and testis, 
albeit at a lower level in skeletal muscle; BPGAP1 is also present in all except brain, 
liver and spleen, with highest expression in kidney and placenta (Johnstone et al., 
2004). Since both RhoGAP proteins possess the same genome organization with 
correspondingly identical domain architecture and a high overall amino acid identity, 
it is likely that these two genes have evolved from a common ancestor via gene 
duplication (Johnstone et al., 2004).  
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1.3.2 Expression of BPGAP1 is upregulated in colorectal and cervical cancers 
 The mapping of ARHGAP8 to a region in human chromosome 22q13.31 that 
frequently exhibits loss-of-heterozygosity in colorectal and breast tumors (Castells et 
al., 2000; Castells et al., 1999) suggests that BPGAP1 may be implicated in these 
cancers. In mutational analysis of colorectal and breast tumors by PCR-SSCP 
(Polymerase chain reaction-single strand conformation polymorphism), six germline 
missense variants were identified, whereas no somatic mutation have been detected 
(Johnstone et al., 2004). Even though epigenetic silencing of ARHGAP8 in tumors 
may occur through hypermethylation of the 5’ CpG island, this is not the case and 
surprisingly, ARHGAP8 mRNA is found to be overexpressed in the majority of 
colorectal tumors. This upregulation occurs irrespective of tumor location, stage or 
level of differentiation (Johnstone et al., 2004). Recently, increased transcription of 
ARHGAP8 is also detected in cervical cancer (Song et al., 2008). While upregulation 
of ARHGAP8 may potentially constitute a negative feedback loop to counteract 
overexpression of Rho GTPases in these cancers (Johnstone et al., 2004), it is also 
possible that BPGAP1 may play a role in cancer progression, in accordance to studies 
which demonstrate that BPGAP1 has the ability to promote prolonged ERK activation 
and cell migration (Lua and Low, 2004; Lua and Low, 2005a; Shang et al., 2003). 
 
1.3.3 Multi-domain nature of BPGAP1 mediates its functions 
 BPGAP1 harbors a domain organization characterized by a N-terminal 
protein-protein interaction domain - BCH/Sec14p-like domain that also possess lipid 
binding properties, followed by a proline-rich motif that potentially contain more than 
one consensus sequence PXXP for binding to SH3 and lastly a C-terminal RhoGAP 
domain with a highly conserved arginine residue (Figure 1.10) (Shang et al., 2003). 
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This multi-domain nature of BPGAP1 therefore presents a new array of potential 
functions in association with these functional modules that may serve to regulate its 
primary function as a RhoGAP, dictate its subcellular localization or integrate 
multiple signaling pathways. These domains may act either independently or in 
unison to bring about their designated cellular effects. Thus far, studies on BPGAP1 
have implicated it with enhancing cell migration (Lua and Low, 2004; Shang et al., 
2003) and induction of ERK activation (Lua and Low, 2005a; Pan et al., 2010), 
mediated through interactions with the various identified partners. Functions of 
BPGAP1 brought about by its domains will be described in the following sections.  
 
1.3.3.1 BPGAP1 functions biochemically as a RhoA GAP and regulates cell 
morphology via its BCH and GAP domains 
 To fulfill its role as a negative regulator of Rho GTPase function, the GAP 
domain of BPGAP1 harbors an invariant arginine residue at position 232. Mutation of 
this conserved arginine residue to alanine (R232A mutant) abolishes its RhoGAP 
activity (Shang et al., 2003), consistent with the critical role of a canonical arginine 
finger in the GAP domain for catalyzing GTP hydrolysis. In vitro analysis of the 
activity level of RhoA, Rac1 and Cdc42 reveals that BPGAP1 is active towards RhoA 
and Cdc42, with a significant preference for the latter. Such activity, however, is not 
observed for Rac1 (Shang et al., 2003). While it has been demonstrated for some 
RhoGAPs that the in vitro substrate profile may not truly reflect the in vivo substrate 
selectivity (Ridley et al., 1993), in vivo analysis has indeed indicated that BPGAP1 
exerts its GAP activity solely on RhoA despite the ability of BPGAP1 to also form 
complexes with Rac1 and Cdc42 (Shang et al., 2003).  
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 As a mainly cytosolic protein, ectopic expression of BPGAP1 induces the 
formation of distinctive short and long protrusions (pseudopodia) via its BCH and 
GAP domains, respectively. These unique cellular morphological changes are 
mediated through a GAP-dependent mechanism that attenuates RhoA signaling and 
also via an unknown mechanism that involve signaling downstream of active Cdc42 
and Rac1, as demonstrated by the use of constitutive active and dominant negative 
mutants of these Rho GTPases (Shang et al., 2003). Therefore, inactivation of RhoA 
by the GAP domain generates long protrusions, whereas active Cdc42 or Rac1 
contributes to the induction of short, branched extensions. 
 
1.3.3.2 BPGAP1 facilitates cell migration via concerted interplay of its functional 
modules for cell morphological changes and translocation of cortactin to 
the cell periphery 
 In line with the generation of cellular protrusions, BPGAP1 also serves to 
promote cell migration. Despite omission of the need for proline-rich region in 
inducing cellular morphological changes, its presence is required to trigger cell 
motility (Shang et al., 2003). This absolute requirement of the proline-rich region in 
BPGAP1-induced cell migration could potentially imply the involvement of other 
interacting partners since this motif may mediate binding to SH3, WW and 
Enabled/VASP homology domains (Zarrinpar et al., 2003). As predicted, cortactin, 
which contains a C-terminal SH3 domain and functions as a molecular scaffold 
protein that mediates actin cytoskeleton assembly and organization (Lua and Low, 
2005b), is identified as an interacting partner of BPGAP1 along with many others as 
revealed by proteomics. 
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 Further analyses demonstrate that cortactin is indeed a bona fide target of 
BPGAP1 and their interaction occurs through the consensus PXXP motif within the 
proline-rich region of BPGAP1, with proline residues 184 and 186 being the critical 
residues (Lua and Low, 2004). In addition, cortactin is shown to translocate to the cell 
periphery, accompanied by an increase in filamentous actin assembly in the presence 
of BPGAP1 but does not require growth factor stimulation. Cooperatively, BPGAP1 
and cortactin enhance cell migration in epithelial cells, an effect that is not seen with 
increased expression of either protein alone (Lua and Low, 2004). As such, BPGAP1 
may function to integrate cortactin and Rho GTPase signaling by facilitating the 
translocation of cortactin to the cell periphery, coupling changes in cell morphology 




Figure 1.11 Model for BPGAP1-induced cell morphological changes and 
migration. BPGAP1 elicits the formation of unique short and long protrusions via its 
BCH and GAP domains, respectively, while the proline-rich region targets cortactin 
and facilitates its translocation to the cell periphery, thereby coupling changes in cell 
morphology to enhancement of cell migration. [Adapted from Shang et al., 2003; Lua 
and Low, 2004]. 
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1.3.3.3 BPAGP1 activates EGF receptor endocytosis and ERK signaling, 
mediated by its functional RhoGAP domain and interaction with 
EEN/endophilin II  
 Identification of novel BPGAP1-interacting partners by proteomics has 
introduced an exciting means by which cellular functions of BPGAP1 can be 
uncovered. Following the characterization of cortactin, another protein known as 
extra eleven-nineteenth (EEN)/Endophilin II that belongs to the endocytic endophilin 
family has also been extensively studied for its interaction with BPGAP1. This family 
of proteins has been associated with regular cellular processes such as endocytosis 
and cell cycle, as well as implicated in pathological diseases including human 
leukemia and Huntington’s disease (Lua and Low, 2005a).  
 Similar to cortactin, BPGAP1 interacts with the C-terminal SH3 domain of 
EEN via its proline-rich region through the canonical EEN-binding motif PPXRP in 
this instance, with Pro184 and Pro186 being the critical residues. While both BPGAP1 
and EEN individually promote EGF receptor internalization, they function 
synergistically to augment this endocytic effect. Integration of signaling pathways of 
these two proteins has been demonstrated through utilization of a BPGAP1 mutant 
that is incapable of mediating direct interaction with EEN (PP mutant) or a dominant 
mutant of EEN that lacks its C-terminal SH3 domain (NT fragment), which shows 
that similar augmentation effect on EGF receptor endocytosis cannot be achieved 
when either mutant is coexpressed with the wild-type protein of the other. Moreover, 
use of the RhoGAP catalytic inactive mutant (R232A) is sufficient to cause a 
reduction in either BPGAP1-induced or EEN- and BPGAP1-induced EGF receptor 
internalization. Taken together, these results indicate that BPGAP1 enhances EGF 
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receptor endocytosis via concerted action of its interaction with EEN and its RhoGAP 
activity (Lua and Low, 2005a).   
 Although internalization of growth factor-bound receptors can serve either to 
initiate or terminate signaling (Le Roy and Wrana, 2005), the former applies to both 
BPGAP1- and EEN-induced EGF receptor endocytosis, leading to activation of 
MAPK pathway and ERK1/2 phosphorylation (Lua and Low, 2005a). The 
corresponding increase in levels of phosphorylated ERK1/2, as induced by BPGAP1 
and EEN individually or collectively, is in accordance with their effect on EGF 
receptor endocytosis. While the dominant negative mutant of EEN exerts an 
inhibitory effect on BPGAP1-induced ERK1/2 phosphorylation in a similar manner to 
its effect on BPGAP1-induced endocytosis, both the non-interactive and RhoGAP 
inactive mutants still promote ERK1/2 phosphorylation while still exerting their 
inhibitory effect on EEN-induced ERK1/2 phosphorylation. Therefore, there exists an 
alternative mechanism by which BPGAP1 can facilitate phosphorylation of ERK1/2, 
independent of its direct interaction with EEN and the functional GAP domain. 
Indeed, BPGAP1 can activate MAPK pathway separately via its BCH domain, 
leading to ERK1/2 phosphorylation (Lua and Low, 2005a). In short, BPGAP1 and 
EEN function cooperatively to facilitate EGF receptor endocytosis through integration 
of RhoGAP and endophilin-mediated signaling pathways, thereby regulating 
Ras/MAPK pathway to promote ERK1/2 phosphorylation (Figure 1.12) (Lua and 









Figure 1.12 Model for BPGAP1- and EEN-mediated EGF receptor endocytosis 
and ERK1/2 phosphorylation. EGF receptor undergoes internalization upon EGF 
stimulation and triggers ERK1/2 phosphorylation. These processes are mediated by 
both BPGAP1 and EEN, either individually or synergistically through interaction 
between BPGAP1 proline rich region and SH3 domain of EEN. EEN devoid of its 
SH3 domain (NT) functions as a dominant negative mutant and completely inhibit the 
effects of BPGAP1 on receptor internalization and ERK1/2 phosphorylation. On the 
other hand, both non-interactive (PP) and GAP inactive (R232A) mutants reduce 
BPGAP1-, EEN-mediated, as well as BPGAP1- and EEN-coinduced endocytosis, 
indicating the requirement of GAP activity in this process. Since ERK1/2 
phosphorylation can still occur in the presence of these mutants, this suggests that 
BPGAP1 can enhance ERK1/2 phosphorylation via an endocytosis independent 
pathway through its BCH domain. [Adapted from Lua and Low, 2005a].  
 
 
1.3.3.4 Interaction between Pin1 and BPGAP1 mediated by active MEK2 
suppresses BPGAP1-induced acute ERK activation and cell migration 
 While earlier work has established that BPGAP1 modulates cell migration 
dynamics and promotes ERK activation, a recent study identifies Pin1 as a negative 
regulator of BPGAP1 signaling at least in cell migration. Pin1 is a WW domain-
containing peptidyl-propyl cis/trans isomerase and functions to modify protein 
conformations via its isomerase activity. Although the WW domain of Pin1 generally 
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recognizes and binds to its targets via a core motif containing a phosphorylated 
Ser/Thr followed by a proline residue (Lu et al., 1999), BPGAP1 and Pin1 interact 
through the type II WW domain-binding PPXP motif within the proline-rich region of 
BPGAP1, while the PPI domain of Pin1 targets the DDYGD motif of RhoGAP 
domain. Such interactions require the presence of active MEK2 as a scaffold (Pan et 
al., 2010).  
 When present in the cell, Pin1 can suppress BPGAP1-induced acute ERK 
activation in a GAP-independent manner, and attenuate Rho signaling by stimulating 
its RhoGAP activity. In addition, Pin1 is found to exert a negative effect on cell 
migration induced by BPGAP1 and active MEK2. Taken together, it is possible that 
Pin1 simultaneously downregulates both ERK and Rho signaling, hence suppressing 
BPGAP1- and MEK2-coinduced cell motility (Pan et al., 2010).  
 Thus far, understanding on the regulation and functions of BPGAP1 has arisen 
from the associations between proline-rich motif of BPGAP1 and its interacting 
partners. Analysis on properties of the protein-protein interaction domain - BCH 
domain, may therefore provide the basis for further exploration of BPGAP1 functions 
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1.4 Family of BCH domain-containing proteins  
 First identified as a novel functional module more than a decade ago, BCH 
domain is discovered as a region of homology shared by both BNIP-2 and 
Cdc42GAP/p50RhoGAP, and hence termed as BNIP-2 and Cdc42GAP homology 
(BCH) (Figure 1.13) (Low et al., 1999; Low et al., 2000a; Low et al., 2000b). This 
unique protein domain comprises approximately 150 amino acids and is 
evolutionarily conserved among many organisms such as Saccharomyces cerevisiae, 
Caenorhabditis elegans, Homo sapiens and Aradidopsis thaliana, indicative of an 
important physiological function confers by this domain (Low et al., 2000a). Early 
studies have shown that BCH domain is a protein-protein interaction domain capable 
of mediating homophilic and heterophilic interactions between same and different 
proteins harboring this domain, respectively (Low et al., 2000a; Shang et al., 2003). In 
addition, this domain contains specific motifs that allow binding to Rho GTPases 
(Low et al., 2000b; Zhou et al., 2010; Zhou et al., 2005), confer non-canonical GAP 
activity in vitro (Low et al., 1999; Low et al., 2000b) or for establishing 




Figure 1.13 Schematic diagram of homologous BCH domains in 
Cdc42GAP/p50RhoGAP and BNIP-2. BCH domains within BCH domain-
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1.4.1 BCH domain: a distinct subset of Sec14 superfamily 
 Intriguingly, bioinformatics analysis has revealed that BCH domain shares 
subtle homology of less than 20 % with a lipid binding module known as Sec14 
domain, thereby bringing BCH domain-containing proteins under the wing of Sec14 
superfamily (Low et al., 2000a). The yeast Sec14p is the prototypic representative of 
this superfamily and functions as a transport protein for phosphatidylinositol (PtdIns) 
and phosphatidylcholine (PtdCho) (Mousley et al., 2007; Saito et al., 2007; Schaaf et 
al., 2008). This same domain is also known as CARL_TRIO domain in the 
mammalian counterparts, named after the two proteins containing this module – 
cellular retinaldehyde binding protein and Trio protein (Saito et al., 2007). However, 
this PtdIns transport function of Sec14p in higher eukaryotes has been assumed by 
another group of structurally unrelated family of PtdIns transfer proteins (PITPs). 
Nevertheless, Sec14 domain still retains lipid-binding ability and some may have 
evolved for carrying out more specialized transport functions that are vital for the 
maintenance of organelle physiology (Saito et al., 2007). Indeed, the biological 
significance of members in the Sec14 superfamily in mammals is reflected by the 
association of human diseases with dysfunctions of Sec14 domain in these proteins, 
which include autosomal-dominant cancers linked to reduced level of neurofibromin, 
ataxia due to loss of function of caytaxin/BNIP-H and retinal degeneration syndromes 
as a consequence of CRALBP deficiencies (Bankaitis et al., 2010).  
 Annotated in the NCBI database are approximately 1550 Sec14 domain-
containing proteins (Bankaitis et al., 2010) of which some are Sec14-like, while 
others are multi-domain proteins including those that can function as protein tyrosine 
phosphatases (PTP-MEG2), RhoGAP (p50RhoGAP), RhoGEFs (Trio, Dbl, Duo) and 
RasGAP (NF1) (Bankaitis et al., 2010; Saito et al., 2007). Given the limited 
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homology of BCH domain with Sec14 domain and the ability of BCH domain to 
mediate protein-protein interactions in addition to lipid binding properties, it is 
possible that BCH domain-containing proteins have diverged sufficiently from the 
Sec14 superfamily to constitute a distinct subset (Low et al., 2000a). Two different 
domain organizations with respect to BCH domain have been described such that 
proteins with their BCH domain located at the C-terminal are of type I distribution, 
whereas those of type II distribution have a N-terminal BCH domain that precedes a 
GAP domain at the C terminus (Low et al., 2000a).  
 
1.4.2 BNIP-2 is the prototype of BNIP-2 family of BCH domain-containing 
protein 
 Termed as Bcl-2 and E1B Nineteen kDa Interacting Protein 2, BNIP-2 is first 
cloned and identified as a cellular interacting partner of adenovirus E1B 19 kDa 
protein using yeast two-hybrid screen (Boyd, 1994). By utilizing the same screening 
system, this protein is later found to be a putative substrate of fibroblast growth factor 
(FGF) receptor and can be tyrosine phosphorylated upon growth factors stimulation, 
which negatively regulates its interaction with other proteins (Low et al., 1999). 
BNIP-2, which consists of 314 amino acids, has a simple molecular architecture 
comprising of a single EF-hand calcium-binding motif at the N-terminal region and a 
then newly described BCH domain at its C-terminal. Strikingly, this protein localizes 
in the cytosol in a punctate manner and concentrates at the leading edge of cell 
protrusions (Zhou et al., 2005), as well as in the nuclear envelope/endoplasmic 
recticulum region (Boyd, 1994).   
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1.4.2.1 BNIP-2 induces cell elongation and membrane protrusions via Cdc42 
signaling  
 With only a single recognizable domain, much attention has been focused on 
the BCH domain when characterizing BNIP-2. Indeed, it has been demonstrated that 
through the BCH domain, BNIP-2 is capable of forming homodimer with itself and 
heterodimer with p50RhoGAP/Cdc42GAP via the region 217RRKMP221 (Low et al., 
2000a). Apart from p50RhoGAP, BNIP-2 also binds to Cdc42 using a separate region 
within the BCH domain that corresponds to residues 285 to 292 (Low et al., 2000b).  
 Interestingly, while transient expression of BNIP-2 or its BCH domain alone 
was able to elicit cellular morphological changes, distinctively cell elongation and 
membrane protrusions, non-interacting BNIP-2 mutant devoid of the Cdc42-
interacting motif and mutants lacking the immediate upstream sequence of 34 amino 
acids failed to promote such changes. Furthermore, since BNIP-2-induced 
morphological changes can be abolished by inhibiting the Cdc42 signaling pathway 
using Cdc42 dominant negative mutants T17N and PAK-CRIB (Cdc42 and Rac1 
Interacting Binding) domain but not by blockage of the association of BNIP-2 with 
Cdc42GAP using a non-interacting BNIP-2 mutant, this establishes that the observed 
effect of BNIP-2 on cell morphology is mediated by Cdc42 signaling without the 
involvement of Cdc42GAP (Figure 1.14) (Zhou et al., 2005).  
 With the inhibition of BNIP-2-induced cell elongation and membrane 
protrusions, the unique distribution of BNIP-2 in punctate spots and its concentration 
at the leading edge of membrane protrusions was replaced by a more diffused 
appearance. As such, it is possible that cell protrusions elicited by BNIP-2 are coupled 
to its translocation (Zhou et al., 2005). Of note, although BNIP-2 displays in vitro 
catalytic GAP activity towards Cdc42 via a non-canonical arginine patch within its 
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BCH domain (Low et al., 2000b), such enhancement of Cdc42 GTPase activity is not 
detected in vivo and is not conferred by the BCH domain of Cdc42GAP (Zhou et al., 
2005).  
 




         b 
 
 
Figure 1.14 BNIP-2 induces cell elongation and membrane protrusions. (a) BNIP-
2 BCH domain mediates homophilic interaction to itself, heterophilic interaction to 
Cdc42GAP, and signals to Cdc42 to induce membrane protrusions via distinct motifs. 
(b) Cells transfected with BNIP-2 display unique BNIP-2 distribution in punctate 
spots and also concentrates at the leading edge of membrane protrusions. [Adapted 
from Zhou et al., 2005]. 
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1.4.2.2 BNIP-2 functions as a scaffold to facilitate integration of Cdc42 signaling 
and p38α/β MAPK activity during myogenic and neuronal differentiation 
 In more recent studies, use of siRNA has demonstrated the requirement of 
BNIP-2 in both myogenic and neuronal differentiation, downstream of receptor Cdo 
(Kang et al., 2008; Oh et al., 2009). Cdo is a cell surface receptor belonging to 
Immunoglobulin (Ig) superfamily and is highly expressed in both myoblast and 
neuronal progenitors (Oh et al., 2009). It has previously been established that during 
myogenesis, Cdo binds via its intracellular region to JLP, a scaffold protein for 
p38α/β MAPK pathway, which in turn binds p38α/β (Takaesu et al., 2006). Through 
downstream activation of p38α/β MAPK pathway mediated by these interactions, this 
leads to the phosphorylation of E proteins that are heterodimeric partners of lineage-
specific bHLH (basic helix-loop-helix) transcription factors, and other proteins that 
regulate myogenesis. Subsequent heterodimerization of specific E protein and bHLH 
transcription factor thereby induces gene expression essential for myogenic 
differentiation (Kang et al., 2008; Oh et al., 2009). 
 Independent of JLP, Cdo also associates with BNIP-2 through a 31-amino acid 
region (residues 261-292) in the BCH domain. In C2C12 cells, induction of BNIP-2 
expression promotes myotube formation and increases the level of muscle-specific 
protein markers, whereas downregulation of BNIP-2 proteins by siRNA leads to an 
opposite effect. Such positive effect on myogenic differentiation induced by BNIP-2 
is dependent on its interaction with both Cdc42 and Cdo as demonstrated with the 
respective non-interacting mutants. In addition, Cdc42 activity level, which is 
required for myogenesis, varies correspondingly with the protein levels of BNIP-2 
and Cdo in differentiating C2C12 cells and myoblasts in a positive manner. 
Consistently, alteration of Cdc42 activity through expression of Cdc42GAP or 
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BPGAP1 impairs myogenesis, whereas introduction of siRNA against Cd42GAP 
promotes myogenesis. With the activation of p38α/β MAPK downstream of Cdc42 
signaling, this implies that Cdo by coordinating mutual interactions with both BNIP-2 
and JLP, integrates signaling of Cdc42 to p38α/β as mediated by Cdo-BNIP-2-Cdc42 
and Cdo-JLP-p38α/β interactions (Kang et al., 2008). A similar mechanism is also 
involved in neuronal differentiation (Oh et al., 2009). Taken together, BNIP-2 may 
function as a scaffold protein for dynamic regulation of Cdc42 signaling (Figure 1.15) 




Figure 1.15 Model of Cdo-mediated p38α/β activation leading to myogenic or 
neurogenic differentiation. Cdo induces myogenic or neurogenic differentiation in 
lineage-specific cells via concerted action of scaffold proteins JLP and BNIP-2 that 
bind p38α/β and Cdc42, respectively, thereby promoting activation of p38α/β 
downstream of active Cdc42. Heterodimerization of phosphorylated E protein with 
myogenic or neurogenic basic helix loop helix (bHLH) factors (M/N) subsequently 
triggers expression of genes necessary for myogenic or neurogenic differentiation. 
[Adapted from Kang et al., 2008; Oh et al., 2009].   
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1.4.2.3 BNIP-2 is a potentially pro-apoptotic protein 
 Following the discovery of BNIP-2 as an interacting partner of Bcl-2 and p19 
E1B pro-survival factors, several studies have implicated BNIP-2 as a pro-apoptotic 
protein. For instance, BNIP-2 gene is found to be downregulated in SK-ER3 
neuroblastoma cells upon 17 beta-estradiol treatment which confers neuroprotection. 
On the other hand, overexpression of BNIP-2 in these neuroblastoma cells triggers 
massive cell death, which can be counteracted by cotransfection of Bcl-2, indicating 
that BNIP-2 and Bcl-2 act in an opposing manner. The anti-apoptotic effect of 
estrogen in decreasing BNIP-2 expression also delays TNFα-induced apoptosis in 
non-neuronal cells such as MCF-7 epithelial cells and U937 monoblastoid cells 
(Belcredito et al., 2001). Similarly, a decrease in BNIP-2 expression is detected in 
murine lung adenomas and carcinomas, suggesting a decrease in apoptotic signaling 
during cancer development (Bonner et al., 2004).  
 Furthermore, cleavage of BNIP-2 by caspases during apoptosis induced in 
MCF-7 cells has also been reported, with the region I80DLDGLDT identified as the 
putative cleavage site. This motif harbors two potential cleavage sites including 
D83GLD↓T that can be recognize by caspase-3 and I80DLD↓G which can be 
recognized by caspase-6 and caspase-8 (Valencia et al., 2007). More recently, a 
candidate granzyme B cleavage site has also been proposed using bioinformatics 
analysis. While it is demonstrated that BNIP-2 can be cleaved by granzyme B in vitro, 
cleavage of endogenous BNIP-2 is also detected in tumor cells that are subjected to 
killing by nature killer cells (Scott et al., 2010). Although majority of the studies have 
implicated BNIP-2 as a pro-apoptotic gene whose upregulation is associated with 
apoptosis, downregulation of this gene has also been reported in neutrophils, 
coincident with their apoptosis (Kobayashi et al., 2005).  
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1.4.3 BCH domain-containing proteins regulate various aspects of cellular 
dynamics 
 Amongst the many BCH domain-containing proteins, a few including BNIP-2, 
BNIP-H (BNIP-2 Homology), BNIP-Sα (BNIP-2 Similar), BNIPXL (BNIP-2 extra 
long), p50RhoGAP and BPGAP1 have been extensively characterized by members in 
our laboratory. These BCH domain-containing proteins, whose functions are elicited 
mainly by their respective BCH domains, are implicated in a spectrum of cellular 
processes as shown in Figure 1.16. Although different BCH domains can mediate 
diverse aspects of cellular dynamics, many of them are involved in the regulation of 
Rho GTPase signaling, which will be further discussed in the following section.  
 
 
Figure 1.16 BCH domain-containing proteins and their functions. Members of 
the BNIP-2 and p50RhoGAP families of BCH domain-containing proteins mediate 
diverse aspects of cellular dynamics, mainly via the highly conserved BCH domain.  
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1.4.4 BCH domain functions as a new class of regulatory domain for GTPases 
signaling  
 From the numerous studies on BCH domain-containing proteins, there are 
increasing evidences that these different BCH domains participate in mediating and 
regulating Rho GTPases signaling, thereby leading to their designated cellular effects. 
As discussed previously, BNIP-2 BCH domain elicits cell elongation and membrane 
protrusions by signaling to Cdc42, and promote myogenic and neurogenic 
differentiation downstream of Cdo receptor by coupling Cdc42 signaling to activation 
of p38α/β. Other members of the BNIP-2 family, such as BNIP-Sα and BNIPXL, 
have also been shown to regulate RhoA signaling in concert with their cognate 
regulators, p50RhoGAP and Lbc (Lymphoid blast crisis) RhoGEF, respectively. 
 For BNIP-Sα, its BCH domain harbors a RhoA binding region that interacts 
specifically with RhoA and another overlapping region that mediates heterophilic 
interaction with BCH domain of p50RhoGAP, an inactivator of RhoA signaling. 
These overlapping yet specific binding motifs result in a tripartite competition 
whereby BNIP-Sα competes with and sequesters p50RhoGAP from binding to RhoA, 
hence preventing RhoA inactivation. Separately, BNIP-Sα can induce RhoA 
activation through its BCH domain. Therefore, BNIP-Sα acts by displacing 
p50RhoGAP and facilitating RhoA activation to promote cell rounding and apoptosis 
through its BCH domain (Figure 1.17a) (Zhou et al., 2006).  
 In another example, BNIPXL reduces the level of active RhoA through its 
ability to associate with both RhoA and a RhoA-specific RhoGEF – Lbc, via its BCH 
domain, thus preventing RhoA activation by competing away Lbc. Moreover, the N-
terminal region of BNIPXL without its BCH domain can also associate with the 
proline-rich motif of Lbc to exert an inhibitory effect on cellular transformation. 
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Taken together, BNIPXL inhibits RhoA activation via its BCH domain by 
sequestering Lbc, thereby suppressing Lbc-induced cellular transformation (Figure 
1.17b) (Soh and Low, 2008).  
 While there are ample examples of BCH domain functioning as a regulatory 
domain for Rho GTPases signaling that it is likely to act in concert with other 
immediate regulators such as RhoGAP and RhoGEF, a few studies also show that 
BCH domain can serve as a regulatory module when present in cis within the 
molecule. p50RhoGAP, which has a BCH domain at its N terminus and a C-terminal 
RhoGAP domain, exists in an autoinhibited state as mediated in part by an 
intramolecular interaction region within its BCH domain (Moskwa et al., 2005). A 
recent study further demonstrates that this BCH domain-mediated inhibition of the 
adjacent RhoGAP activity requires an essential RhoA-binding moiety within the BCH 
domain, without which the RhoGAP domain is free to target RhoA for inactivation. 
This absolute requirement of the RhoA-binding moiety in BCH domain for regulating 
RhoGAP activity is complemented by the previously identified intramolecular 
interaction region. Intriguingly, the BCH domain of p50RhoGAP exerts its inhibitory 
effect only when in cis but not in trans. Taken together, BCH domain of p50RhoGAP 
binds RhoA through its RhoA-binding motif and sequesters it from inactivation by the 
adjacent RhoGAP domain (Figure 1.17c) (Zhou et al., 2010).  
          a 
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          b 
 
 
          c 
 
 
Figure 1.17 BCH domain functions as a regulatory module for Rho GTPases 
signaling. (a) BNIP-Sα, through overlapping regions in its BCH domain, interacts 
with both RhoA and p50RhoGAP in a mutually exclusive manner. As such, BNIP-Sα 
facilitates RhoA inactivation to promote cell rounding and apoptosis in part by 
sequestering p50RhoGAP and by displacing p50RhoGAP from RhoA. (b) Similar to 
BNIP-Sα, BNIP-XL BCH domain mediates interaction with RhoA and sequesters 
another of its immediate regulator, Lbc RhoGEF. These interactions suppress RhoA 
activation and lead to stress fibers disruptions and inhibition of cellular transformation 
triggered by oncogenic Lbc. (c) BCH domain of p50RhoGAP inhibits the activity of 
its adjacent GAP domain in cis by associating with RhoA via the RhoA-binding 
motif, which is further complement by intramolecular interactions existing within the 
BCH and GAP domains [Adapted from Zhou et al, 2006; Soh and Low, 2008; Zhou et 
al., 2010]. 
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1.5  Hypothesis and objectives  
 Along with the identification of BCH as the conserved region of homology 
between BNIP-2 and p50RhoGAP/Cdc42GAP and a novel protein-protein interaction 
domain that is capable of mediating homophilic interaction with itself and 
heterophilic interaction with other homologous BCH domains, it is established that 
BNIP-2 with type I BCH domain distribution has the ability to interact with 
p50RhoGAP that is of type II BCH domain organization (Low et al., 1999), as 
suggested by Boyd et al. (1994). In terms of function, association of BNIP-2 and 
p50RhoGAP is required neither in BNIP-2-induced cell elongation and membrane 
protrusions (Zhou et al., 2005), nor in BNIP-2-facilitated myogenic and neuronal 
differentiation (Kang et al., 2008). Heterophilic interactions between these two forms 
of BCH domain-containing proteins might therefore be involved in regulatory 
functions. 
 Indeed, mounting evidences from different studies on BCH domain-containing 
proteins have ascertained that BCH domains together form a class of regulatory 
module that mediates Rho GTPases signaling, which in turn govern multiple aspects 
of cellular dynamics. Notably, the regulatory effect of BCH domain extends not only 
to the Rho GTPases, but also to their immediate regulators - RhoGAPs and RhoGEFs. 
For instance, BNIP-Sα BCH domain mediates RhoA activation to induce cell 
rounding by displacement and sequestration of p50RhoGAP (Zhou et al., 2006), while 
BNIP-XL prevents RhoA activation by Lbc RhoGEF and inhibits cellular 
transformation via a similar mechanism (Soh and Low, 2008). Intriguingly, apart 
from regulation by accessory proteins, GAP activity of p50RhoGAP is also governed 
by intramolecular interactions and the adjacent BCH domain in cis (Zhou et al., 
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2010), clearly demonstrating the importance of BCH domain as a regulatory module 
for BCH domain-containing proteins-mediated Rho GTPase signaling. 
Apart from p50RhoGAP, BPGAP1 is another BCH domain-containing protein 
with a RhoGAP domain (Shang et al., 2003) and is held also by intramolecular 
interactions (Ravichandran and Low, unpublished). While this protein has been 
extensively characterized in terms of its functions, recent studies focus on its 
regulation by other interacting partners. In this regard, earlier work using 
immunoprecipitation studies with overexpressed proteins has shown that BNIP-2 
interacts with BPGAP1. When introduced separately into cells, both BNIP-2 and 
BPGAP1 induced cellular protrusions (Shang et al., 2003; Zhou et al., 2005), 
indicating the possibility of their involvement in common downstream pathways or 
processes. Taken together and via a candidate approach, we hypothesize that BNIP-2 
could potentially exert a regulatory function towards BPGAP1 through its BCH 
domain. With the ability of BCH domain-containing proteins to modulate RhoGAP 
activity and Rho GTPases signaling, we aim to decipher what impact does BNIP-2 
and BPGAP1 interaction have in these aspects. Furthermore, is/are there any effect(s) 
on cell physiology that is/are conferred by BNIP-2-BPGAP1 signaling? To this end, 
this thesis work aims to: 
i) ascertain that BNIP-2 and BPGAP1 interact endogenously; 
ii) investigate the involvement of BNIP-2-BPGAP1 interaction in Rho GTPase 
signaling; 
iii) determine the impact of BNIP-2 on BPGAP1 RhoGAP activity; 
iv) delineate the domain(s) and specific region(s) essential for their binding; and 
v) examine the cellular effect(s) mediated by BNIP-2-BPGAP1 interaction  
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 By identifying regulators of BPGAP1 and along with the understanding on the 
mechanisms underlying its regulation, it is hoped that a greater insight on the 





Figure 1.18 Schematic representation of the objectives in the study of BNIP-2 
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2 Materials and Methods 
 
2.1 Generation of expression plasmids  
2.1.1 Cloning and expression vectors 
 Constructs used in this study were kindly provided by colleagues for re-
transformation and subsequent usage, cloning into expression vectors using 
Polymerase Chain Reaction (PCR) or sub-cloning. Identities of the cloned constructs 
were confirmed by DNA sequencing and their expressions in the mammalian cells 
were verified. For generation of internal deletion and domain truncation mutants, 
secondary structure analyses of BNIP-2 and BPGAP1 were carried out using Jpred, a 
secondary structure prediction server (available at 
http://www.compbio.dundee.ac.uk/www-jpred/), to avoid disruption of any 
recognizable secondary structure motifs such as α-helices and β-sheets. Two types of 
expression vector, pXJ40 and pGEX-4T-1, were utilized for inducing protein 
expression in mammalian and bacterial systems, respectively.  
 
2.1.1.1 pXJ40 expression vector series 
pXJ40 expression vector (courtesy of Dr. E. Manser, Institute of Molecular 
and cell Biology, Singapore), a 4.3 kb plasmid vector, can be differentially tagged to 
insert a FLAG epitope (DYKDDDDK), a hemagglutinin (HA) epitope 
(YPYDVPDYA) or other fluorescence protein sequences such as green fluorescence 
protein (GFP) at the N-terminal of the expressed protein. A pXJ40-mCherry vector 
encoding for fluorescence protein mCherry was generated for the purpose of this 
study. Expression of the target genes was driven by cytomegalovirus (CMV) 
promoter and enhancer flanking the multiple cloning sites (MCS). The vector also 
  Chapter 2 Materials and Methods 
 68 
harbors a β-globin intron to improve gene expression in mammalian cells and an 
ampicillin-resistance gene to facilitate selection of the plasmids in bacteria.  
 
2.1.1.2 pGEX-4T-1 expression vector 
 pGEX-4T-1 (Amersham Biosciences) is a 4.95 kb vector plasmid that contains 
a Glutathione S-Transferase (GST) gene immediately upstream of the MCS and this 
feature allows generation of a N-terminal GST-tagged fusion protein. Within the 
vector, there is an ATG start site in the GST gene, a ribosome-binding site controlled 
by tac promoter and inducible by 1 to 5 mM Isopropyl Thio-β-D-Galactoside (IPTG), 
an ampicillin-resistance gene, as well as a thrombin cleavage site that allows removal 
of the GST protein.  
 
2.1.2 Polymerase Chain Reaction  
 For designing of primers used in PCR, online program NEBcutter V2.0 
(http://tools.neb.com/NEBcutter2/) was utilized to search for restriction enzymes that 
do not cut the sequence in query and BioMath Calculators available on Promega 
website (http://www.promega.com/biomath/) was employed to calculate the melting 
temperatures (Tm) of oligonucleotides. PCR was performed using plasmid constructs 
as templates and the respective designed primers as listed in Table 2.1. In general, a 
50 μl reaction was set up to contain the template, 0.2 nM of dNTPs, 0.2 μM each of 
forward and reverse primers, 1 x DyNAzyme EXT buffer and 1 U of high fidelity 
DyNAzyme EXT DNA polymerase (Finnzymes). For templates longer than 1 kb, 2.5 
U of Pfu Turbo DNA polymerase (Stratagene) and its corresponding 1 x buffer were 
used instead. PCR reaction was carried out in a thermal cycler (BioRad) under the 
following cycling conditions: an initial denaturation step at 94 oC for 2 mins, followed 
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by 30 iterative cycles of denaturation at 94 oC for 30 s; annealing at the appropriate 
Tm for 30 s and extension at 72 oC for 40 s/kb, and a last step of final extension at 72 
oC for 10 mins before maintaining the mixture at 4 oC.  
 
Table 2.1 Primer sequences used for cloning. The template and primer sequences 
used for cloning the various constructs are listed as follow. F: Forward; R: Reverse. 
 
Construct name Template Primer Sequence 
BNIP-2 Δ167-184 FLAG-BNIP-2 F: 5’ CCC CTC GAG TAC CTG ATG GAC 
AAT CTT TTT AAA 3’ 
R: 5’ CCC CTC GAG GGC ATT TAA TCC ATC 
CCC ATA ATA 3’ 
BNIP-2 Δ185-211 FLAG-BNIP-2 F: 5’ CCC CTC GAG AAT GGT GCA ACA 
ACT CGA AGA AAA 3’ 
R: 5’ CCC CTC GAG TCT ATA GTT AGG CTG 
ACT ACT TTC 3’ 
PGAP (168-281) FLAG-BPGAP1 F: 5’ CCC AAG CTT CAG AGC CTG CAC 
GAG GGC 3’  
R: 5’ CCC C TC GAG CTA GGT CAG AAG 
CGG CTG 3’ 
PGAP (168-310) FLAG-BPGAP1 F: 5’ CCC AAG CTT CAG AGC CTG CAC 
GAG GGC 3’  
R: 5’ CCC CTC GAG CTA GAG GCT CCG 
TAA GAT CTG 3’ 
pXJ40-mCherry  
vector 
pmCherry-C1 vector  
(Clonetech 
Laboratories) 
F: 5’ AAA GAA TTC ACC ATG GTG AGC 
AAG GGC GAG GAG G 3’  
R: 5’ AAA GGA TCC CTT GTA CAG CTC 
GTC CAT GC 3’ 
pXJ40-mCherry-
BPGAP1 
FLAG-BPGAP1 F: 5’ CCC AAG CTT CG ACC ATG GCT GGC 
CAG GAT CCT 3’  
R: 5’ CCC GGT ACC CTA GAG ACG TCT TCT 





F: 5’ CCC AAG CTT CG ACC ATG GCT GGC 
CAG GAT CCT 3’  
R: 5’ CCC GGT ACC CTA GAG ACG TCT TCT     
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2.1.3 Agarose gel electrophoresis 
 Agarose gels of 1 to 2 % (w/v) were first casted by dissolving agarose (1st 
Base) in 1 x TAE buffer and SYBR®Safe DNA gel stain (Invitrogen Life 
Technologies) was added at a dilution of 1:50 000 for visualization of DNA bands 
under ultraviolet (UV) radiation. Separation of DNA fragments mixed with 6 x 
Loading Dye (Fermentas), alongside with either GeneRulerTM 100bp DNA ladder 
Plus or 1 kb DNA ladder (Fermentas), was carried out using agarose gel 
electrophoresis in 1 x TAE buffer [40 mM Tris-base; pH 8.0 with glacial acid, 10 mM 
EDTA].  
 
2.1.4 Gel extraction  
 Images of the size-fractioned DNA bands after gel electrophoresis were 
captured using Quantity One 1-D analysis software of Molecular Imager Gel Doc XR 
system (BioRad). Alternatively, for gel extraction, DNA bands were visualized under 
the ultraviolet transilluminator at 50 % UV radiation and the desired bands were 
excised quickly using a sterile blade. DNA was extracted and purified using 
QIAquick gel extraction kit (Qiagen) in accordance with manufacturer’s protocol. 
 
2.1.5 Restriction enzyme digestion 
 Gel purified PCR products were digested at 37 oC for 4 to 8 hrs with 25 U 
each of the respective restriction enzymes predetermined during primer design. Each 
μg of vector plasmid was similarly digested with 4 U each of the restriction enzymes. 
All reactions were carried out in 1 x reaction buffer and/or BSA as recommended by 
manufacturer’s instructions and with total enzyme composition not exceeding 10 % of 
the reaction volume. Restriction enzymes were selected base on their presence in the 
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MCS of vectors but yet do not cut within the sequence of interest. In general, the 
cloning sites used for generation of BNIP-2 constructs were Hind III and Sma I, while 
those used for BPGAP1 constructs were Hind III and Xho I. After digestion, the 
released fragments were separated using gel electrophoresis and the desired products 
were extracted and purified.  
 
2.1.6 Ligation 
 Next, a ligation mixture comprising 200 U of T4 DNA Ligase (New England 
Biolabs), 1 x Ligase buffer, as well as insert DNA and vector DNA at a molar ratio of 
3:1 was set up. For generation of internal deletion mutants, the insert and vector DNA 
were replaced by single restriction enzyme digested PCR product for self-ligation. 
The ligation reaction was carried out either at room temperature for 4 hrs or overnight 
at 4 oC.    
 
2.1.7 Preparation of competent cells (Escherichia coli strain DH5α) 
 E. coli DH5α is a strain of bacteria commonly used for cloning due to 
presence of a mutation in the endA gene that reduces the level of endonuclease 
activity, thereby allowing production of high yield and high purity DNA. To prepare 
competent E. coli DH5α, bacteria cells were first streaked onto antibiotics-free Luria 
Bertani (LB) agar plate for overnight incubation at 37 oC. A single colony was then 
picked, inoculated into 5 ml of antibiotics-free LB broth and cultured overnight at 37 
oC with constant agitation at 250 rpm. On the following day, starter culture was added 
into 50 ml of antibiotics-free LB broth at a dilution ratio of 1:500 and grown at 37 oC 
with shaking at 250 rpm until the optical density (OD) measured at 600 nm fell within 
the range of 0.3 to 0.6. Next, the bacteria culture was kept on ice for 10 mins and 
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centrifuged at 5500 rpm for 15 mins at 4 oC to pellet the cells. The cell pellet was 
reconstituted by gentle vortexing in 17 ml (approximately 1/3 of original culture 
volume) of ice-cold calcium/manganese based buffer (CCMB) [80 mM CaCl2.2H2O, 
20 mM MnCl2.4H2O, 10 mM MgCl2.6H2O, 10 mM KoAc, 10 % (v/v) glycerol; final 
pH 6.4] before further incubating on ice for 20 mins. Lastly, the bacteria suspension 
was centrifuged at 3000 rpm for 10 mins at 4 oC, after which the pellet was again 
resuspended in 4 ml (approximately 1/12 of original culture volume) of chilled 
CCMB. Aliquots of competent cells were snap-frozen in liquid nitrogen and stored at 
-80 oC. 
 
2.1.8 Plasmid transformation into bacteria 
2.1.8.1 Heat shock transformation  
 For cloning, ligated products were introduced into competent E. coli DH5α by 
heat shock transformation. A 100 μl aliquot of frozen competent cells was thawed on 
ice into which the ligated product was added and mixed gently by tapping. Next, the 
mixture was kept on ice for 30 mins and subjected to a brief heat-shock at 42 oC for 
90 s. After heat shock, the mixture was immediately incubated on ice for 2 mins and 
900 μl of antibiotics-free LB broth was added. The bacteria cells were then allowed to 
recover by incubating at 37 oC for 1 hr with constant shaking at 250 rpm. After 
recovery, these cells were briefly centrifuged at 800 rpm for 1 min. Excess LB broth 
was removed to concentrate the cells into 100 μl for plating onto LB agar containing 
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2.1.8.2 Re-transformation by KCM 
 To propagate the plasmid DNA, DNA uptake into competent E. coli DH5α 
was facilitated by KCM method. A small volume of DNA of approximately 0.2 to 0.5 
μl was added into 15 μl of pre-chilled KCM solution [100 mM KCl, 30 mM CaCl2, 50 
mM MgCl2] and mixed with an equal volume of freshly thawed E. coli DH5α 
competent cells. The mixture was left on ice for 30 mins and plated on LB agar 
containing 100 μg/ml of ampicillin. The plates were then incubated overnight at 37 
oC.  
 
2.1.9 Plasmid extraction and purification 
 Single colonies of plasmid-containing bacteria grown successfully on 
ampicillin-containing LB agar plate were individually picked and inoculated into 5 ml 
of ampicillin-containing LB broth for growing overnight at 37 oC with constant 
agitation at 250 rpm. Subsequently, the bacteria culture may be used directly for 
plasmid DNA isolation and purification using Miniprep kit (Axygen or Qiagen) or as 
a starter culture for overnight culturing of a larger volume (50 ml) of bacteria to be 
used for extraction of plasmid DNA by Midiprep  (Axygen or Qiagen), both 
according to manufacturer’s instructions.  
 
2.1.10 Quantification of plasmid DNA by spectrophotometry 
 After DNA extraction, the quantity and purity of plasmid DNA was assessed 
by spectrophotometry. Concentration of DNA can be calculated from the absorbance 
value at 260 nm, while a ratio of absorbance values at 260 nm and 280 nm (ratio 
260/280) of within 1.8 to 2.0 indicates that the DNA is of high purity with minimum 
contamination. To determine DNA concentration, the plasmid DNA was diluted 200 
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times in deionized water, the same type of solvent used for DNA elution, and its 
absorbance was measured at 260 nm. Actual DNA concentrated was then calculated 
with the following formula: DNA concentration (μg/ml) = OD260nm x dilution factor x 
50 μg/ml.  
 
2.1.11 Colony screening by PCR 
 Single colonies of bacteria grown on ampicillin-containing LB plate after heat 
shock transformation were screen using colony PCR for positive clones containing the 
desired plasmid constructs. In brief, single colonies were individually picked and 
resuspended in 10 μl of sterile deionized water for use as template in PCR. Reaction 
mixtures were set up as outlined in section 2.1.2 for DNA amplification with 
DyNAzyme II DNA polymerase (Finnzymes) under the following cycling conditions: 
an initial denaturation step at 94 oC for 2 mins, followed by 25 iterative cycles of 
denaturation at 94 oC for 30 s; annealing at 55 oC for 30 s and extension at 72 oC for 
40 s/kb, and a last step of final extension at 72 oC for 10 mins. The amplified products 
were then resolved by agarose gel electrophoresis and visualized under UV. Positive 
colonies that contain the desired plasmid constructs were inoculated into 5 ml of 
antibiotics-containing LB broth and cultured overnight at 37 oC with shaking at 250 
rpm for subsequent plasmid extraction and quantification as described in sections 
2.1.9 and 2.1.10. 
 
2.1.12 DNA sequencing  
 To confirm the identity and to determine the exact nucleotide sequence of the 
cloned plasmids, DNA sequencing reactions of 5 μl were set up to contain the 
following components: 50 to 125 ng plasmid, 0.8 μM each of T7 promoter forward 
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(5’ TAATACGACTCACTAT 3’) or pXJ40 reverse (5’ 
GAGCGCAGCGAGTCAGTGAG 3’) sequencing primers in separate reactions, 1 μl 
Big-Dye Terminator Ready Reaction Mix and 1 μl of 5 x sequencing buffer. 
Sequencing products were generated in 25 iterative cycles with each cycle composed 
of denaturation at 96 oC for 30 s, annealing at 55 oC for 15 s and extension at 60 oC 
for 4 mins. During ethanol precipitation of the products, 5 μl of PCR sample was 
added to 80 μl of precipitating solution [3 μl of 3 M Sodium acetate; pH 4.6, 62.5 μl 
of 95 % ethanol, 14.5 μl of deionized water] and incubated at room temperature for 10 
mins. Precipitated DNA was centrifuged at 14 000 rpm for 10 mins and the DNA 
pellet was washed once with 500 μl of 75 % ethanol before centrifuging for another 5 
mins at 14 000 rpm. Lastly, the DNA pellet was dried on 85 oC heat block for 1 to 2 
min to remove any residual ethanol. To perform DNA sequencing, dried DNA pellet 
was reconstituted in 10 μl of HiDi formamide by vortexing and processed using the 
automated ABI PRISM 3130 Genetic Analyzer (Applied Biosystems). Sequencing 
results obtained were analyzed using DNAMAN sequence analysis software and 
BLAST (Basic Local Alignment Search Tool) program available on NCBI (National 
Center for Biotechnology Information) website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
 
2.1.13 Expression check of cloned constructs  
 Before carrying out experiments with the sequenced constructs, expression of 
proteins as encoded by these plasmids were first verified by transient transfection of 
the plasmid DNA into 293T cells as described in section 2.3.1 to obtain whole cell 
lysates for Western blot analysis as outlined in section 2.5.  
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2.2 Cell culture – Cell lines and maintenance 
2.2.1 293T  
 Human embryonic kidney 293T epithelial cell (American Type Cell Culture), 
hereby referred as 293T, is a highly transfectable clonal derivative of 293 adherent 
cell line stably expressing simian virus 40 (SV40) large T-antigen. These cells were 
cultured as monolayer on surface treated tissue culture dishes (Nunc) in RPMI 
(Roswell Park Memorial Institute)-1640 medium (Hyclone Laboratories) 
supplemented with 10 % (v/v) defined fetal bovine serum (PAA Cell Culture), as well 
as 2 mM L-glutamine, 10 mM HEPES, 2 g/L sodium bicarbonate, 100 U/ml penicillin 
and 100 U/ml streptomycin (all from Hyclone Labratories) and maintained in 
humidified 5 % CO2 incubator at 37 oC. For subculturing, the cell monolayer was 
trypsinized with 0.25 % trypsin-EDTA (Hyclone Laboratories) and harvested in 
serum-containing medium. An appropriate number of cells was seeded for subsequent 
experiments or general maintenance.  
 
2.2.2 CHO and CV-1 
 Epithelial-like CHO (Chinese Hamster Ovary) is a cell line derived from the 
ovary of an adult Chinese Hamster (Cricetulus griseus), while CV-1 is propagated as 
fibroblast initiated from the kidney of a male adult African green monkey 
(Cercopithecus aethiops) (American Type Cell Culture). Both cell types were grown 
as monolayer on surface treated tissue culture dishes (Nunc) in high glucose DMEM 
(Dulbecco’s modified Eagle’s medium) supplemented with 10 % (v/v) defined fetal 
bovine serum (PAA Cell Culture), as well as 3.7 g/L sodium bicarbonate, 1 mM 
sodium pyruvate, 100 U/ml penicillin and 100 U/ml streptomycin (all from Hyclone 
Labratories) and maintained in humidified 5 % CO2 incubator at 37 oC. To passage 
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the cells, cell monolayer was trypsinized using 0.25 % trypsin-EDTA (Hyclone 
Laboratories) and harvested in serum-containing medium. An appropriate number of 
cells was then seeded for subsequent experiments or general maintenance.  
 
2.3 Transient transfection 
2.3.1 293T and CHO  
 Transient introduction of plasmid DNA into 293T or CHO cells was 
performed using TransIT®-LT1 Transfection Reagent (Mirus Bio) in accordance to 
manufacturer’s protocol. Cells were grown for 18 to 24 hrs to achieve a confluency of 
approximately 50 % to 80 % and the culture medium was replaced with fresh 
complete growth medium just prior to transfection. As recommended, 3 μl of 
transfection reagent was diluted in 100 μl of serum-free medium and let stand for 5 
mins at room temperature. Care was taken to avoid any contact of the transfection 
reagent with walls of the plastic tubes. Next, 1 μg of high purity plasmid DNA was 
introduced into the pre-mixed solution and let stand for 20 mins at room temperature 
before being added drop-wise to the cells. The plates were swirled gently to ensure 
uniform distribution of transfection complexes and the cells were cultured for 18 to 24 
hrs at 37 oC in a humidified 5 % CO2 incubator. 
 
2.3.2 CV-1 
 A confluency of approximately 50 % at the time of transfection was desired 
for CV-1 and these cells were grown in antibiotics-free medium for 18 to 24 hrs on 
13-mm microscope cover glasses (EINST Technology) placed in 6-well cell culture 
dishes (Nunc). Just before transfection, the culture medium was replaced with serum-
free medium without any antibiotics and LipofectamineTM 2000 (Invitrogen Life 
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Technologies) was used for transfection according to manufacturer’s instructions. In 
brief, 2 μg of high purity plasmid DNA was added to 100 μl of Opti-MEM® I reduced 
serum medium (Gibco), while 4 μl of Lipofectamine transfection reagent was 
similarly diluted in 100 μl of Opti-MEM® medium and let stand for 5 mins at room 
temperature. Both solutions were later combined and further incubated for 20 mins at 
room temperature, after which it was added drop-wise to the cells. The plates were 
then swirled gently to ensure uniform distribution of transfection complexes and 
returned to 37 oC incubator with humidified 5 % CO2. To reduce toxicity to cells due 
to transfection reagent, medium containing the transfection complexes was replaced 
with fresh growth medium without antibiotics 4 hrs post-transfection.  
 
2.4 Immunoprecipitation studies 
2.4.1 Preparation of mammalian whole cell lysates 
 293T cells plated on 6-well cell culture dishes were transfected with construct-
containing expression plasmids or empty vectors as control as described in section 
2.3.1. At time of harvest, medium was aspirated from each well and cells were lysed 
with 250 μl of chilled RIPA (Radio Immuno Precipitation Assay) lysis buffer [50 mM 
Tris-HCl; pH 7.3, 150 mM sodium chloride, 0.25 mM EDTA, 1 % (w/v) sodium 
deoxycholate, 0.2 % (w/v) sodium fluoride, 1 % (v/v) Trition X-100] freshly 
supplemented with 5 mM sodium orthovanadate, 25 mM glycerol phosphate and 
protease inhibitors cocktail (Roche Applied Science). Harvested lysates were 
vortexed briefly and centrifuged at 14 000 rpm for 15 mins at 4 oC. Without 
disturbing the cell debris pellet, the supernatant was transferred into fresh tubes for 
subsequent experiments.  
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2.4.2 Semi-endogenous pull down and immunoprecipitation 
For semi-endogenous detection of protein-protein interaction, 5 μl of 
Glutathione Sepharose 4B beads (Amersham Biosciences) was added to a fraction of   
the whole cell lysates harvested from control cells or 293T cells transfected with 
either mammalian GST-tagged BPGAP1 or empty expression vector and incubated at 
4 oC for 3 hrs with constant rotation to facilitate binding of GST-tagged protein 
complexes to the beads. Semi-endogenous immunoprecipitation was performed in a 
similar manner using harvested whole cell lysates of 293T cells transfected with 
FLAG-tagged plasmids and protein complexes were immunoprecipitated with 5 μl of 
anti-FLAG® M2 Affinity Gel (Sigma-Aldrich) instead. After incubation, the beads 
were washed thrice, each with 1 ml of chilled RIPA lysis buffer. Bound proteins were 
then denatured in Laemmli loading buffer [0.1 M Tris-HCl; pH 6.8, 15 % (v/v) 
glycerol, 3 % (v/v) SDS, 7.5 % (v/v) β-mercaptoethanol, 0.005 % (w/v) bromophenol 
blue] at 85 oC for 5 mins and separated by gel electrophoresis for Western blot 
analysis.  
 
2.4.3 Co-immunoprecipitation  
In co-immunoprecipitation studies, whole cell lysates of 293T cells co-
transfected with FLAG- and HA-tagged expression plasmids were prepared as 
outlined in section 2.4.1. Similarly, 5 μl of anti-FLAG M2 beads was added to a 
portion of the supernatant and subjected to 3 hrs of immunoprecipitation at 4 oC with 
constant rotation. The beads were subsequently washed with ice-cold RIPA lysis 
buffer and heated in Laemmli loading buffer at 85 oC for 5 mins before running the 
samples on denaturing polyacrylamide gels for Western blot analysis.  
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2.5 Western blot analysis 
2.5.1 SDS-PAGE (Sodium Dodecyl Sulphate - Polyacrylamide Gel 
Electrophoresis) and electrophoretic transfer  
 Protein samples were resolved for analysis using varying percentages of SDS 
polyacrylamide gels according to molecular weight (MW) of the proteins. Different 
percentages of resolving SDS-containing polyacrylamide gels containing the 
following components: 10 % to 15% (v/v) acrylamide solution [40 % acrylamide/bis 
solution, 29:1 (3.3 % cross-linker concentration)] (Biorad), 0.375 mM Tris-HCl; pH 
8.8, 0.1 % (w/v) SDS, 0.0075 % (w/v) ammonium persulphate (APS) (Sigma) and 
0.05 % (v/v) N, N, N’, N’-tetramethylethylenediamine (TEMED) (Sigma) were first 
casted and allowed to polymerize. Next, stacking gel solution comprising 5% (v/v) 
acrylamide, 0.125 mM Tris-HCl; pH 6.8, 0.1 % (w/v) SDS, 0.0075 % (w/v) APS and 
0.08 % (v/v) TEMED was prepared and overlaid on the solidified resolving gel.  
 Sets of protein samples were loaded alongside the Precision Plus pre-stained 
protein standards (BioRad) and gel electrophoresis was carried out in Mini-
PROTEAN 3 electrophoresis system (BioRad) with 1 x electrophoresis buffer [25 
mM Tris-base (1st Base), 0.19 M glycine; pH 8.3, 0.1 % (w/v) SDS] at a constant 
current of 50 mA for 1 hr. After electrophoresis, the size-fractioned proteins were 
transferred onto PVDF membrane (Polyvinylidene fluoride Immobilon-P transfer 
membrane) (Millipore) in 1 x transfer buffer [33.7 mM Tris-HCl, 0.256 nM glycine, 
20 % (v/v) methanol, 0.1 % (w/v) SDS] at 100 V for 1 to 1.5 hrs in 4oC using Mini 
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2.5.2 Western blot detection 
 After completion of electrophoretic transfer process, the membranes were 
immersed in blocking buffer [1 x PBS (phosphate-buffered saline), 0.1 % (v/v) Tween 
20, 1 % (w/v) Bovine serum albumin (BSA) (Sigma)] and placed on an orbital shaker 
for blocking either 1 hr at room temperature or overnight at 4 oC. Next, the 
membranes were incubated in primary antibodies diluted in blocking buffer for 1 hr at 
room temperature or overnight at 4 oC, with gentle shaking. To remove any non-
specifically-bound antibodies, the membranes were rinsed 4 times with wash buffer 
(PBST) [1 x PBS, 0.1 % (v/v) Tween 20], each with 5 mins of constant agitation, 
before incubating with appropriate secondary antibodies diluted in wash buffer for an 
hour at room temperature on the orbital shaker.  Similarly, these blots were rinsed in 
wash buffer after secondary antibody incubation to remove any non-specifically-
bound antibodies and treated with Supersignal West Pico chemiluminiscent substrate 
(Thermo Scientific) to visualize the protein bands using either Kodak X-ray medical 
films (Eastman Kodak Company) or Fuji Super RX Blue medical X-Ray films 
(FUJIFILM Medical Systems USA).  
For re-probing of membrane with other primary antibodies, the original 
membrane was first stripped off of the bound antibodies in the presence of stripping 
buffer (pH 2) [25 mM glycine, 1 % (v/v) SDS] and constant agitation. Subsequently, 
the membrane was washed multiple times to remove any residual stripping buffer and 
blocked in blocking buffer before repeating the entire process beginning from primary 
antibody incubation.  
 Common primary antibodies used for detection of tagged proteins in this study 
include polyclonal anti-FLAG (Sigma) [1:10 000] and polyclonal anti-HA (Zymed) 
[1:2500]. Other protein-specific primary antibodies such as anti-RhoA and anti-
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PCNA (Santa Cruz Biotechnologies), anti-BNIP-2 and anti-BPGAP1 (purified in our 
laboratory), anti-phospho-Histone H3 (Millipore), anti-Histone H3 (Abcam) and anti-
β-tubulin (Invitrogen Life Technologies) were also used. Common secondary 
antibodies used were anti-mouse IgG and anti-rabbit IgG (Sigma) [1:2500].  
 
2.6 Antibody purification 
 Frozen sera of rabbits injected with His-tagged BNIP-2, obtained from one of 
our collaborators Dr. Lin Sheng-cai (Xiamen University, Xiamen, Fujian, China), or 
frozen sera of rabbits immunized with GST-tagged BPGAP1 by our colleague Dr. 
Lua B.L., were used for antibodies purification. To extract the respective antibodies, 
bacterially produced purified GST-BNIP2 proteins or His-tagged PGAP  (proline-rich 
region and GAP domain of BPGAP1) fragment was resolved by SDS-PAGE gel 
electrophoresis and immobilized onto PVDF membrane as described in section 2.5.1. 
A single long band corresponding to the approximate size of the protein was excised 
from the membrane and further cut into smaller pieces of dimension 1 mm by 1 mm. 
These small pieces of membrane were transferred to a tube containing 1 ml of serum 
and incubated overnight at 4oC with constant rotation. After removal of serum, the 
membrane pieces were washed repeatedly, each with 1.5 ml of TTBS [20 mM Tris-
Cl; pH 7.8, 0.1 % (v/v) Tween-20, 0.01% NaN3] supplemented with 0.5 M NaCl, until 
the measured absorbance at 280 nm dropped below 0.02. Antibodies were then eluted 
with 100 μl of 0.2 M glycine at pH 2.8 containing 0.02 % NaN3, and vortexed to 
release the bound antibodies. Following elution, the antibody solution was neutralized 
with 5 μl of 1 M Tris; pH 8.5 and stored at -80 oC in small aliquots. The antibody titre 
and specificity were tested subsequently.  
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2.7 In vivo RBD (Rho-binding domain) assay 
2.7.1 Expression and purification of GST-fusion proteins in bacteria  
 Plasmid vector pGEX-4T-1 containing the gene construct for GST fusion with 
Rho-binding domain of Rhotekin (GST-RBD) or the empty vector was re-transformed 
into E. coli DH5α competent cells and streaked onto LB agar plate containing 100 
μg/ml of ampicillin for overnight incubation at 37 oC. Single colonies for the 
respective plasmids were picked, inoculated into 5 ml of LB broth containing 
ampicillin and cultured overnight at 37 oC with constant agitation at 250 rpm. The 
starter culture was diluted into 100 ml of LB broth with ampicillin at a ratio of 1:500 
and grown at 37 oC, 250 rpm until the measured OD600nm fell within the range of 0.3 
to 0.6 before adding 10 μM of IPTG for overnight induction of protein production. 
Subsequently, the culture was centrifuged at 5500 rpm for 15 mins at 4 oC to pellet 
the cells and bacteria pellets were stored at -80 oC after supernatant was discarded.   
 
2.7.2 Preparation of beads  
Frozen pellets of GST-RBD and GST alone were thawed and reconstituted in 
10 ml of chilled lysis buffer [1 x PBS, 1 % (v/v) Triton X-100] freshly supplemented 
with 100 mM dithiothreitol (DTT) and protease inhibitors cocktail. The bacteria 
suspension was sonicated on ice using Sonicator XL 2020 (Misonix Incorporated) at 
20 % amplitude for 3 mins, with iterative cycles of 3 s pulses followed by 6 s of lag 
time. Lysed sample was then centrifuged at 5500 rpm for 1 hr at 4 oC to remove the 
cell debris. For binding, the supernatant was transferred to a fresh 15 ml falcon tube 
for overnight incubation with 300 μl of Glutathione Sepharose 4B beads at 4 oC with 
constant rotation. Next, the beads were washed thrice with 10 ml of chilled lysis 
buffer and twice with chilled 1 x PBS, each wash with centrifugation at 500 rpm for 1 
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min at 4 oC. After the last wash, the beads were resuspended in an equal volume of 1 
x PBS. 
To check for protein expression, 5 and 10 μl of beads suspension, together 
with 10, 25 and 50 μg of BSA, were separately prepared by denaturing the samples in 
Laemmli loading buffer at 85 oC for 5 mins. These samples were then resolved via 
SDS-PAGE, stained with Coomassie Brilliant Blue solution [0.2 % (w/v) Coomassie 
blue R250, 40 % (v/v) methanol, 10 % acetic acid] for an hour and destained with 
water.  
 
2.7.3 RhoA activity assay 
 Level of active RhoA in cells can be examined by using Rho-binding domain 
of Rhotekin - an effector of RhoA, which binds only to RhoA in the GTP-bound form. 
When bound, Rhotekin RBD inhibits both intrinsic and GAP-induced GTP 
hydrolysis, thereby giving a reflection on the amount of GTP-RhoA present (Ren and 
Schwartz, 2000). Cell transfected with the appropriate plasmids were lysed as 
outlined in section 2.4.1 and serial dilutions were performed to achieve 5 x, 10 x and 
20 x dilutions of the whole cell lysates. Subsequently, 10 μg of either GST-RBD or 
GST proteins bound to glutathione sepharose beads was added to 200 μl each of the 
diluted whole cell lysates and subjected to gentle rotation for 45 mins at 4 oC to allow 
binding. The beads were then washed thrice, each with 1 ml of RIPA buffer, before 
heating in Lamelli buffer to prepare for SDS-PAGE and Western blot analysis. The 
level of active RhoA was detected using either polyclonal anti-HA or monoclonal 
anti-RhoA [1:1000]. After detection, the blots were stained with amido black to 
ascertain equal loading of the GST-fusion proteins. 
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2.7.4 Statistical analysis 
 To enable quantitative comparison of active RhoA level in the presence or 
absence of proteins of interest, densitometry analysis of the protein bands on X-ray 
films was performed using gel analyzer function in ImageJ software 
(http://rsbweb.nih.gov/ij/). In brief, the bands of interest within a data set were 
outlined separately using the rectangular selection tool to generate lane profile plots, 
which reflect the mean intensity and number of pixels of each sample. Output of each 
dataset was presented on a spreadsheet as relative percentage of each band amongst 
all the bands analyzed.  
In the data analysis, densitometry profiles of active RhoA pulldown by 
Rhotekin-RBD were normalized against corresponding level of total RhoA present 
within the cells before comparing the relative amount present in each sample with the 
control sample. Means of 3 or more independent sets of experiments were tabulated 
and standard error mean was derived from division of the standard deviation by 
square root of sample size. The p-value was then generated using two-tailed Student’s 
t-test with unequal variance available in Microsoft Excel to determine the statistical 
significance across pairs of samples.  
 
2.8 Immunofluorescence studies 
2.8.1 Immunostaining  
 CV-1 cells seeded on coverslips and transfected as described in section 2.3.2 
were washed twice with 1 x PBS and fixed with pre-warmed 3.7 % paraformaldehyde 
for 15 mins at room temperature. After fixation, the coverslips were washed twice 
with 1 x PBS, followed by another 2 washes with 1 x PBS containing 50 mM 
ammonium chloride and washed twice again with 1 x PBS. To permeabilize the cells 
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for immunostaining, the coverslips were incubated with 1 x PBS containing 0.2 % 
(v/v) triton X-100 for 15 mins at room temperature and blocked for an hour at room 
temperature with blocking buffer [1 x PBS, 2 % (w/v) BSA, 2 % (v/v) defined fetal 
bovine serum].  
During primary antibody staining, the coverslips were incubated face-down 
for an hour at room temperature in 50 μl of blocking buffer containing diluted primary 
antibodies at the respective dilutions: monoclonal mouse anti-FLAG M2, clone M2 
(Sigma) [1:200], polyclonal rabbit anti-HA (Zymed) [1:100]. Filamentous actin was 
examined using Alexa Fluor® 633 phalloidin (Invitrogen) [1:200].  After incubation, 
the coverslips were washed thrice in 1 x PBS containing 0.2 % (v/v) triton X-100 and 
twice with 1 x PBS, with each wash lasting for 2 mins with constant shaking to 
remove any unbound primary antibodies. The cells were then stained with 
fluorophore-conjugated secondary antibodies by incubating the coverslips face-down 
in 50 μl of diluted secondary antibodies for 1 hr at room temperature. Common 
secondary antibodies used include Alexa Fluor® 488 donkey anti-mouse IgG, 568 
donkey anti-mouse IgG, 568 donkey anti-rabbit IgG, 633 goat anti-mouse IgG, 633 
goat anti-rabbit IgG and pacific-blue goat anti-mouse IgG (all from Invitrogen) 
[1:100]. After secondary antibody staining, the coverslips were similarly washed to 
remove any unbound antibodies and mounted onto glass slides using FluorSave 
reagent (Calbiochem) before leaving to dry overnight at room temperature.  
 
2.8.2 Immunofluorescence detection 
 For immunofluorescence analysis by confocal fluorescence microscopy, cells 
fixed and stained as outline in section 2.8.1 were viewed and imaged on Carl Zeiss 
Laser Scanning Microscope (LSM) 510 Meta at 63 x magnifications (Plan-
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Apochromat 63 x/1.4 NA oil objective lens). The captured images were merged using 
the LSM 510 software (Carl Zeiss).  
 To examine cell morphology and integrity of filamentous actin in CV-1 cells 
in the absence or presence of BNIP-2 and/or BPGAP1, fluorescence images of 
filamentous actin stained with Alexa Fluor® 633 phalloidin were captured using 
wide-field fluorescence Delta Vision Core at 10 x magnifications (PL FL 10 x/0.40 
NA air objective lens) and viewed with softWoRx software (Applied Precision). 
 
2.8.3 Statistical analysis 
 In statistical analysis on the significance of observed changes in cell 
morphology and integrity of stress fibers, at least 3 independent sets of experiments 
were performed and a minimum of 150 transfected cells per sample were evaluated. 
Transfected cells were scored for either rounding or shrinkage as one category and 
neither of the observed effects for the other. Similarly, for analysis of stress fiber 
integrity, transfected cells were divided into two groups based on the presence or 
absence of stress fiber. The data obtained were expressed as percentages of total 
number of transfected cells counted and mean values were computed from data 
derived from at least 3 independent sets of experiments. Standard error mean was 
expressed as division of standard deviation by square root of sample size. Statistical 
significance (p-value) across pairs of samples was analyzed using two-tailed 
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2.9 Proliferation studies 
2.9.1 Preparation of samples 
 CHO cells were seeded on 6-well cell culture dishes and transfected with 
various expression constructions as described in section 2.3.1. After 24 hrs of 
transfection, cells in the individual wells were washed once with 1 x PBS and treated 
with 0.25 % trypsin-EDTA before harvesting in equal volume of serum-containing 
medium. Cells in each sample were reseeded at 50 % into 10-cm tissue culture dishes 
(Nunc) each containing a 13-mm microscope cover glass and allowed to grow for the 
next 24 hrs post-transfection at 37 oC in a humidified 5 % CO2 incubator to achieve a 
confluency of approximately 50 % on the following day. 
 
2.9.2 BrdU (5-bromo-2’-deoxyuridine) cell proliferation assay 
 BrdU cell proliferation assay was performed using In Situ Cell Proliferation 
Kit, FLUOS (Roche Applied Science) according to manufacture’s protocol. At 24 hrs 
post-reseeding of the cells after transfection, the coverslip in each tissue culture dish 
was transferred using a sterile forceps into 12-well multi-dishes (Nunc) containing 
fresh growth medium. The cells were then incubated in 10 μM BrdU labeling solution 
diluted in fresh growth medium for an hour at 37 oC in a humidified 5 % CO2 
incubator to allow for incorporation of BrdU into the DNA of proliferating cells.  
After incubation, the cells were washed thrice in 1 x PBS and fixed with 
ethanol fixative solution [30 % (v/v) glycine solution (50 mM glycine; pH 2.0), 70 % 
(v/v) absolute ethanol] for 45 mins at room temperature. The coverslips were then 
washed twice with 1 x PBS and incubated in 4 M HCl for 10 to 20 mins at room 
temperature to denature the DNA. Next, the coverslips were washed thrice in 1 x PBS 
at 5 mins per wash with constant shaking to neutralize the acid before incubating in 
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blocking buffer [1 x PBS, 0.5 % (w/v) BSA, 0.1 % (v/v) Tween 20] at room 
temperature for 10 mins. To detect the incorporated BrdU by immunofluorescence, 
the coverslips were incubated face-down in 50 μl of immunolabelling solution 
containing flurophore-conjugated anti-BrdU antibody (anti-BrdU-FLUOS) diluted in 
blocking buffer at a ratio of 1:10, as well as monoclonal mouse anti-FLAG [1: 200]. 
After 1 hr of incubation at room temperature, the coverslips were wash thrice in 1 x 
PBS at 5 mins per wash with constant shaking.  
For identification of transfected cells, the coverslips were incubated face-
down in 50 μl of diluted Alexa Fluor® 633 goat anti-mouse IgG [1:100] for 1 hr at 
room temperature. Coverslips were washed to remove any unbound secondary 
antibodies and mounted onto glass slides using FluorSave reagent before leaving to 
dry overnight at room temperature. The cells were imaged using wide-field 
fluorescence Delta Vision Core at 10 x magnifications (PL FL 10 x/0.40 NA air 
objective lens) and viewed with softWoRx. 
 
2.9.3 Western blot analysis of proliferation markers 
2.9.3.1 Bradford assay  
 Cells seeded in 10-cm plates (Section 2.9.1) were lysed and harvested in RIPA 
buffer as described in section 2.4.1. Protein concentration of each sample was 
quantified using spectrophotometry analysis of the absorbance values of Bradford 
reagent measured at 595 nm after its addition to the samples. Protein standards of 0, 2, 
4, 6, 8 and 10 μg of BSA in 20 μl solutions were prepared from BSA stock solution 
(10 mg/ml) and these samples were prepared by diluting 1 μl of whole cell lysate into 
19 μl of deionised water. Next, 980 μl of freshly diluted Bradford reagent (1:5) was 
added to each of the 20 μl standards as well as samples and incubated for 15 mins at 
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room temperature before measuring their absorbance at 595 nm. A Bradford standard 
curve was plotted for calculating the concentrations of samples, which were then 
diluted accordingly to achieve equal protein concentration in each sample for Western 
blot analysis. 
 
2.9.3.2 Western blot analysis 
 Whole cell lysates of samples with equal protein concentration were denatured 
in Lamelli buffer and heated at 85 oC for 5 mins before separation by gel 
electrophoresis and immobilization onto membranes as outlined in section 2.5.1. 
Western blot analysis was carried out by incubating the cut membranes in the 
following primary antibodies diluted in blocking buffer: rabbit polyclonal anti-PCNA 
[1:1000], rabbit polyclonal anti-phospho-Histone H3 (Ser10) [1:3000] or mouse 
monoclonal anti-β-tubulin [1:1000], followed by incubation in the respective 
secondary antibodies for detection by chemiluminiscence as described in section 
2.5.2.  
 
2.9.4 Statistical analysis 
 Proliferation level of cells differentially transfected with various expression 
constructs was evaluated by BrdU and Western blot analysis of different proliferation 
markers in 3 independent sets of experiments. In BrdU cell proliferation assay, at least 
100 transfected cells per sample were imaged, scored for the presence or absence of 
BrdU, and expressed as relative percentages of total number of transfected cells 
counted. For analyzing the level of proliferation markers in each experimental set, 
levels of PCNA (Proliferating cell nuclear antigen) and phospho-Histone H3 (Ser10) 
in different samples were determined by densitometry analysis using ImageJ software 
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as detailed in section 2.7.4. Densitometry profiles of PCNA and phospho-Histone H3 
(Ser10) were then normalized against corresponding level of loading control β-tubulin 
before comparing the values of samples with vector control. Similarly, to assess 
statistical significance of the data obtained, means values and standard error mean 
were tabulated for calculation of p-values across pairs of samples using two-tailed 






























3.1 BNIP-2 is a bona fide endogenous interacting partner of BPGAP1  
 Using an overexpression system in immunoprecipitation study, BNIP-2 has 
previously been shown to bind BPGAP1 (Shang et al., 2003). To ascertain that BNIP-
2 is indeed an endogenous interacting partner of BPGAP1, lysates of control cells and 
293T cells transfected with mammalian GST-tagged BPGAP1 or empty vector were 
used in pull-down experiments with glutathione sepharose beads and probed with 
BNIP-2 antibodies. Endogenous BNIP-2 was detected in pull-downs from lysates of 
cells transfected with mammalian GST-BPGAP1 but not in those from cells 
expressing empty vector or untransfected cells (Figure 3.1b), thereby confirming that 
BNIP-2 is indeed a bona fide interaction partner of BPGAP1. BNIP-2 was resolved as 
multiple bands when analyzed by SDS-PAGE, which could represent either 
alternatively spliced isoforms or phosphorylated forms of BNIP-2 (Kang et al., 2008; 
Low et al., 1999). Neither reciprocal semi-endogenous immunoprecipiation studies 
involving overexpressed BNIP-2 and endogenous BPGAP1, nor immunoprecipitation 
studies of endogenous BNIP-2 and BPGAP1 were carried out due to the lack of 
specific antibodies for BPGAP1.  
Given that harvesting of cell lysates yields a mixture of proteins regardless of 
their cellular localization, we next examined where BNIP-2 and BPGAP1 interactions 
occur within the cells by co-expressing these two proteins in fibroblast CV-1 and 
analyzed their localization using confocal immunofluorescence microscopy. These 
cells have an extensive cytoplasmic area that allows for suitable analysis of protein 
localization within the cytoplasm and also for analysis of actin cytoskeleton network. 
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Consistent with earlier observations in other cell types including HeLa and Cos-1 
cells (Zhou et al., 2005), BNIP-2, when expressed alone, localized in the cytoplasm as 
punctate structures with distinct regions of concentration at the edges of cellular 
protrusions (Figure 3.2, first row). In comparison, BPGAP1 appeared more diffused 
within the cytosol (Figure 3.2, second row). However, when co-expressed, these two 
proteins co-localized at areas within the cytoplasm, as well as at the edges of cellular 
protrusions (Figure 3.2, third row merged image and inserts, white arrows), which 
further supports the finding that BNIP-2 interacts with BPGAP1 in vivo, at specific 
localities that might be important for certain cellular functions.  
       a 
                 
                   
 
       b  
 
 
Figure 3.1 BPGAP1 interacts with endogenous BNIP-2. (a) Schematic diagram of 
domain architecture of full-length BPGAP1 and BNIP-2. Domain boundaries were as 
indicated by the respective amino acid residue numbers. (b) 293T cells were 
transfected with either mammalian GST-tagged BPGAP1 or expression vector for 20-
24 hrs. Lysates of control or transfected cells were incubated with glutathione 
sepharose beads and the proteins pulled down were separated using SDS-PAGE, 
blotted and probed with anti-BNIP-2 antibodies to detect any bound endogenous 
BNIP-2 (first panel) and with anti-BPGAP1 antibodies to verify the presence of 
mammalian GST-BPGAP1 (second panel). Cell lysates were similarly analyzed by 
Western blot for detection of endogenous BNIP-2 (third panel) and overexpressed 
BPGAP1 (fourth panel). PD: Pull-down.  






Figure 3.2 BNIP-2 and BPGAP1 co-localized within the cytoplasm and at the 
edges of membrane protrusions. CV-1 cells were transfected with plasmids 
encoding HA-BNIP-2, FLAG-BPGAP1 or in combination as indicated for 20 hrs. 
After which, the cells were fixed, permeabilized and stained for indirect 
immunofluorescence detection by confocal fluorescence microscopy as described in 
Materials and Methods. HA-BNIP-2 and FLAG-BPGAP1 were labeled with 
polyclonal rabbit anti-HA and monoclonal mouse anti-FLAG antibodies, respectively, 
followed by the appropriate fluorophore-conjugated secondary antibodies. Regions of 
co-localization between HA-BNIP-2 (red) and FLAG-BPGAP1 (green) were 
represented by yellow spots in the merged image and inserts, indicated by white 
arrows. Scale bar, 20 μm. 
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3.1.1 BCH domains mediate heterophilic interaction between BNIP-2 and 
BPGAP1  
 BCH domain-containing proteins can form homo or heterodimers through 
their BCH domains (Low et al., 2000a; Shang et al., 2003). Therefore, it is plausible 
that interaction between BNIP-2 and BPGAP1 is mediated by their respective BCH 
domains. To test this possibility, transient transfection of two BPGAP1 mutants, each 
harboring a distinct moiety of either BCH domain or GAP domain with the proline-
rich region (PGAP) as depicted in Figure 3.3ai, was carried out to examine their 
ability to interact with endogenous BNIP-2 that has only a single recognizable BCH 
domain. Similar to full-length BPGAP1, its BCH domain was capable of binding to 
endogenous BNIP-2 (Figure 3.3b) and this demonstrates that the BCH domains 
mediate heterophilic interaction between BNIP-2 and BPGAP1. To our surprise, 
PGAP region of BPGAP1 was also able to capture endogenous BNIP-2.  Although 
the faster migrating band of BNIP-2 was weaker, it could be detected after longer 
exposure. This association between PGAP region and BNIP-2 therefore indicates that 
interaction between BNIP-2 and BPGAP1 is not due simply to heterophilic interaction 
of the BCH domains but also involves the PGAP region, which plays a role that is 
currently yet unclear.  
 In order to confirm that interaction between BNIP-2 and BPGAP1 occurs via 
BNIP-2 BCH domain and not its N-terminal region, mutant constructs corresponding 
to either of these regions (Figure 3.3aii) were co-transfected with full-length 
BPGAP1, BCH domain (BPGAP1) or PGAP region in immunoprecipitation studies. 
Figure 3.3c shows that while both BNIP-2 and its BCH domain alone were able to 
bind full-length and various domains of BPGAP1, no interaction was detected with 
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the N-terminal region, thereby confirming that BCH domain is indeed important for 
mediating heterophilic interaction between BNIP-2 and BPGAP1.  
 




     aii 
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Figure 3.3 BCH domains are important for heterophilic interaction between 
BNIP-2 and BPGAP1. (a) Schematic representations of full-length and truncation 
mutants of (i) BPGAP1: BCHP (BCH domain with proline-rich region; amino acids 
1-206), BCH (BCH domain; amino acids 1-167), PGAP (C terminus without BCH 
domain; amino acids 168-433) and of (ii) BNIP-2: N (N terminus without BCH 
domain, amino acids 1-166), BCH (BCH domain; amino acids 167-314). (b) 293T 
cells were transfected with FLAG-tagged BPGAP1 truncation mutants or expression 
vector as indicated for 20-24 hrs. Harvested lysates of control or transfected cells 
were subjected to immunoprecipitation with anti-FLAG M2 beads. Bound proteins, 
along with cell lysates, were separated by SDS-PAGE, blotted and probed with anti-
BNIP-2 antibodies for detection of endogenous BNIP-2 (first and third panel) and 
with anti-FLAG antibodies to verify the presence of overexpressed FLAG-tagged 
BCH (BPGAP1) and PGAP (second and fourth panel). (c) Transfected cells 
expressing HA-tagged BPGAP1 or its domains in the presence of FLAG-tagged 
BNIP-2 or its truncation mutants were harvested and lysates were subjected to 
immunoprecipitation with anti-FLAG M2 beads. Associated proteins and cell lysates 
were analyzed by Western blot and probed with anti-HA and anti-FLAG antibodies 
for detection of bound proteins (first and second panel), as well as expression of the 
constructs introduced (third and fourth panel). IP: Immunoprecipitates.  
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3.1.2 Possible associations of BNIP-2, BPGAP1 and RhoA in a tripartite 
complex 
 Having established the interaction between BNIP-2 and BPGAP1, we sought 
to decipher the relationship between these two proteins and RhoA as previous work in 
our laboratory has shown that BPGAP1 functions biochemically as a GAP towards 
RhoA in vivo (Shang et al., 2003). Through individual interactions of BPGAP1 with 
BNIP-2 and RhoA, it is possible that these associations could result in the formation 
of a tripartite complex. Alternatively, BNIP-2 might compete against BPGAP1 for 
binding to RhoA, hence preventing their interaction. To test these possibilities, 
immunoprecipitation studies were performed by co-expressing BPGAP1 with BNIP-2 
and RhoA, either together or separately as indicated, to determine if BPGAP1 could 
associate with both BNIP-2 and RhoA in the presence of each other. Subsequent 
analyses by Western blot revealed that RhoA was captured by BPGAP1 in the 
presence of BNIP-2 or vice versa (Figure 3.4). This result indicates the possible 
existence of a tripartite complex or in another instance; separate pools of BPGAP1 
could exist to interact with BNIP-2 and RhoA independently.  
 On the basis that proteins forming interacting complexes exist in close 
proximity in the same subcellular region to carry out specific functions, confocal 
immunofluorescence study was also carried out to explore the relationship between 
BNIP-2, BPGAP1 and RhoA. Interestingly, analyses of confocal microscopy images 
demonstrate that BNIP-2 together with BPGAP1, stained red and blue respectively, 
exhibit partial co-localization with GFP-RhoA (green) at regions within the cytoplasm 
and at the cell periphery. These areas of co-localization appeared white in the merged 
image and inserts as indicated by the white arrows (Figure 3.5). Taken together, it is 
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therefore possible that BNIP-2, BPGAP1 and RhoA could exist in a tripartite complex 







Figure 3.4 BPGAP1 associates with both BNIP-2 and RhoA in the presence of 
each other. 239T cells were transfected with FLAG-BPGAP1, HA-tagged BNIP-2 or 
RhoA as indicated by the + sign or with an equivalent amount of similarly tagged 
expression vector control, indicated by the – sign. Harvested lysates were subjected to 
immunoprecipitation with anti-FLAG M2 beads and associated proteins were 
separated on SDS-PAGE, blotted and detected with anti-HA (first and second panel) 
and anti-FLAG antibodies (third panel). Protein expression was verified by Western 
blot analyses of cell lysates using anti-FLAG (bottom panel) and anti-HA antibodies 






















Figure 3.5 BNIP-2, BPGAP1 and RhoA co-localize at regions within the 
cytoplasm and at the cell periphery. HA-BNIP-2, FLAG-BPGAP1 and GFP-RhoA 
were expressed in CV-1 cells, fixed after 20 hrs, permeabilized and stained for 
immunofluorescence detection by confocal fluorescence microscopy as described in 
Materials and Methods. The expressed HA-BNIP-2 and FLAG-BPGAP1 were 
labeled with polyclonal rabbit anti-HA and monoclonal mouse anti-FLAG antibodies, 
respectively, followed by the appropriate fluorophore-conjugated secondary 
antibodies. Co-localization of BNIP-2 (red), BPGAP1 (blue) and RhoA (green) at 
regions in the cytoplasm and cell periphery were represented by white spots in the 
merged image and inserts, indicated by white arrows. Scale bar, 20 μm. 
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3.2. BNIP-2 associates with Rho-like family of Rho GTPases, and the BCH 
domain mediates interaction of BNIP-2 or BPGAP1 with RhoA 
 Next, to further examine the possibility of tripartite complex formation 
between BNIP-2, BPGAP1 and RhoA using immunoprecipitation study, in which 
each of these three proteins was used separately to capture the remaining two 
proteins; one important prerequisite of this method is that there must not be any direct 
interaction between one pair of these proteins and in this case, BNIP-2 and RhoA. As 
such, this study was continued by first assessing whether BNIP-2 itself associates 
with RhoA.  
 
3.2.1 BNIP-2 interacts with RhoA  
 Within the Rho GTPase family, the three most well-characterized Rho 
GTPases – RhoA, Cdc42 and Rac1, were expressed in HA-epitope and tested for their 
ability to interact with BNIP-2 using immunoprecipitation study. Western blot 
analyses revealed that RhoA, as compared to Rac1 and Cdc42, was selectively co-
immunoprecipitated by BNIP-2 (Figure 3.6), suggesting that BNIP-2 may potentially 
function to regulate RhoA signaling as demonstrated for other BCH domain-
containing proteins including BNIP-Sα, BNIP-XL and p50RhoGAP (Soh and Low, 
2008; Zhou et al., 2010; Zhou et al., 2006).  
Interestingly, though BNIP-2 has previously been shown in 293T cells to bind 
Cdc42 in GST pull-down and conferred GAP activity towards Cdc42 via a non-
canonical arginine patch motif (Low et al., 1999; Low et al., 2000a; Low et al., 
2000b), interaction between these two proteins has not been directly observed when 
co-expressed for immunoprecipitation studies in this case. On the other hand, other 
studies have indicated that Cdc42 signaling was indeed necessary for BNIP-2 induced 
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cell elongation and membrane protrusions in MCF-7 (Zhou et al., 2005), and BNIP-2 
functions as a scaffold for Cdo signaling to Cdc42 during myogenic and neuronal 
differentiation in C2C12 and C17.2 neural precursor cells, respectively (Kang et al., 
2008; Oh et al., 2009). While the importance of functional association between BNIP-
2 and Cdc42 in some cell types could not be undermined, interaction between these 
proteins might vary under different cellular conditions and in different cell types.  
 
                     
 
 
Figure 3.6 BNIP-2 binds specifically to RhoA in 293T cells. Lysates of control cells 
and cells transfected with FLAG-BNIP-2, along with HA-tagged RhoA, Cdc42 or 
Rac1, were incubated with anti-FLAG M2 beads. Bound proteins were separated on 
SDS-PAGE, blotted and probed with anti-HA antibody. Similarly, whole cell lysates 
were analyzed by Western blot to verify expression of proteins using anti-HA and 





Consistent with previously reported observations (Roberts et al., 2008), RhoA 
proteins, as observed in immunofluorescence studies, were distributed in the 
cytoplasm, as well as localized to the plasma membrane of the cell (Figure 3.7, 
second row). Intriguingly, when BNIP-2 and RhoA were co-expressed, they exhibited 
regions of co-localization within the cell and in particular at area near the tips where 
BNIP-2 was found to be concentrated (Figure 3.7, third row merged image and 
inserts, white arrows).  This observed co-localization at specific localities reinforces 
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earlier finding that BNIP-2 interacts with RhoA as shown by immunoprecipitation 





Figure 3.7 BNIP-2 and RhoA co-localize at specific areas of cellular tips. HA-
BNIP-2, GFP-RhoA or in combination were expressed in CV-1 cells as indicated. The 
cells were fixed after 20 hrs, permeabilized and stained for immunofluorescence 
detection by confocal fluorescence microscopy as described in Materials and 
Methods. HA-BNIP-2 was first labeled with polyclonal rabbit anti-HA antibody, 
followed by the fluorophore-conjugated secondary antibody. BNIP-2 (red) and RhoA 
(green) co-localized within the cell, in particular at tips of cellular extensions, as 
represented by yellow spots in the merged image and inserts, indicated by white 
arrows. Scale bar, 20 μm.  
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3.2.2 RhoA and RhoC are enriched by BNIP-2 in immunoprecipitation 
 
RhoA, RhoB and RhoC, despite sharing a high sequence identity of 85 % and 
induce stress fibers in cells, are functionally different in several aspects. RhoA, which 
has been studied extensively for its major role in regulating actomyosin contractility, 
promotes oncogenic transformation, whereas RhoC is involved in cell migration and 
tumor metastasis. RhoB, on the other hand, participates mainly in endosomal 
trafficking and delivery of signaling proteins (Vega and Ridley, 2008; Wheeler and 
Ridley, 2004). These variations in functionalities may be attributed to differential 
localization, specific interactions or unequal affinities for regulators or target proteins. 
For instance, GEF XPLN (eXchange factor found in platelets, leukemic and neuronal 
tissues) acts solely on RhoA and RhoB, excluding RhoC (Arthur et al., 2002), while 
BCH domain of BNIP-XL, a regulator of RhoA and its positive regulator Lbc 
RhoGEF, associates specifically with RhoA and RhoC (Soh and Low, 2008). By 
acting through different targets, RhoA and RhoC perform distinct roles in processes 
such as migration and invasion (Vega et al., 2011). Associations with specific Rho 
isoforms may therefore provide an indication on the functional roles of interacting 
proteins. Thus, we sought to find out if BNIP-2 displays such differences in affinity 
towards these three Rho GTPases.  
BNIP-2, together with RhoA, RhoB or RhoC, were introduced into 293T cells 
and the lysates subjected to co-immunoprecipiation were analyzed by Western blot. 
Though BNIP-2 interacted with all three Rho isoforms, RhoA and RhoC were 
enriched in immunoprecipitation by BNIP-2, suggesting a preference towards these 
two proteins (Figure 3.8a). To confirm these selective interactions, reciprocal co-
immunoprecipitation was carried out and similarly, a comparatively weaker band 
corresponding to interaction between RhoB and BNIP-2 was observed (Figure 3.8b). 
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However, it is possible that weaker binding occurred as a result of differential 
localization but not due to variations in affinity towards the different Rho isoforms.  
 
        a 
                                  
 
        b 
 
        
 
Figure 3.8 BNIP-2 associates preferentially with RhoA and RhoC.  Expression 
constructs of (a) FLAG-BNIP-2 and HA-tagged RhoA, RhoB or RhoC; (b) HA-
BNIP-2 with each of the FLAG-tagged Rho isoforms, were introduced into the cells 
as indicated. Co-transfections of reciprocally tagged BNIP-2 and Cdc42 were 
included as negative control. Control and transiently transfected cells were lysed after 
20-24 hrs, immunoprecipitated with anti-FLAG M2 beads and associated proteins 
were analyzed using Western blot by probing with anti-HA (first panel) and anti-
FLAG antibodies (second panel). WCL were similarly resolved by SDS-PAGE and 
probed with anti-HA and anti-FLAG antibodies to verify the presence of 
overexpressed proteins (third and fourth panel).  
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3.2.3 BPGAP1 displays similar interaction profile to Rho isoforms as BNIP-2 
Next, we examined whether BPGAP1, a previously identified GAP for RhoA, 
could also interact with specific Rho isoforms. To investigate this through 
immunoprecipitation study, FLAG-BPGAP1 and HA-tagged RhoA, RhoB or RhoC 
were co-expressed in the cells and incubated with anti-FLAG M2 beads. Interestingly, 
BPGAP1 clearly demonstrated specificity towards RhoA and RhoC, as shown by 
their enrichment in the immunoprecipitates (Figure 3.9a). These preferential 
interactions were recapitulated in reciprocal immunoprecipitation studies in which 
HA-BPGAP1 was selectively captured by FLAG-tagged RhoA and RhoC (Figure 
3.9b). In contrast, only a weak interaction could be detected for BPGAP1 and RhoB. 
These results therefore indicated that BPGAP1 acts specifically towards RhoA and 
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Figure 3.9 BPGAP1 binds selectively to RhoA and RhoC. Immunoprecipitation 
studies were performed using lysates from control cells and cells co-expressing (a) 
FLAG-BPGAP1 and HA-tagged RhoA, RhoB or RhoC; (b) HA-BPGAP1 with each 
of the FLAG-tagged Rho isoforms. To detect the bound proteins, lysates were 
resolved on SDS-PAGE, blotted and probed with anti-HA (first panel) and anti-FLAG 
antibodies (second panel). WCL were also analyzed by Western blot to verify the 
expression of these proteins by anti-HA and anti-FLAG antibodies as indicated (third 





3.2.4 Both BNIP-2 and BPGAP1 target RhoA via the BCH domain 
Previous work has established that the respective BCH domain of BNIP-Sα, 
BNIP-XL and p50RhoGAP modulates RhoA signaling through direct binding of the 
protein and including its direct regulators in some instances (Soh and Low, 2008; 
Zhou et al., 2010; Zhou et al., 2006). Focusing on the associations of BNIP-2 and 
BPGAP1 with RhoA, we aimed to determine if these interactions are mediated by 
their respective BCH domains. To do so, RhoA was expressed in the cells together 
with expression vector control, BNIP-2, BPGAP1 or their truncation mutants as 
depicted in Figure 3.3a for immunoprecipitation studies. Of the two BNIP-2 
truncation mutants, only BCH (BNIP-2) could bind readily to RhoA, whereas no 
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binding was observed for the N-terminal alone (Figure 3.10). Hence, this indicates 
that the BCH domain is indeed responsible for the interaction of BNIP-2 with RhoA.  
Furthermore, both truncation mutants of BPGAP1 harboring the BCH domain, 
namely BCH (N terminus with BCH domain) and BCHP (BCH domain with proline-
rich region), were able to immunoprecipitate HA-RhoA (Figure 3.10). However, only 
a weak interaction could be detected between PGAP (C terminus without BCH 
domain) and RhoA despite BPGAP1 having GAP activity towards RhoA. This could 
be due to the high turnover, as well as transient nature of enzyme-substrate 
interaction. Collectively, these data demonstrate that BCH domains are essential for 
binding of RhoA by both BNIP-2 and BPGAP1, further raising the possibility that 
BCH domains of these two proteins might also function as regulatory modules for 
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Figure 3.10 BCH domains of BNIP-2 and BPGAP1 are important for RhoA 
binding. 293T cells were transfected with HA-RhoA, in the presence of expression 
vector control, full-length BNIP-2, BCH (BNIP-2), N terminal (N), full-length 
BPGAP1 or the respective domains as indicated, all expressed in FLAG-epitope. For 
immunoprecipitation studies, cell lysates were harvested after 20-24 hrs, incubated 
with anti-FLAG M2 beads and associated proteins were analyzed by Western blot. 
Bound and expressed proteins resolved by SDS-PAGE were probed with anti-HA 





3.2.4.1 RhoA binding motif of BNIP-2 lies within residues 167-211 of BCH 
domain 
 In the study of RhoA signaling regulation by BNIP-Sα, a unique RhoA 
binding motif has been identified to reside within BNIP-Sα BCH domain (residues 
133-177) (Zhou et al., 2006). Since BCH domains of BNIP-2 and BNIP-Sα share a 
high degree of sequence homology (85 %) (Zhou et al., 2002), it is possible that 
BNIP-2 may also contain a site for RhoA interaction. To identify the potential RhoA 
binding motif, sequence alignment of primary amino acid sequences of BNIP-2 and 
BNIP-Sα BCH domains was performed and residues within BNIP-2 BCH domain that 
correspond to RhoA binding motif of BNIP-Sα BCH domain were identified as the 
putative RhoA binding motif (courtesy of Dr. Zhou Y.T.) (Figure 3.11a).  
Next, to further examine if the putative RhoA binding motif of BNIP-2 
modulates binding to RhoA, a series of internal deletion mutants generated based on 
secondary structure predictions were tested for their ability to interact with RhoA 
using co-immunoprecipitation studies. Analyses of lysates of cells transfected with 
HA-RhoA and mutants expressed in FLAG-epitope (Figure 3.11b) by Western blot 
revealed that BNIP-2 mutant that is devoid of amino acid residues 167 to 211 of BCH 
domain could no longer associate with RhoA while the remaining internal deletion 
mutants all retained binding to RhoA (Figure 3.11c). Taken together, the region 
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comprising residues 167 to 211 of BNIP-2 BCH domain indeed constitutes a unique 
RhoA binding motif, suggesting that there may be a consensus sequence within BCH 
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Figure 3.11 Residues 167-211 of BNIP-2 BCH domain constitute a unique RhoA 
binding motif. (a) Amino acid sequence alignment of BNIP-Sα (AY078983) RhoA 
binding motif and BNIP-2 (U15173) BCH domain using BLASTp and formatted with 
BOXSHADE. (b) Schematic representation of expression plasmids encoding BNIP-2 
and its deletion mutants. Interaction of each protein with RhoA is denoted by either 
the positive (+) or negative (–) sign. (c) Lysates of cells co-transfected with FLAG-
tagged BNIP-2 BCH domain deletion mutants and HA-RhoA were subjected to 
immunoprecipitation by anti-FLAG M2 beads. Co-expression of HA-RhoA with 
FLAG-tagged full length BNIP-2, N terminal or expression vector control was 
included as controls. To detect associated proteins, immunoprecipitated lysates were 
separated using SDS-PAGE, blotted and probed with anti-HA (first panel) and anti-
FLAG antibodies (second panel). WCL were also analyzed by Western blot to verify 





3.2.4.2 B1 region (residues 34-74) of BPGAP1 BCH domain is important for 
RhoA binding 
 From the results of immunoprecipitation studies shown in Figure 3.10, it was 
found that RhoA was enriched by the BCH domain of BPGAP1, implying the 
existence of a RhoA binding region within this domain. To further define the specific 
region required for interaction with RhoA, immunoprecipitation studies as described 
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earlier were similarly employed to examine the RhoA binding abilities of various 
internal deletion and truncation mutants of BPGAP1 BCH domain (Figure 3.12a). As 
summarized in Figure 3.12a, mutants lacking amino acid residues 34 to 74 including 
ΔB1 and B23P, failed to interact with RhoA. Although deletion mutants ΔB1A (Δ34-
47) and ΔB1B (Δ48-74) were able to associate with RhoA, their interactions were 
very weak and sometimes undetectable, suggesting that residues 34 to 74 constitute 
the full region necessary for forming stable associations with RhoA (Figure 3.12b). 
Indeed, sequence alignment of p50RhoGAP and BPGAP1 BCH domains revealed 
that RhoA binding motif of p50RhoGAP (Zhou et al., 2010) corresponds to residues 
35 to 75 within BCH domain of BPGAP1 (Figure 3.12c). This further supports that 
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Figure 3.12 RhoA binding motif of BPGAP1 lies within B1 region (residues 34-
74) of its BCH domain. (a) Schematic representation of BPGAP1 and its BCH 
domain mutants. The positive (+) or negative (–) sign denotes the ability of each 
protein to bind RhoA. (b) Lysates of cells co-expressing each of the BPGAP1 BCH 
domain mutants and HA-RhoA as indicated were immunoprecipitated with anti-
FLAG M2 beads. BCH domain (BPGAP1) and expression vector were used as 
controls. For analyses, immunoprecipitates and cell lysates were resolved on SDS-
PAGE, blotted and probed with anti-HA (first and third panel) and anti-FLAG 
antibodies (second and fourth panel). IP: Immunoprecipitates. (c) Protein sequence 
alignment of p50RhoGAP (Q07960) RhoA binding motif and BPGAP1 (AAN40769) 
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3.2.4.3 BCH domains of BNIP-2 and BPGAP1 recognize specific forms of RhoA 
 Small GTPases can exist in either active GTP-bound or inactive GDP-bound 
state. BNIP-XL, a member of BNIP-2 family of BCH domain-containing proteins that 
regulates RhoA signaling via its BCH domain, has been shown to bind specific RhoA 
conformers in vivo (Soh and Low, 2008). Thus, we investigated whether BNIP-2 and 
BPGAP1, and their respective BCH domains, could also recognize specific RhoA 
conformers by examining their interactions with various RhoA constitutively active or 
dominant negative mutants. Constitutively active mutants G14V and Q63L are locked 
in an active conformation mimicking GTP-RhoA and thus rendering them 
constitutively active, whereas the mutant F30L behaves like wild-type RhoA but with 
an accelerated GDP to GTP exchange. Conversely, dominant negative mutant T19N 
could possibly hinder RhoA activation by sequestering multiple RhoGEFs, suggesting 
the presence of a higher GDP-RhoA level.  
From the results of immunoprecipitation studies, RhoA mutants F30L and 
T19N displayed enhanced interactions with both BNIP-2 and BPGAP1, as well as 
their BCH domains. In contrast, these proteins failed to associate with the 
constitutively active mutants G14V and Q63L (Figure 3.13a and b). Since both BNIP-
2 and BPGAP1 recognize RhoA that can cycle between active and inactive states but 
not to the constitutively active forms, it is likely that these proteins can detect RhoA 
conformation changes through their BCH domains as similar to BNIP-XL BCH 













































Figure 3.13 BCH domains of BNIP-2 and BPGAP1 mediate associations with 
specific forms of RhoA. FLAG-tagged (ai) BNIP-2; (aii) BNIP-2 BCH domain; (bi) 
BPGAP1 and (bii) BPGAP1 BCH domain was each tested for their interactions with 
different RhoA mutants, including constitutive active mutants G14V and Q63L, fast 
cycling mutant F30L and dominant negative mutant T19N, all expressed in HA-
epitope. After incubation of the cell lysates with anti-FLAG M2 beads, bound 
proteins were analyzed by Western blot and probed with anti-HA and anti-FLAG 
antibodies to detect the immunoprecipitated (first and second panel) and 
overexpressed proteins (third and fourth panel).  
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3.3 BNIP-2 functions in synergism with BPGAP1 to promote RhoA 
inactivation in vivo 
 So far, it is established that interaction between BNIP-2 and BPGAP1 occurs 
through their BCH domains, as well as PGAP region of BPGAP1, and both proteins 
associate with RhoA via distinct RhoA binding motifs within their BCH domains. On 
the basis that BPGAP1 exerts its GTPase activating activity towards RhoA in vivo to 
reduce active RhoA level (Shang et al., 2003) and BNIP-2 is able to associate with 
both BPGAP1 and RhoA via its BCH domain, RhoA activity assay was next carried 
out to explore the functional effect of BNIP-2 and BPGAP1 on RhoA activity.  The 
results of this assay are presented in the following sections. 
 
3.3.1 BNIP-2 promotes the reduction of RhoA activity by BPGAP1 in vivo  
While it has been established that BPGAP1 functions as a RhoGAP 
specifically towards RhoA in vivo (Shang et al., 2003), the role of BNIP-2 in 
regulating Rho GTPase activity remains unclear. Although BNIP-2 has previously 
been reported to display in vitro GAP activity towards Cdc42 via a non-canonical 
arginine patch in its BCH domain (Low et al., 2000b), this increment in Cdc42 
GTPase activity was not detected in vivo (Zhou et al., 2005). After assessing the 
interactions between BNIP-2, BPGAP1 and RhoA, we proceeded to investigate 
whether the individual proteins, as well as when present together, have any effect on 
RhoA activity in vivo.  
To do so, cells were transfected with expression plasmids of RhoA, along with 
either BNIP-2 or BPAGP1, or both. Harvested lysates were subjected to pull-down 
using pre-prepared GST-RBD- or GST-bound glutathione sepharose beads and the 
amount of active RhoA present in the cells was reflected by the magnitude of 
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interaction with RBD of Rho effector, Rhotekin, as described in Materials and 
Methods. Both GST-RBD- and GST-bound beads were first tested for their specificity 
towards GTP-RhoA such that the GST-RBD-bound beads were able to capture Q63L 
that mimicks GTP-RhoA but not T19N, whereas GST-bound beads function as 
control and could bind neither of the expressed proteins (Figure 3.14a).  
Results of RhoA activity assay demonstrate that in the presence of BPGAP1, 
the amount of active RhoA was reduced as compared to control cells that were 
overexpressing only RhoA proteins (Figure 3.14b, first panel, lane 3 and 4). This 
decrease is likely attributed to the enhancement of GTP hydrolysis stimulated by GAP 
activity of BPGAP1. Co-expression of BNIP-2 and RhoA, on the other hand, led only 
to a minimal decrease in RhoA activity (Figure 3.14b, first panel, lane 2). More 
importantly, introduction of BPGAP1 and RhoA in the presence of BNIP-2 further 
augmented the reduction in active RhoA amount to approximately half the magnitude 
of the control cells (Figure 3.14b, first panel, lane 1 and 4). Collectively, data from 
three independent sets of experiments reflect that BNIP-2 and BPGAP1, when co-
introduced into the cells, cooperate to induce a greater degree of suppression on RhoA 
activity (Figure 3.14c). This observation raises the possibility that BNIP-2 might 
function in synergism with BPGAP1 to enhance its GAP activity towards RhoA, 
thereby promoting RhoA inactivation.  
In assessing the binding specificity of BNIP-2 and BPGAP1, as well as their 
domains, to different RhoA mutants, a greater amount of mutant F30L was detected in 
the immunoprecipitates as compared to wild-type RhoA (Figure 3.13). Since the fast 
cycling mutant retains regular GTP hydrolysis, RhoA activity assay was similarly 
carried out with mutant F30L, in replace of wild-type RhoA, to corroborate the 
synergistic effect of BNIP-2 and BPGAP1 in decreasing active RhoA level. Indeed, 
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similar activity profile (Figure 3.14d) and trend (Figure 3.14e) were obtained for 
mutant F30L, thereby supporting the earlier observations obtained with wild-type 
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Figure 3.14 BNIP-2 promotes reduction of RhoA activity by BPGAP1 in vivo. (a) 
Lysates of 293T cells transfected with HA-tagged RhoA mutants Q63L or T19N were 
incubated with GST-RBD- or GST-bound beads to confirm the specificity of GST-
RBD. Associated active RhoA mutant Q63L and WCL were subjected to Western 
blot analyses using anti-HA antibody (first, third and bottom panel) and amido black 
staining was used to show equal loading of the beads (second and fourth panel). To 
measure Rho GTPase activity, (b) wild-type HA-RhoA with either HA-BPGAP1 or 
FLAG-BNIP-2 or both; (d) fast cycling mutant HA-RhoA (F30L) with either HA-
BPGAP1 or FLAG-BNIP-2 or both, were expressed in 293T cells as indicated for 20-
24 hrs, lysed and incubated with GST fusion of RBD of Rhotekin immobilized on 
glutathione sepharose beads as described in Materials and Methods. GST proteins 
were used as negative control (third panel). Bound active RhoA or RhoA (F30L) 
proteins were resolved on SDS-PAGE, blotted and probed with anti-HA antibody 
(first panel). Protein expression of RhoA or RhoA (F30L), BPGAP1 and BNIP-2 in 
the cell lysates was confirmed by Western blotting using the respective anti-HA or 
anti-FLAG antibodies (fifth, sixth and bottom panel). Equal loading of GST fusion 
proteins and GST proteins were shown using amido black staining in second and 
fourth panel, respectively. PD: Pull-down. For quantitative analysis, amount of active 
(c) wild-type RhoA; (e) RhoA (F30L), was normalized to total RhoA or RhoA (F30L) 
present in the cell lysates, respectively, and represented as fold of active RhoA or 
RhoA (F30L) relative to cells transfected with the respective forms of RhoA (set as 
1), as described in Materials and Methods. Data derived from three independent sets 
of experiments are expressed as mean + standard error mean and differences between 
values that are statistically significant at p < 0.05, measured by two-tailed Student’s t-
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3.3.2 Synergistic effect of BNIP-2 and BPGAP1 on RhoA inactivation is 
coupled to the GAP activity of BPGAP1 
 As a RhoGAP, BPGAP1 harbors an invariant arginine residue at position 232, 
which when mutated to alanine (R232A), results in the abolishment of its GAP 
activity (Shang et al., 2003). To further validate the hypothesis that BNIP-2 augments 
RhoA inactivation through enhancement of BPGAP1 GAP activity, RhoA activity 
assay was carried out using GAP inactive mutant BPGAP1(R232A) in the presence or 
absence of BNIP-2, together with RhoA as indicated. Certainly, Western blot analyses 
reveal that BPGAP1(R322A) alone failed to induce a significant decrease in active 
RhoA level as compared to the control consisting of overexpressed RhoA alone 
(Figure 3.15a, first panel, lane 3 and 4). Although there was a slight reduction in 
RhoA activity when BNIP-2 and BPGAP1(R232A) were co-transfected with RhoA in 
comparison to the control (Figure 3.15a, first panel, lane 1 and 4), no significant 
difference in active RhoA level was observed for cells co-expressing 
BPGAP1(R232A) and RhoA with or without BNIP-2 (Figure 3.15a, first panel, lane 1 
and 3).  
From the results of three independent sets of experiments, it is evident that 
BNIP-2 did not induce any significant decrease in active RhoA level when RhoA 
activity assay was performed with BPGAP1(R232A) mutant (Figure 3.15b), as 
opposed to the augmentation effect observed for wild-type BPGAP1 (Figure 3.14c). 
Taken together, these data therefore suggest that synergistic effect of BNIP-2 and 
BPGAP1 in promoting reduction of active RhoA level is coupled to the GAP activity 
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Figure 3.15 Synergistic effect of BNIP-2 and BPGAP1 on RhoA inactivation is 
coupled to the GAP activity. (a) 293T cells expressing wild-type HA-RhoA with 
either HA-BPGAP1(R232A) or FLAG-BNIP-2 or both were lysed 20-24 hrs post-
transfection and incubated with GST-RBD or GST immobilized on glutathione 
sepharose beads as described in Materials and Methods. GST proteins were used as 
negative control (third panel). Active RhoA proteins captured by the beads were 
analyzed by western blotting using anti-HA antibody (first panel), while expression of 
RhoA, BPGAP1(R232A) and BNIP-2 in the cell lysates were verified with the 
respective anti-HA or anti-FLAG antibodies (fifth, sixth and bottom panel). Equal 
loading of GST fusion proteins and GST proteins were shown by amido black 
staining in the second and fourth panel, respectively. PD: Pull-down. (b) For 
quantitative analysis, the amount of active RhoA was normalized to total RhoA 
present in cell lysates and represented as fold of active RhoA relative to cells 
overexpressing RhoA alone (set as 1), as described in Materials and Methods. Data 
derived from three independent sets of experiments are expressed as mean + standard 
error mean and differences between values that are statistically significant at p < 0.05, 
as measured by two-tailed Student’s t-test with unequal variance, are represented by 





 To ascertain that the lack of synergistic effect between BNIP-2 and GAP 
mutant BPGAP1(R232A) in reducing RhoA activity is not attributed to any lost of 
interaction between these proteins, immunoprecipitation studies were performed to 
verify their associations. Cells co-expressing BNIP-2 or RhoA with either BPGAP1 
or BPGAP1(R232A) were harvested for immunoprecipitation and subsequently 
analyzed by Western blot. As observed in Figure 3.16a, comparable amounts of 
bound BPGAP1 and BPGAP1(R232A) proteins were captured by BNIP-2, indicating 
that interaction between BNIP-2 and the GAP mutant was not affected. Similarly, 
BPGAP1(R232A) retains the ability to associate with RhoA (Figure 3.16b). 
Furthermore, investigations on the interaction between GAP mutant 
BPGAP1(R232A) and RhoA in the presence and absence of BNIP-2 did not reveal 
any differences (Figure 3.16c), similar to the interaction profiles for wild-type 
BPGAP1.  
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Consistent with results of the immunoprecipitation studies, regions of co-
localization were also observed for BNIP-2, BPGAP1(R232A) and RhoA in confocal 
immunofluorescence studies. These areas of co-localization appeared white in the 
merged image and inserts, as indicated by white arrows (Figure 3.17). It is therefore 
unlikely that the lack of synergistic effect between BNIP-2 and GAP mutant 
BPGAP1(R232A) in reducing RhoA activity is caused solely by any lost in 
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Figure 3.16 BPGAP1(R232A) displays similar interaction profile with BNIP-2 
and RhoA with respect to BPGAP1. 293T cells transiently transfected with FLAG-
tagged BPGAP1 or BPGAP1(R232A) were tested for their interaction with (a) HA-
BNIP-2 and (b) HA-RhoA, respectively. Harvested lysates were immunoprecipitated 
with anti-FLAG M2 beads and the bound proteins were resolved on SDS-PAGE, 
blotted and probed using anti-HA antibody (first panel). Expression of proteins was 
verified by Western blot analyses of cell lysates using anti-FLAG (fourth panel) and 
anti-HA antibodies (third panel). Blots separated by the dotted lines are from the same 
blot with same exposure time. (c) FLAG-BPGAP1(R232A), HA-tagged BNIP-2 or 
RhoA as indicated by the + signs or an equivalent amount of correspondingly tagged 
expression vector control indicated by the – signs, were introduced into 239T cells 
and the harvested lysates were subjected to immunoprecipitation with anti-FLAG M2 
beads. Associated proteins and WCL were analyzed by Western blot and probed with 
anti-HA and anti-FLAG antibodies to detect the bound proteins (first to third panel), 






















Figure 3.17 BNIP-2, BPGAP1(R232A) and RhoA exhibit regions of co-
localization. HA-BNIP-2, FLAG-BPGAP1(R232A) and GFP-RhoA were expressed 
in CV-1 cells, fixed after 20 hrs, permeabilized and stained for immunofluorescence 
detection by confocal fluorescence microscopy as described in Materials and 
Methods. For visualization of the expressed proteins, HA-BNIP-2 and FLAG-
BPGAP1 were labeled with polyclonal rabbit anti-HA and monoclonal mouse anti-
FLAG antibodies respectively, followed by the appropriate fluorophore-conjugated 
secondary antibodies. Co-localization of BNIP-2 (red), BPGAP1(R232A) (blue) and 
RhoA (green) at regions within the cell were represented by white spots in the merged 
image and inserts, indicated by white arrows. Scale bar, 20 μm. 
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3.3.3 BNIP-2 augments BPGAP1 RhoGAP activity to suppress endogenous 
RhoA activity in vivo 
The results obtained so far from RhoA activity assays using overexpressed 
RhoA have suggested that BNIP-2 functions in concert with BPGAP1 to promote 
GTP hydrolysis, thereby further reducing the amount of active RhoA present. As 
such, it is of interest to determine if such concerted action occurs endogenously to 
regulate RhoA activity. To do so, RhoA activity assay as described previously was 
performed using lysates of cells transfected with expression plasmids of BNIP-2, 
BPGAP1 or BPGAP1(R232A), either alone or together as indicated and the 
endogenous level of active RhoA was detected using monoclonal anti-RhoA antibody.  
Consistent with the results from RhoA activity assays performed with 
overexpressed RhoA, expression of BPGAP1 alone led to a decrease in the amount of 
active endogenous RhoA with respect to vector control (Figure 3.18a, first panel, lane 
3 and 4). The magnitude of RhoA inactivation in cells transfected with BNIP-2 alone 
was slightly lesser in comparison after normalization to total endogenous RhoA level 
(Figure 3.18b). When co-expressed, BNIP-2 and BPGAP1 concertedly suppress 
RhoA activity to a greater extent (Figure 3.18a, first panel, lane 1 and 4), similar to 
the results obtained with overexpressed RhoA. In contrast, inactivation of the 
RhoGAP activity of BPGAP1 abolished the synergism between BNIP-2 and BPGAP1 
in suppressing RhoA activity (Figure 3.18a, first panel, lane 1 and 5). A significant 
reduction in RhoA activity was observed only when the effect of BNIP-2 was coupled 
to BPGAP1, but not with the GAP mutant (Figure 3.18b, p < 0.05). In all, these data 
indicate that BNIP-2 functions in synergism with BPGAP1 to promote endogenous 
RhoA inactivation, likely through the enhancement of RhoGAP activity of BPGAP1.   
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Figure 3.18 BNIP-2 functions in concert with BPGAP1 to suppress endogenous 
RhoA activity. (a) To assay endogenous level of active RhoA, FLAG-BNIP-2, HA-
tagged BPGAP1 or BPGAP1(R232A) was expressed in 239T cells either alone or 
together. An equivalent amount of correspondingly tagged expression vector control 
denoted by the – sign was co-transfected as indicated to maintain a constant amount 
of DNA introduced into the cells. After 20-24 hrs, cell lysates were collected and 
incubated with either GST fusion of Rhotekin RBD immobilized on glutathione 
sepharose beads or with GST proteins as controls, as described in Materials and 
Methods. Subsequently, active RhoA proteins captured on GST-RBD beads and cell 
lysates were resolved on SDS-PAGE, blotted and probed with anti-RhoA antibody to 
detect the bound RhoA proteins (first panel) and endogenous total RhoA proteins 
(fifth panel). Similarly, protein expression of HA-tagged BPGAP1, BPGAP1(R232A) 
and FLAG-BNIP-2 was verified by Western blot analyses of WCL using anti-HA 
(sixth panel) or anti-FLAG antibodies (bottom panel). Equal loading of GST fusion 
proteins and GST proteins were shown using amido black staining in second and 
fourth panel, respectively. Blots separated by dotted line are from the same blot with 
same exposure time. PD: Pull-down. (b) For quantitative analysis, the amount of 
active RhoA captured by GST-RBD beads was normalized to total endogenous RhoA 
level in the cell lysates and represented as fold of active RhoA relative to vector-
expressing control cells (set as 1), as described in Materials and Methods. Data 
derived from three or more independent sets of experiments are expressed as mean + 
standard error mean and the different letters represent differences between values that 






3.4 Delineation of BNIP-2-BPGAP1 interacting regions  
 Since BNIP-2 promotes the RhoGAP activity of BPGAP1 to downregulate 
active RhoA level and these two proteins associate through their BCH domains, as 
well as via the PGAP region of BPGAP1, we aim to examine whether this synergism 
between BNIP-2 and BPGAP1 on RhoA inactivation is indeed brought about by the 
functional interaction of these proteins. To address this query, the binding regions 
between BNIP-2 and BPGAP1 are determined in an attempt to generate non-
interacting mutants for assessing the significance of their interaction on the 
synergistic effect observed.  
 
  Chapter 3 Results 
 131 
3.4.1 Residues 167-211 of BNIP-2 BCH domain constitutes the likely 
interacting region for BPGAP1 
 Results from co-immunoprecipitation studies performed earlier have 
demonstrated that BNIP-2 associates with BPGAP1 solely via its BCH domain 
(Figure 3.3c). To further delineate the region required for interaction, BNIP-2 BCH 
domain deletion mutants used previously for identifying the RhoA binding motif were 
tested for their ability to interact with BPGAP1 using immunoprecipitation studies. 
Subsequent western blot analyses of the lysates of cells co-expressing HA-BPGAP1 
and BNIP-2 mutants expressed in FLAG-epitope reveal that interaction with BPGAP1 
was much reduced when amino acid residues 167-211 were deleted from BNIP-2 
BCH domain, though not completely abolished. On the other hand, associations of 
BPGAP1 with other mutants remained intact (Figure 3.19bi).  
Interestingly, the region within BNIP-2 BCH domain that is important for 
binding to BPGAP1 overlaps with the previously identified RhoA binding motif. To 
further delineate the region necessary for interaction with BPGAP1, two internal 
deletion mutants, each comprising of a subdivision of the region from residues 167-
211, were generated based on secondary structure predictions to avoid disruption of 
any major secondary structures such as α-helices and β-sheets (Appendix, Figure 
S1a). Both of these constructs Δ167-184 and Δ185-211, expressed in FLAG-epitope, 
were used in immunoprecipitation studies together with BPGAP1. While deletion of 
the entire region ranging from residues 167 to 211 weakens the binding to BPGAP1 
considerably, removal of smaller sub-regions did not disrupt the interactions to a 
similar extent comparatively (Figure 3.19bii). A summary of the binding profile of 
full-length BPGAP1 to various BNIP-2 deletion mutants is shown in Figure 3.19a. 
Earlier, it has been demonstrated that BNIP-2 associates with both BCH domain and 
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PGAP module of BPGAP1. Therefore, immunoprecipitation studies were also carried 
out to examine if these associations are mediated by separate regions within BNIP-2 
BCH domain. However, no apparent differences were seen in the interaction profiles 
of BNIP-2 mutants with BCH domain or PGAP region as compared to full-length 
BPGAP1 (Appendix, Figure S2).  
Taken together, the interacting region between BNIP-2 and BPGAP1 
comprises at least residues 167 to 211 of BNIP-2 BCH domain and may extent to the 
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Figure 3.19 Residues 167 to 211 of BNIP-2 BCH domain are required for 
interaction with BPGAP1. (a) Schematic diagram of BNIP-2 and its deletion 
mutants. Binding abilities of BPGAP1 to the various mutants were summarized and as 
indicated by the positive (+) or negative (-) sign. (bi) and (bii) Lysates of cells co-
transfected with each of the FLAG-tagged BNIP-2 BCH domain deletion mutants and 
HA-BPGAP1 as indicated were subjected to immunoprecipitation by anti-FLAG M2 
beads. Co-expression of FLAG-tagged full length BNIP-2, N terminal or expression 
vector control with HA-BPGAP1 was included as controls. To detect the associated 
proteins, immunoprecipitated lysates were separated using SDS-PAGE, blotted and 
probed with anti-HA (first panel), before stripping and re-probing with anti-FLAG 
antibodies (second panel). WCL were also analyzed by Western blot to verify the 
expression of proteins (third and fourth panel).  
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 A further examination of BNIP-2 mutant Δ167-211 by confocal 
immunofluorescence microscopy reveals that in opposed to the unique distribution of 
wild-type BNIP-2 that concentrates at the edges of cellular protrusions, such 
distinctive accumulations were rarely observed in cells transfected with this mutant. 
BNIP-2, when devoid of residues 167 to 211, appeared more localized within the 
main body of the cell and away from peripheral regions (Figure 3.20), suggesting that 
this region might be involved in the trafficking of this protein.  A noticeable amount 
of floating cells were also seen following the transfection of 293T cells with this 
mutant. In addition, since deletion of this region affects the binding of BNIP-2 to both 
RhoA and BPGAP1, use of this mutant to examine whether the synergistic effect is 




Figure 3.20 BNIP-2 mutant Δ167-211 fails to display the characteristic 
localization of wild-type BNIP-2. To study cellular distribution of FLAG-BNIP-2 
mutant Δ167-211, CV-1 cells were transfected with the expression plasmid encoding 
this mutant. Cells were fixed after 20 hrs, permeabilized and labeled first with 
monoclonal mouse anti-FLAG antibody, followed by Alexa Fluro 488 donkey anti-
mouse IgG. After which, the labeled cells were visualized by confocal fluorescence 
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3.4.2 Multiple regions within BPGAP1 mediate interaction with BNIP-2 BCH 
domain  
 In Figure 3.3, the immunoprecipitation results demonstrate that both BCH 
domain and PGAP module of BPGAP1 mediate interactions with BNIP-2. In order to 
define the specific interaction motifs, two different sets of mutants, each 
encompassing different regions within BCH or GAP domain, were assessed 
separately for their ability to associate with full-length BNIP-2. The interaction 
profiles are shown in the following sections.  
 
3.4.2.1 B1 region (residues 34-74) of BPGAP1 BCH domain is important for 
binding BNIP-2  
 To find out the residues within BPGAP1 BCH domain that are required for 
binding to BNIP-2, the set of deletion mutants used previously for identification of 
BPGAP1 RhoA binding motif was tested for interaction with BNIP-2 using co-
immunoprecipitation studies. As revealed by Western blot analyses of the 
immunoprecipitated lysates, BNIP-2 displays a similar interaction profile to BPGAP1 
BCH domain deletion mutants as RhoA (Figure 3.21a). In summary, deletion mutants 
that lack amino acid residues 34 to 74, including ΔB1 (Δ34-74) and B23P, failed to 
bind BNIP-2, while mutants ΔB1A (Δ34-47) and ΔB1B (Δ48-74) that encompass 
only part of B1 region associate weakly with this protein. Conversely, enrichment of 
BNIP-2 protein was observed selectively with mutants containing the full B1 region. 
Taken together, these data suggest that residues 34 to 74 are required for mediating 
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Figure 3.21 B1 region (residues 34-74) of BPGAP1 BCH domain mediates 
interaction with BNIP-2. (a) Schematic representation of BPGAP1 and its BCH 
domain deletion mutants. Binding abilities of different mutants to BNIP-2 were 
summarized and as indicated by the positive (+) or negative (-) sign. (b) Plasmids 
encoding HA-BNIP-2 and each of the FLAG-tagged BPGAP1 deletion mutants or 
vector control were introduced into 293T cells as indicated. Transiently transfected 
cells were lysed, incubated with anti-FLAG M2 beads and immunoprecipitated 
proteins were analyzed using Western blot by probing with anti-HA (first panel) and 
anti-FLAG antibodies (second panel). WCL were similarly resolved by SDS-PAGE 
and detected with anti-HA and anti-FLAG antibodies to verify the presence of 
overexpressed proteins (third and fourth panel).  
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3.4.2.2 A full composite GAP domain confers binding to BNIP-2  
 We next proceeded to map the BNIP-2 binding region on PGAP module. In 
addition to the current set of PGAP mutants available, two more GAP domain 
truncation mutants covering residues 168-281 and 168-310 were generated based on 
secondary structure predictions (Appendix, Figure S1b). To define the residues that 
are involved in mediating interaction with BNIP-2, immunoprecipitation studies were 
carried out using a series of PGAP truncation mutants (Figure 3.22a). Interestingly, 
deletion of different sub-regions of PGAP module failed to disrupt the interaction 
with BNIP-2 (Figure 3.22b), unlike the presence of a unique BNIP-2 interacting motif 
within BPGAP1 BCH domain. These results therefore suggest that the full composite 
PGAP region confers binding to BNIP-2.  
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Figure 3.22 A full composite PGAP region confers binding to BNIP-2. (a) 
Schematic diagram of BPGAP1 and its PGAP truncation mutants. (b) Lysates of cells 
co-expressing FLAG-BNIP-2 and each of the HA-tagged PGAP mutants or 
expression vector control were subjected to immunoprecipitation with anti-FLAG M2 
beads. Associated proteins and cell lysates were resolved on SDS-PAGE and 
analyzed by Western blot using anti-HA and anti-FLAG antibodies for detecting the 
bound proteins (first and second panel), as well as for verifying protein expression 




 In the context of this study, deletion of both B1 region within BCH domain 
and the entire GAP domain to generate a non-interacting mutant is experimentally not 
feasible due to the requirement of the GAP domain for assessment of GAP activity in 
subsequent functional assays. Since synergistic effect between BNIP-2 and BPGAP1 
can be abolished with the use of the GAP inactive mutant BPGAP1(R232A) as shown 
by RhoA activity assay (Figure 3.15), this mutant was employed in subsequent studies 
to further investigate the physiological effect(s) of BNIP-2-BPGAP1 interaction on 
RhoA inactivation.  
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3.5 BNIP-2 promotes the ability of BPGAP1 to induce loss of stress fiber via 
its GAP domain in vivo 
 Earlier results from RhoA activity assays on both overexpressed and 
endogenous RhoA have demonstrated that BNIP-2 functions in synergism with 
BPGAP1 to promote RhoA inactivation via the GAP activity of BPGAP1. To further 
determine the physiological function of BNIP-2 and BPGAP1 interaction on RhoA 
inactivation, we proceeded to examine the effects of these two proteins on stress fiber 
formation downstream of RhoA as it is well established that activation of RhoA 
induces formation of stress fibers within the cells (Hall, 1998). CV-1 cells, used 
earlier for confocal immunofluorescence microscopy in this study, display an 
extensive actin cytoskeleton network that allows for analysis of stress fibers. To 
visualize the stress fibers, CV-1 cells expressing the proteins-of-interest or expression 
vector controls as indicated were stained with Alexa Fluor 633 phalloidin to label the 
filamentous actin as described in Materials and Methods. Vector control and 
transfected cells expressing the intended proteins were analyzed using wide-field 
fluorescence microscopy and scored for the number of transfected cells exhibiting 
phalloidin staining which indicates presence of stress fibers. Representative fields of 
cells are shown in Figure 3.23a.  
Consistent with the reduction of RhoA activity as demonstrated in RhoA 
activity assay, 70 % of the cells co-expressing BNIP-2 and BPGAP1 did not show any 
phalloidin staining. This percentage is higher in comparison to single expression of 
either BNIP-2 or BPGAP1 alone. On the other hand, presence of BNIP-2 did not 
appear to affect the percentage of cells that are without phalloidin staining in cells 
expressing the GAP mutant BPGAP1(R232A), with respect to cells transfected with 
BPGAP1(R232A) alone (Figure 3.23b). A comparison of single expression of the 
  Chapter 3 Results 
 140 
GAP mutant with wild-type BPGAP1 shows a 20 % difference in the loss of stress 
fibers. This finding implies that the observed effect on stress fibers are in part due to a 
reduction in RhoA activity brought about by the GAP activity of BPGAP1. 
Intriguingly, 40% of the transfected cells still exhibit loss of stress fiber even when 
the RhoGAP activity was abolished, suggesting the presence of an alternative 
pathway mediated by BPGAP1 that might affect stress fiber.  
Taken together, introduction of BNIP-2 along with BPGAP1 resulted in a 
small but statistically significant increase in the loss of stress fibers as compared to 
the extent induced by BPGAP1 alone. However, BNIP-2, when present together with 
BPGAP1(R232A), failed to induce a concerted effect on the loss of stress fiber with 
respect to expression of the GAP mutant alone. These results therefore imply that 
synergism between BNIP-2 and BPGAP1 on RhoA inactivation affects stress fiber 














  Chapter 3 Results 
 141 










  Chapter 3 Results 
 143 





Figure 3.23 BNIP-2 promotes BPGAP1-induced loss of stress fiber in vivo. (a) 
Representative fields of CV-1 cells expressing vector control, FLAG-BNIP-2, HA-
tagged BPGAP1 or BPGAP1(R232A) or in various combination as indicated. Cells 
were fixed after 20 hrs, permeabilized and stained for immunofluorescence detection. 
Stress fibers were labeled with Alexa Fluor 633 phalloidin for visualization by wide-
field fluorescence microscopy and the expressed proteins were detected with 
polyclonal rabbit anti-HA and monoclonal mouse anti-FLAG antibodies, followed by 
the appropriate fluorophore-conjugated secondary antibodies. Scale bar, 50 μm. (b) 
For quantitative analysis, at least 150 transfected cells per sample per experiment 
were scored for with or without stress fiber and expressed as percentages. Data 
derived from three or more independent sets of experiments are expressed as mean + 
standard error mean and the different letters represent differences between values that 
are statistically significant at p < 0.02, as measured by two-tailed Student’s t-test with 





3.6 BNIP-2 augments RhoGAP activity of BPGAP1 leading to enhanced cell 
rounding in vivo 
 During the examination of stress fibers, it was noticed that a population of the 
cells transfected with BPGAP1 or together with BNIP-2 exhibited rounding or drastic 
cell retraction/shrinkage. Indeed, alterations in actin cytoskeleton are often associated 
with corresponding changes in cellular morphology. In a recent study on p50RhoGAP 
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– a close relative of BPGAP1, it is established that the GAP domain of p50RhoGAP 
triggers cell rounding though inactivation of RhoA (Zhou et al., 2010). Working on 
this basis, we proceeded to investigate the individual and combined effects of BNIP-
2, BPGAP1 or GAP inactive mutant BPGAP1(R232A) on the morphology of 
transfected cells. As described in the previous section for examination of stress fiber, 
transfected cells were scored for changes in cellular morphology including those that 
were round or exhibit drastic cell retraction/shrinkage. Representative fields of cells 
are shown in Figure 3.24a.  
Similar to vector control, introduction of BNIP-2 alone did not result in any 
rounding or drastic retraction/shrinkage of the cells. When BPGAP1 was expressed, 
approximately 30 % of the transfected cells became round or show drastic 
retraction/shrinkage. In contrast to cells transfected with BNIP-2 alone, co-expression 
of BNIP-2 together with BPGAP1 resulted in cell rounding and retraction/shrinkage 
in 42 % of the transfected cells, implying that these two proteins function in 
synergism to induce changes in cellular morphology. More importantly, introduction 
of BNIP-2 and the GAP mutant BPGAP1(R232A) did not further promote the extent 
of morphological changes that were already observed in cells transfected with 
BPGAP1(R232A) alone. In addition, abolishment of the catalytic RhoGAP activity of 
BPGAP1 with the use of GAP inactive mutant BPGAP1(R232A) attenuates cell 
rounding or retraction/shrinkage, thereby indicating that such morphological changes 
are indeed a consequence of the GAP activity of BPGAP1. Collectively, these data 
confirm that BNIP-2 functions in synergism with BPGAP1 to enhance GAP-induced 





  Chapter 3 Results 
 145 
       a 
 





  Chapter 3 Results 
 147 





Figure 3.24 BNIP-2 augments BPGAP1 RhoGAP activity leading to enhanced 
cell rounding in vivo. (a) Representative fields of CV-1 cells expressing vector 
control, FLAG-BNIP-2, HA-tagged BPGAP1 or BPGAP1(R232A) or in various 
combination as indicated. Transiently transfected cells were fixed after 20 hrs, 
permeabilized and stained for immunofluorescence detection. Stress fibers were 
labeled with Alexa Fluor 633 phalloidin for visualization by wide-field fluorescence 
microscopy and the expressed proteins were detected with polyclonal rabbit anti-HA 
and monoclonal mouse anti-FLAG antibodies, followed by the appropriate 
fluorophore-conjugated secondary antibodies. Scale bar, 50 μm. (b) For quantitative 
analysis, at least 150 transfected cells per sample per experiment were scored for cells 
that were round or exhibit drastic retraction/shrinkage and expressed as percentages. 
Data derived from three or more independent sets of experiments are presented as 
mean + standard error mean. Differences between values that are statistically 
significant at p < 0.02, measured by two-tailed Student’s t-test with unequal variance, 





3.7 BNIP-2 and BPGAP1 concertedly suppress cell proliferation  
 Apart from the classical role of Rho GTPases in regulating actin cytoskeleton, 
RhoA is also implicated in the regulation of cell cycle progression and its 
overexpression has been reported in many cancer types (Karlsson et al., 2009). 
Although BPGAP1 functions as a GAP towards RhoA, its upregulation has 
surprisingly been detected in colorectal tumors irrespective of tumor location, stage or 
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level of differentiation (Johnstone et al., 2004), as well as in cervical cancer (Song et 
al., 2008). In addition, studies on BNIP-2 family of BCH domain-containing proteins 
have also revealed that these proteins are involved in processes associated with 
cancer, for instance apoptosis in the case of BNIP-2 and BNIP-Sα and transformation 
for BNIP-XL (Belcredito et al., 2001; Bonner et al., 2004; Scott et al., 2010; Soh and 
Low, 2008; Zhou et al., 2006). To explore whether the decrease in active RhoA level 
as induced by BNIP-2 and BPGAP1 concertedly will have any effect on the 
proliferation ability of cells, which is an important factor during initial tumor growth, 
the level of proliferation markers were determined by Western blot analyses using 
specific antibodies against the respective markers.  
Single expression of either BNIP-2 or BPGAP1 resulted in a reduction in the 
amount of PCNA (proliferating cell nuclear antigen) and phosphorylated form of 
Histone H3 (residue serine10) as compared to cells transfected with only the vector 
controls (Figure 3.25a, first and second panel, lane 2-4). Introduction of BNIP-2 and 
BPGAP1 together further decreased the protein level of these markers as seen in 
Figure 3.25a (first and second panel, lane 1). Conversely, cells transfected with both 
BNIP-2 and the GAP mutant did not appear to show a similar degree of protein 
reduction with respect to expression of BPGAP1(R232A) alone. In all, the data 
derived from three or more independent sets of experiments, after normalization to 
tubulin as the loading control, reveal that co-expression of BNIP-2 and BPGAP1 
resulted in a significantly lower level of proliferation markers including PCNA 
(Figure 3.25bi) and phospho-Histone H3 (Ser10) (Figure 3.25bii).  
 Alternatively, BrdU assay was performed to study the proliferation states of 
transfected cells expressing the proteins-of-interest. To do so, the cells were incubated 
with 5-bromo-2’deoxyuridine (BrdU), a thymine analogue that can be incorporated 
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into cells undergoing DNA synthesis (S phase of cell cycle). Subsequently, these cells 
were labeled with fluorescein-conjugated anti-BrdU monoclonal antibody as 
described in Materials and Methods to enable visualization of the incorporated BrdU. 
Vector control and transfected cells expressing the indicated proteins were then 
analyzed by wide-field fluorescence microscopy and scored for the number of 
transfected cells exhibiting positive BrdU staining.  Interestingly, only the population 
of cells that were expressing both BNIP-2 and BPGAP1 differ in the level of cell 
proliferation as reflected by the proportion of cells undergoing DNA synthesis (Figure 
3.25c). Representative fields of cells are shown in Figure 3.25d. Collectively, these 
data therefore indicate that BNIP-2 and BPGAP1 concertedly suppress proliferation, 



















       bi 
 
 
   
 
 














































  Chapter 3 Results 
 152 
































  Chapter 3 Results 
 155 
Figure 3.25 BNIP-2 and BPGAP1 concertedly suppress cell proliferation. (a) 
CHO cells expressing BNIP-2, BPGAP1 or BPGAP1(R232A), either alone or in 
combination were reseeded at 24 hrs and lysed after 48 hrs. An equivalent amount of 
correspondingly tagged expression vectors denoted by the – sign was co-transfected 
to maintain a constant amount of DNA introduced into the cells. Harvested lysates of 
transfected cells were separated by SDS-PAGE, blotted and probed with antibodies 
against proliferation markers including anti-PCNA (first panel) and anti-phospho-
Histone H3 (Ser10) (second panel), as well as with anti-FLAG and anti-BPGAP1 
antibodies to verify the presence of overexpressed BNIP-2 (fifth panel), BPGAP1 and 
BPGAP1(R232A) (bottom panel). Total Histone H3 and tubulin were used as loading 
controls (third and fourth panel). For quantitative analysis, the amount of (b) PCNA 
and (c) phospho-Histone H3 (Ser10) were normalized to the level of tubulin in cell 
lysates and represented as relative intensity to the vector-expressing control cells (set 
as 1), as described in Materials and Methods. Data derived from three or more 
independent sets of experiments are expressed as mean + standard error mean and the 
different letters represent differences between values that are statistically significant 
at p < 0.05, measured by two-tailed Student’s t-test with unequal variance. (d) 
Quantitative analysis of BrdU assay. The ratio of transfected cells with and without 
BrdU was scored and at least 100 transfected cells were counted per sample per 
experiment. Data from three independent sets of experiments are presented as mean + 
standard error mean and the asterisk indicates differences between values that are 
statistically significant at p < 0.02, measured by two-tailed Student’s t-test with 
unequal variance. (e) Representative fields of CHO cells expressing vector controls, 
FLAG-BNIP-2, mCherry-BPGAP1 or BPGAP1(R232A) or in combination as 
indicated. Transiently transfected cells were incubated with BrdU, fixed and labeled 
with fluorescein-conjugated anti-BrdU monoclonal antibody as described in Materials 
and Methods before visualizing with wide-field fluorescence microscopy. Scale bar, 
10 μm.  
 
 



































4.1 BNIP-2 acts in synergism with BPGAP1 to downregulate RhoA activity  
Previous studies on characterizing the functions of various BCH domain-
containing proteins have established that BCH domain mediates the diverse spectrum 
of cellular dynamics associated with these proteins (Figure 1.16). Notably, BCH 
domain has widely been implicated in small GTPases signaling, and its role as an 
accessory regulatory module for the small GTPases and their regulators (Soh and 
Low, 2008; Zhou et al., 2006) is of particular interest. In this study, endogenous 
BNIP-2 is confirmed as a bona fide interacting partner of BPGAP1, further supported 
by regions of co-localization of these two proteins in the cell.  
With its unique localization at the leading edge of cellular protrusions, BNIP-2 
induces cell elongation and protrusions through the Cdc42 signaling pathway (Low et 
al., 1999; Low et al., 2000a; Low et al., 2000b; Zhou et al., 2005). In addition, it 
contributes to both myogenic and neuronal differentiations by facilitating the 
integration of Cdc42 and p38α/β MAPK signaling pathways (Kang et al., 2008; Oh et 
al., 2009). Although previous studies on the functions of BNIP-2 are centered on its 
association with Cdc42, we herein focus on its effect on another Rho GTPase – 
RhoA, for which BPGAP1 has been demonstrated to serve as a RhoGAP specifically 
for RhoA in vivo (Shang et al., 2003). Immunoprecipitation studies using transient 
expression system have established that BNIP-2 could interact with RhoA specifically 
via its BCH domain and interestingly they co-localized predominantly at regions of 
cellular protrusions where BNIP-2 are concentrated. This interaction is not too 
unexpected given that many other BCH domain-containing proteins such as BNIP-Sα, 
BNIP-XL, p50RhoGAP and including BPGAP1 as shown in this study, have also 
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been found to interact with RhoA through their BCH domains (Soh and Low, 2008; 
Zhou et al., 2010; Zhou et al., 2006). Intriguingly, despite the presence of a highly 
conserved BCH domain, BNIP-H, a brain-specific member of the BCH domain-
containing protein family, fails to interact with RhoA. This further highlights the 
specificity in interaction between each of the BCH domain-containing proteins with 
RhoA.  
 Results from immunoprecipitation studies have revealed that BPGAP1 is able 
to associate with both BNIP-2 and RhoA in the presence of each other, which could 
indicate independent associations of BPGAP1 with either BNIP-2 or RhoA, or 
association of these three proteins in a tripartite complex. Co-localization of BNIP-2, 
BPGAP1 and RhoA in the cells further suggests that they could exist in a functional 
complex. These observations are at first glance surprising given that BNIP-2 interacts 
with both BPGAP1 and RhoA via a common motif within its BCH domain. However, 
since deletion of RhoA binding region (residues 167-211) within BNIP-2 BCH 
domain totally abolished the interaction between BNIP-2 and RhoA but not its 
binding with BPGAP1, hence there is no complete overlap of the RhoA binding 
region with the BPGAP1 interacting site. Moreover, the extent of loss of binding 
between BNIP-2 and BPGAP1 was reduced when deletion mutants encompassing 
smaller regions within residues 167 to 211 were used, implying that the occlusion of a 
smaller motif will not lead to a complete loss of interaction between BNIP-2 and 
BPGAP1. Whether the RhoA binding region of BNIP-2, predicted using sequence 
alignment with the established RhoA binding motif of BNIP-Sα, constitutes the 
minimal region required for interaction, needs to be further elucidated using deletion 
mutants that cover smaller motifs. This overlapping of the RhoA binding region with 
BPGAP1 interactive motif on BNIP-2 BCH domain may on the other hand serves to 
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facilitate close association of BPGAP1 with RhoA. Indeed, a similar model of 
association is also observed for Myosin phosphatase-Rho Interacting Protein (M-RIP) 
whose RhoA binding region overlaps with the site for mediating interaction with 
myosin binding subunit (MBS) of myosin phosphatase, thereby bringing RhoA into 
close proximity with MBS for regulation of myosin phosphorylation state (Surks et 
al., 2003).   
 Besides having a highly conserved GAP domain that is required for catalyzing 
the GTPase activity of Rho GTPases, RhoGAPs contain multiple additional functional 
modules. The presence of varying combinations of these different domains allow for 
spatiotemporal regulation of these RhoGAPs through recruitment of other interacting 
partners that may serve as regulators, facilitation of crosstalk among proteins and 
integration of different signaling pathways, targeting to specific subcellular 
localization, mediating posttranslational modifications and/or removal of auto-
inhibition (Bos et al., 2007; Moon and Zheng, 2003). Being multi-modular in nature, 
many of the characterized functions of BPGAP1 involve the concerted action of its 
various modules including BCH and GAP domains, as well as the proline-rich region; 
and are attributed to its interactions with other proteins mediated by these modules. 
For instance, BPGAP1 promotes cell migration through the interplay of its BCH and 
GAP domains to induce morphological changes and by its interaction with cortactin 
via the proline-rich region to translocate cortactin to the cell periphery (Lua and Low, 
2004; Shang et al., 2003). It can also trigger EGF receptor endocytosis either 
independently or by interacting with EEN/endophilin II through the proline-rich 
region (Lua and Low, 2005). Moreover, BPGAP1 can induce ERK1/2 signaling via 
both its BCH and GAP domains (Lua and Low, 2005).  
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While the earlier studies uncover mainly the functions of BPGAP1, recent 
work has shed more light on the regulation of this protein. For example, upon the 
release of BPGAP1 auto-inhibition by active MEK2 that targets the proline-rich 
region, Pin1 functions to suppress BPGAP1-induced acute ERK activation in a GAP-
independent manner and attenuate Rho signaling via stimulation of the GAP activity 
(Pan et al., 2010). Another protein, SmgGDS, also serves as a negative regulator by 
sequestering BPGAP1 through its BCH domain, thereby preventing BCH domain-
mediated activation of Ras and subsequent ERK-induced differentiation 
(Ravichandran and Low, unpublished data). A more recent study on BPGAP1 and its 
interacting partner, human LanCL1, reveals that complex formation between these 
two proteins suppresses their individual effects on Ras and ERK activation, and 
delays the effect of BPGAP1 on neuronal potentiation at suboptimal level of NGF 
stimulation (Sharmy and Low, unpublished data). In this current study, through the 
employment of immunoprecipitation and immunofluorescence studies, RhoA activity 
assays, as well as examination of the impact of BNIP-2-BPGAP1 interaction on cell 
proliferation, we have further identified BNIP-2 as an accessory protein that functions 
as a regulator of BPGAP1.  
 Results from RhoA activity assays using transient RhoA overexpression 
demonstrate that BNIP-2 synergistically enhanced the RhoGAP activity of BPGAP1 
such that the overall reduction in RhoA activity was greater than the total impact 
brought about by each of the two proteins alone. A similar synergistic effect on RhoA 
inactivation can be seen with the fast cycling mutant RhoA(F30L). By introducing a 
RhoGAP catalytically inactive mutant - BPGAP1(R232A), the stimulatory effect of 
BNIP-2 on RhoA inactivation was abolished, indicating that such effect is coupled to 
the GAP activity of BPGAP1. Consistently, assessment on the endogenous active 
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RhoA level reveals a similar activity profile in comparison to the RhoA 
overexpression system. Similarly, removal of the RhoGAP activity restored the level 
of endogenous active RhoA. These observations further support the notion that BNIP-
2 synergizes with BPGAP1 to induce RhoA inactivation by coupling to the RhoGAP 
activity. However, due to the lack of a non-interacting mutant that is able to uncouple 
the binding between BNIP-2 and BPGAP1 while retaining interaction with RhoA, we 
can only speculate that the observed synergistic effect is brought about by the 
interaction between BNIP-2 and BPGAP1.  
In an overexpression system, the introduced protein-of-interest is present in 
greater excess as compared to the endogenous level. As such, the observed effect is 
most likely attributed to the protein introduced. Furthermore, overexpression of the 
protein allows the functional effect brought about by that particular protein to be 
unmasked and made more pronounced by diluting the amount of endogenous 
regulators present. In this regard, we conclude from both RhoA overexpression and 
endogenous RhoA systems that BNIP-2 functions in synergism with BPGAP1 to 
augment RhoA inactivation by promoting the RhoGAP activity of BPGAP1.  
 
4.2 BNIP-2 synergistically promote RhoGAP activity of BPGAP1 leading to 
BPGAP1-mediated loss of stress fiber and cell rounding 
Typically, disruption of actin cytoskeletal structures can occur as a 
consequence of RhoA inactivation mediated by GAP activity and is accompanied by 
changes in cell morphology including cell rounding. ARAP1 (ArfGAP and RhoGAP 
with ankyrin repeat and PH domains), which contains both Arf and Rho GAP 
domains, modulates active RhoA level in vivo through its RhoGAP domain and 
causes a reduction in stress fibers. A greater degree of cell rounding also occurs upon 
  Chapter 4 Discussion 
 161 
serum starvation in the presence of overexpressed ARAP1 but not the RhoGAP-dead 
[R338K]ARAP1 mutant  (Miura et al., 2002). In other instances, cells overexpressing 
DLC1 or DLC2 (deleted in liver cancer) exhibit inhibition of LPA-induced actin 
stress fiber formation and altered morphology with extensive cell rounding. Such 
effects could be suppressed by abolishing the RhoGAP function through mutation of 
the conserved residue(s) crucial for catalytic activity (Leung et al., 2005; Wong et al., 
2005).  
By examining the morphology of transfected cells, we show that BPGAP1-
expressing cells induced a marked increase in the percentage of round or retracting 
cells. These changes in cell morphology occur as a result of the RhoGAP activity of 
BPGAP1 since expression of the GAP-deficient mutant BPGAP1(R232A) did not 
bring about a similar extent of cell rounding or retraction/shrinkage. Indeed, a recent 
study has also shown that the GAP domain of p50RhoGAP confers GAP activity 
towards RhoA and results in extensive cell rounding, which can be blocked by either 
the catalytic inactive triple-point mutant or constitutive active RhoA(G14V) mutant 
(Zhou et al., 2010). Although the effect of BNIP-2 itself on cell rounding or 
retraction/shrinkage is negligible, co-expression of both BNIP-2 and BPGAP1 further 
promotes these morphological effects as observed, clearly demonstrating a synergistic 
increase in BPGAP1-mediated cell rounding or retraction/shrinkage. On the contrary, 
abolishment of the RhoGAP activity can abrogate this synergism. The consistency in 
cell rounding or retraction/shrinkage with inhibition of RhoA activity as brought 
about by the RhoGAP function further supports that BNIP-2 functions in synergism 
with BPGAP1 to augment its RhoGAP activity and consequently suppresses RhoA 
activity.  
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RhoA, amongst members of Rho GTPases that function as key regulators of 
cytoskeleton dynamics, induces the assembly of stress fibers by activating its 
downstream effectors mDia and ROCK (Bishop and Hall, 2000; Hall, 1998; Jaffe and 
Hall, 2005). With the positive correlation between cell rounding/retraction and 
reduced RhoA activity, it is highly plausible that these morphological changes are 
attributed to the collapse of actin cytoskeletal structures. As expected, a higher 
percentage of BNIP-2 and BPGAP1-expressing cells display loss of stress fibers in 
comparison with cells that express either BNIP-2 or BPGAP1 alone. Similarly, 
suppression of RhoGAP activity using the GAP-deficient mutant reduces the 
percentage of cells that are without stress fibers and introduction of BNIP-2 did not 
further promote the disruption of actin stress fibers. Together, these results imply that 
BNIP-2 and BPGAP1 work in concert to mediate disruption of stress fiber and this 
loss of actin stress fibers as induced by inactivation of RhoA correlates in part to the 
observed effect on cell rounding/retraction. 
Intriguingly, unlike the effect observed for RhoA activity and cell rounding or 
retraction/shrinkage, suppressing the RhoGAP activity in this instance could not fully 
restore the percentage of transfected cells expressing stress fibers. This result suggests 
that BPGAP1 may regulate actin stress fiber within the cells via a separate mechanism 
independent of its functional GAP domain and its effect on RhoA inactivation. In this 
regard, previous study on BPGAP1 has demonstrated that in addition to its 
biochemical function as a negative regulator of RhoA through its GAP activity, it is 
also able to induce morphological changes via pathways involving other members of 
the Rho GTPase family including active Rac1 and Cdc42 (Shang et al., 2003). This 
insight thus raises our speculation that BPGAP1 may target other proteins that 
mediate actin stress fiber formation independently of RhoA.  
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To our knowledge, another member of the Rho GTPase family - Rif (Rho in 
filopodia), is also able to stimulate the formation of actin stress fiber. Interestingly, 
this Rif-induced stress fiber formation does not occur through the canonical pathway 
involving RhoA, but by directly interacting with mDia1, downstream of RhoA, and 
this process is found to be dependent on ROCK activity (Fan et al., 2010). Although 
the authors have reported that formation of stress fibers triggered by Rif only occurs 
in cells of epithelial origin but not in fibroblasts, it remains to be determined if this 
protein can induce stress fiber formation in the cell line used in this context and if 
BPGAP1 can indeed affect the activity of this particular Rho GTPase, either directly 
or indirectly.  
 
4.3 BNIP-2 and BPGAP1 concertedly suppress cell proliferation  
Rho GTPases, known classically for their role in modulating actin cytoskeletal 
dynamics, are also widely implicated in the control of signal transduction pathways 
for cell proliferation. Inhibition of RhoA activity with Rho inhibitor exoenzyme C3 
transferase or by introducing RhoA dominant negative mutant prevents entry into cell 
cycle whereas microinjection of constitutive active RhoA mutant sufficiently 
promotes progression from G1 to S phase in quiescent fibroblast (Olson et al., 1995; 
Yamamoto et al., 1993). Indeed, this growth promoting property of RhoA has 
subsequently been shown to associate with the regulation of several key proteins 
involved in cell cycle progression. Mainly, RhoA mediates anchorage-dependent cell 
growth by promoting sustained ERK activation to achieve an optimal level and timing 
of Cyclin D1 expression during mid-G1 phase (Liberto et al., 2002; Welsh et al., 
2001). Progression from G1 to S phase is further complemented by RhoA-induced 
suppression of p21 transcription (Liberto et al., 2002; Olson et al., 1998; Sahai et al., 
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2001). In addition, RhoA is involved in furrow formation and actomyosin ring 
contraction during cytokinesis (Barr and Gruneberg, 2007). This process requires 
active GDP/GTP cycling of RhoA (Morin et al., 2009) and is regulated 
spatiotemporally by RhoGEF Ect2, as well as RhoGAPs such as MgcRacGAP and 
p190RhoGAP (Hall, 2009; Manchinelly et al., 2010; Su et al., 2009).  
Since RhoA contributes to many aspects of cell cycle progression and 
proliferation, downregulation of RhoA activity by RhoGAP-containing proteins 
should therefore contribute to the suppression of cell growth. As illustrated, DLC1, 
which has been demonstrated in RBD pull-down assay and RhoA biosensor analysis 
to decrease RhoA activity via its RhoGAP domain (Holeiter et al., 2008; Wong et al., 
2003), inhibits cell proliferation and anchorage-independent growth in hepatocellular 
carcinoma (Wong et al., 2005). Similarly, DLC2-expressing HepG2 cells with 
reduced level of active RhoA exhibit lower proliferative ability (Leung et al., 2005). 
However, such scenario may not be absolute. Instead of suppressing cell growth, 
p200RhoGAP promotes cell cycle progression and proliferation by mediating 
crosstalk between Ras and Rho signaling pathways to stimulate activation of ERK1/2 
downstream of Ras (Shang et al., 2007). In the case for BPGAP1, clues to the 
potential involvement of this protein in proliferation came from earlier studies in 
which PP mutant, a BPGAP1 mutant that has its proline residues at 184 and 186 
within the proline rich region substituted with alanines, has been observed to 
accumulate in the cleavage furrow during cell division (Lua and Low, unpublished). 
Although BPGAP1 functions biochemically as a GAP to reduce level of active RhoA, 
surprisingly its upregulation was reported in majority of colorectal tumors and also in 
cervical cancer (Johnstone et al., 2004; Song et al., 2008).  
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In the context of this study, introduction of BNIP-2 along with BPGAP1 
suppresses proliferation as reflected by the significantly lower number of cells with 
positive BrdU, further supported by a corresponding decrease in the level of 
proliferation markers. This synergism between BNIP-2 and BPGAP1 on cell 
proliferation is no longer observed when the GAP activity of BPGAP1 is abolished. 
Therefore, it is possible that the suppression on proliferative property could be linked 
to the reduction in RhoA activity induced by the RhoGAP domain. However, such 
association requires further investigation as expression of BPGAP1 alone did not 
appear to alter the percentage of cells undergoing proliferation even though these cells 
displayed modest decease in the level of proliferation marker, phospho-Histone H3.  
Intriguingly, BPGAP1 interacts with all three Ras isoforms including H-Ras, 
K-Ras and N-Ras (Ravichandran and Low, unpublished), and is capable of inducing 
sustained ERK1/2 activation upon EGF stimulation (Lua and Low, 2005; Pan et al., 
2010). In particular, BCH domain of BPGAP1 alone enhances K-Ras activity 
(Ravichandran and Low, unpublished) and triggers a more robust level of prolonged 
ERK activation (Soh, F.L., MSc thesis). Notably, treatment of BPGAP1-expressing 
PC12 cells with EGF for an extended period induces neurite protrusions, which is 
reminiscent of the differentiation response induced by sustained ERK activation in the 
presence of NGF. This result therefore indicates that BPGAP1 is able to promote 
prolonged ERK activation upon EGF stimulation. Prolonged activation of Ras-
induced ERK/MAPK pathway in response to growth factor stimulation is essential for 
Cyclin D1 induction (Balmanno and Cook, 1999; Cook et al., 1999) and for 
subsequent S phase entry (Yamamoto et al., 2006) and this sustained level of ERK 
activity has been shown to be dependent on RhoA signaling (Coleman et al., 2004; 
Welsh et al., 2001).  
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Taken together, while the possible involvement of BPGAP1 in proliferation 
could not be undermined, the exact role of this protein and how it affects this process 
requires further examination under synchronized conditions. In addition, it remains to 
be determined on how BNIP-2 and BPGAP1 together can bring about the reduction in 
proliferation. Despite the above mentioned, the data presented here indicates that 
BNIP-2 functions in synergism with BPGAP1 to suppress cell proliferation, through a 
yet unknown pathway. 
 
4.4 BNIP-2 positively regulates RhoGAP function of BPGAP1 – a conceptual 
framework 
Functioning as key regulators that terminate Rho GTPases signaling, the 
RhoGAP function is often subjected to tight regulation and clearly, the multi-domain 
nature of RhoGAPs forms the basis by which this biochemical activity of these 
negative regulators of Rho GTPases can be modulated. Several mechanisms exist to 
regulate the function of RhoGAPs including alteration of phosphorylation states or 
protein-protein or protein-lipid interactions. These common mechanisms serve to 
directly affect the GAP activity, relieve autoinhibition or target the proteins to specific 
subcellular locations. Alternatively, the GAP activity of RhoGAPs may be 
downregulated through protein degradation.  
It is worth noting that a single RhoGAP protein could be modulated in 
multiple ways under different cellular contexts as observed for p190RhoGAP. For 
example, phosphorylation of p190RhoGAP by Src family tyrosine kinases or Brk - an 
intracellular Src-like family of tyrosine kinases, augments its RhoGAP activity 
towards RhoA, as well as promotes the association between p190RhoGAP and 
p120RasGAP (Hu and Settleman, 1997; Roof et al., 1998; Shen et al., 2008). On the 
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other hand, formation of this p190RhoGAP/p120RasGAP complex, when triggered 
downstream of integrin signaling through Arg (Abl-related gene), would recruit 
p190RhoGAP to the plasma membrane where it inhibits Rho activity (Bradley et al., 
2006). There are also evidences whereby the GTP binding domain (GBD) located at 
the N terminus of p190RhoGAP and the middle region in between the GBD and C-
terminal RhoGAP domain, function to promote p190RhoGAP GAP activity through 
interaction with GTP and the small GTPase Rnd, respectively (Tatsis et al., 1998; 
Wennerberg et al., 2003). Moreover, p190RhoGAP is also implicated in the 
cytokinesis process such that its downregulation by an ubiquitin-proteasome pathway 
mediated by the GBDS1 region is essential for the successful completion of 
cytokinesis (Manchinelly et al., 2010; Su et al., 2003).  
Amongst the various mechanisms of RhoGAP regulation, intramolecular 
interaction is a critical regulatory mode commonly present in the GAPs and GEFs. 
Frequently, the existence of intramolecular interaction serves to block access to the 
catalytic domain. In the case of DLC1, deletion of the SAM domain from the N-
terminal substantially increases the RhoGAP activity of DLC1, suggesting that SAM 
domain could negatively regulate the catalytic RhoGAP domain via intramolecular 
interaction (Healy et al., 2008; Kim et al., 2008). The inhibition of RhoGAP activity 
by another region through intramolecular interaction is also observed for 
Oligophrenin-1 (Fauchereau et al., 2003). In another instance, binding of PH domain 
located at the N-terminal of p120GAP to the C terminus RasGAP domain hinders the 
interaction between Ras and the catalytic subunit and this interference can in turn be 
relieved by competitive binding of Ras (Drugan et al., 2000).  
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Previous findings on BPGAP1 have implied that this protein exists in a 
“closed” conformation held by intramolecular interaction, potentially mediated by 
amino acids 34 to 74 within the N-terminal BCH domain and amino acids 389 to 433, 
a segment located beyond the GAP domain at the C terminus (Ravichandran and 
Low, unpublished). The presence of a proline-rich region in between the BCH and 
GAP domains further supports the notion as proline residues are likely to introduce 
turns and kinks, and a proline-rich region may adopt an omega loop structure (Kim 
and Roeder, 1993; Leszczynski and Rose, 1986) that functions as a hinge for 
mediating associations of proteins (Bernacchi et al., 2011) or perhaps adjacent 
domains. Indeed, p50RhoGAP – a close relative that shares the same domain 
architecture as BPGAP1, exists in an autoinhibited state held by intramolecular 
interaction between a segment within the BCH domain and the GAP module 
(Moskwa et al., 2005). However, this intramolecular interaction alone does not fully 
account for the suppression of its RhoGAP activity and is complemented by 
sequestration of RhoA by the RhoA-binding motif distal to the intramolecular 
interaction region (Zhou et al., 2010). Intriguingly, such inhibition of the catalytic 
GAP activity conferred by p50RhoGAP BCH domain acts solely in cis but not in 
trans and the concerted action of intramolecular interaction and RhoA sequestration is 
necessary to restore the RhoGAP activity (Zhou et al., 2010).  
In this current study, we have demonstrated that BNIP-2, when present 
together with BPGAP1, augments the RhoGAP activity of GAP domain towards 
RhoA. Consistent with the downregulation of active RhoA level, enhanced GAP 
activity also leads to a further loss of stress fiber, an increase in GAP-induced cell 
rounding and an overall decrease in cell proliferation. This synergism and the 
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downstream effects are however abolished upon inactivation of the RhoGAP activity 
with the use of BPGAP1(R232A) GAP inactive mutant.  
Based on our current experimental findings and already established work in 
the field, it is tempting to propose the following model as shown in Figure 4.1a that 
BPGAP1 in its native form is held by intramolecular interaction between the BCH 
domain and PGAP module, which may serve to block the catalytic site of the GAP 
domain and hence inhibiting its GAP activity. BNIP-2, in this context, could function 
to relieve the autoinhibition within BPGAP1 by inducing a conformational change 
mediated via heterophilic interaction of their BCH domains, while acting as a scaffold 
to bring BPGAP1 and RhoA into close proximity through its BCH domain. Indeed, 
BNIP-2 has been shown previously to act as a scaffold to facilitate the integration of 
Cdc42 signaling and p38α/β MAPK activity during myogenic and neuronal 
differentiation (Kang et al., 2008; Oh et al., 2009). Upon removal of the 
autoinhibitory effect, this allows the catalytic module of GAP domain to act on the 
nearby RhoA with a higher efficiency. The BCH domain of BNIP-2 could also help in 
stabilizing the “open” structure of BPGAP1 for it to exert its catalytic activity on 
RhoA, which probably explains the interaction observed between BNIP-2 BCH 
domain and GAP domain of BPGAP1.  
Besides regulation by autoinhibitory intramolecular interaction, suppression of 
the GAP activity of p50RhoGAP has been demonstrated in a recent study to involve 
also the sequestration of RhoA by the RhoA binding motif within the adjacent BCH 
domain (Zhou et al., 2010). While it remains to be determined if sequestration of 
RhoA by BPGAP1 BCH domain is similarly required for inhibition of its GAP 
activity, there is a possibility that this mode of regulation exists within BPGAP1 since 
p50RhoGAP and BPGAP1 are two closely related proteins that share the same 
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domain architecture. In the alternative model (Figure 4.1b), apart from mediating 
conformation changes in BPGAP1 to relieve the autoinhibition through heterophilic 
interaction of the BCH domains, it is conceivable that BNIP-2 could also serve to 
release the sequestered RhoA via simple displacement of this protein away from the 
RhoA binding site of BPGAP1. With the displacement, this frees the RhoA protein 
and allows it to be acted upon by the nearby GAP domain, while the interaction 
between BNIP-2 BCH domain and GAP domain of BPGAP1 serves a stabilizing 
purpose. This mode of regulation, as described, is not unprecedented. In one case, 
BNIP-Sα through its BCH domain can displace away and prevent p50RhoGAP from 
inactivating RhoA while separately inducing RhoA activation to mediate cell 
rounding and apoptosis (Zhou et al., 2006). On a similar note, BNIP-XL competes off 
Lbc RhoGEF from RhoA using its BCH domain to inhibit RhoA activation, thereby 
suppressing Lbc-induced cellular transformation (Soh and Low, 2008).  
Our study herein establishes that association of BNIP-2 with BPGAP1, 
mediated by heterophilic interaction between BCH domains of these two proteins, as 
well as binding between BNIP-2 BCH domain and GAP module of BPGAP1, 
promotes RhoA inactivation, leading to further loss of stress fibers, enhanced cell 
rounding and a decrease in proliferation. This is in addition to the described examples 
on BNIP-Sα and BNIP-XL, another study which supports the findings that Type I 
BCH domain-containing proteins are involved in modulating Rho GTPases, as well as 
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Figure 4.1 Proposed models of synergism between BNIP-2 and BPGAP1 in 
regulating RhoA activity and downstream cellular effects. (a) BPGAP1, held 
possibly in a closed conformation by intramolcular interactions, displays marginal 
GAP activity towards RhoA. Through heterophilic association of the BCH domains of 
BNIP-2 and BPGAP1, BNIP-2 interacts and introduces a conformation change within 
BPGAP1 to relieve this autoinhibition, while acting as a scaffold to bring BPGAP1 
and RhoA in close proximity for inactivation. (b) Alternatively, the GAP activity of 
BPGAP1 in its native state may be suppressed by both autoinhibitory intramolecular 
interaction, as well as sequestration of RhoA by the adjacent BCH domain. Through 
heterophilic association of the BCH domains of BNIP-2 and BPGAP1, BNIP-2 not 
only functions to relieve the autoinhibition via introduction of conformational change, 
but also aids in the displacement of RhoA to allow the GAP domain to gain access to 
and inactivate RhoA. In both models, interaction between BCH domain of BNIP-2 
and PGAP module of BPGAP1 may serve to stabilize the resultant structure of 
BPGAP1 for better catalytic efficiency. Altogether, interactions between BNIP-2 and 
BPGAP1 allow the GAP domain to act on and promote inactivation of the nearby 
RhoA, thereby bringing about an increase in loss of stress fiber, alteration in cell 
morphology and a decrease in cellular proliferation. This study therefore adds to the 
mounting evidences that BCH domain-containing proteins function to modulate Rho 





4.5 BCH domain as a small GTPase regulatory domain  
With the exception of the brain specific member – BNIP-H, all of the 
remaining BCH domain-containing proteins studied in our laboratory possess the 
ability to associate with RhoA via their respective BCH domains and also with other 
Rho GTPases such as Cdc42 or Rac1 for some of these proteins. Amongst these 
RhoA-interacting members of the BCH domain-containing family, BCH domain of 
BNIP-XL harbors multiple RhoA interacting sequences (Soh and Low, 2008), 
whereas BNIP-2, BNIP-Sα, p50RhoGAP and BPGAP1 each contains a specific RhoA 
binding motif and are aligned using multiple sequence alignment as shown in Figure 
4.2. The authenticity of these motifs in binding to RhoA has been verified primarily in 
immunoprecipitation studies (Zhou et al., 2010; Zhou et al., 2006) and further 
confirmed by structure analysis at least in the case of p50RhoGAP in a current study. 
These results together suggest the possible existence of a consensus sequence or 
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critical residues for RhoA binding within the BCH domains. However, positive 
interactions between BCH domain-containing proteins and RhoA might not solely 
rely on the presence of this interacting motif but are also dependent on other spatial 
and temporal factors.  
 
 
p50RhoGAP  IIVFSACRMP----PSHQLDHSKLLGYLKHTLDQYVESDYTLLYL   
BPGAP1  VVTFSCCRMP----PSHELDHQRLLEYLKYTLDQYVENDYTIVYF   
BNIP-Sα   VILFASCYLPRSSIPNYTYVMEHLFRYMVGTLELLVAENYLLVHL   
BNIP-2  IVVFAVCFMPESSQPNYRYLMDNLFKYVIGTLELLVAENYMIVYL  
 
 
Figure 4.2 Possible existence of a consensus RhoA binding sequence within BCH 
domains. Multiple sequence alignment of the verified RhoA binding regions within 
BCH domains of Homo sapiens p50RhoGAP (Q07960), BPGAP1 (AAN40769), 
BNIP-Sα (AY078983) and BNIP-2 (U15173) using ClustalW and formatted using 
BOXSHADE. Identical residues are shaded black while grey shadings represent 





Intriguingly, not only does BCH domain possess the ability to target Rho 
GTPases per se, it is also able to alter the level of active Rho GTPases indirectly by 
modulating the activity of their immediate regulators RhoGAPs and RhoGEFs as seen 
in the many examples discussed, including BNIP-Sα, BNIP-XL and p50RhoGAP 
(Soh and Low, 2008; Zhou et al., 2010; Zhou et al., 2006). Our study herein has also 
demonstrated that BNIP-2 can function in synergism with BPGAP1 to negatively 
regulate RhoA activity by enhancing the GAP function of BPGAP1, thereby adding to 
the repertoire of evidences supporting the role of BCH domain as a regulator for both 
Rho GTPases and their immediate upstream activators or inactivators.  
Further to regulating the Rho family of small GTPases, interestingly BCH 
domain can also modulate members of the Ras GTPase family. It has been 
demonstrated in PC12 cells that BCH domain of BPGAP1 is able to activate K-Ras, 
leading to formation of neurite-like protrusions (Ravichandran and Low, 
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unpublished). This new insight on substrates beyond the Rho GTPase family that are 
acted upon by the BCH domain certainly demonstrates the versatility of this highly 
conserved domain in mediating signaling pathways of a diverse range of small 
GTPases. In fact, other than Rho and Ras GTPases, ongoing work by colleagues have 
shown that BCH domain could also associate with members of other families under 
the Ras superfamily, including Rab.  
Crosstalk of different small GTPase signaling pathways mediated by complex 
formation is not unprecedented given that p190RhoGAP associates with 
p120RasGAP upon phosphorylation (Roof et al., 1998) and formation of this complex 
can facilitate crosstalk between Rho and Ras. This crosstalk leads to an overall 
decrease in active RhoA and a corresponding increase in the level of activated Ras 
due to enhanced RhoGAP activity and suppression of RasGAP activity, respectively 
(Bradley et al., 2006; Moran et al., 1991; Shen et al., 2008). The presence of a 
conversed BCH domain within BCH domain-containing proteins that can target 
different families of small GTPases while at the same time modulate their respective 
regulators therefore would suggest that these proteins may function in concert to 
mediate crosstalks of the different small GTPases signaling pathways. In this regard, 
BCH domain could well serve as a scaffold in regulating the activity of a single small 
GTPase protein or in linking signaling events of multiple small GTPases and in some 
cases with other signaling pathways. For example, BNIP-2 BCH domain is known to 
function as a scaffold to connect Cdo receptor signaling to the Cdc42 signaling 
pathway (Kang et al., 2008).  
Besides being able to interact with small GTPases, BCH domain also harbors 
lipid binding ability (Zhou and Low, unpublished) due to its limited homology with 
the Sec14p domain that is involved in phosphatidylinositol and phosphatidylcholine 
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transfer (Mousley et al., 2007; Saito et al., 2007; Schaaf et al., 2008). Through 
possible associations with lipids, BCH domain could serve to target these BCH 
domain-containing proteins and the bound proteins to designated subcellular 
compartments, thereby providing an additional form of regulation in terms of spatial 
regulation. Notably, substrate preference of p190GAP towards either Rho or Rac 
GTPases can be altered by the various physiological phospholipids (Ligeti et al., 
2004; Ligeti and Settleman, 2006). This finding thus raises the possibility that other 
forms of lipid-mediated regulatory mechanisms could exist to modulate the functions 
of BCH domain-containing proteins. Further exploration on the multiple roles of this 
BCH domain in regulating the functions of small GTPases will therefore open up a 




















 Chapter 5 Conclusions and Future Perspectives 
 176 
5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
5.1 Conclusions 
Since the identification of BPGAP1 as a member of the Homo sapiens multi-
modular RhoGAP family, much effort has been made to characterize this protein in 
terms of its GAP activity and its cellular functions conferred through associations 
with various interacting partners identified from proteomics pull-down. In addition to 
its known function as a RhoGAP protein with specificity towards RhoA in vivo 
(Shang et al., 2003), BPGAP1 was found to promote cell migration, which requires its 
GAP activity and the BCH domain for inducing morphological changes, as well as the 
proline rich region for translocation of cortactin (Lua and Low, 2004; Shang et al., 
2003). Further to this role, the GAP domain is also involved in promoting ERK 
signaling downstream of EGF receptor endocytosis (Lua and Low, 2005). With the 
RhoGAP activity contributing significantly to the various functions mediated by 
BPGAP1, this explains the paramount importance in identifying regulators that 
modulate this catalytic activity and to elucidate the mechanisms behind this 
regulation.  
In this regard, the focus in recent work has been shifted to exploring and 
understanding the possible ways by which BPGAP1 can be regulated while 
continuing to uncover more biological functions of this protein. In one such study, the 
evidence presented supports the role of Pin1 as a regulator of BPGAP1 such that it 
attenuates RhoA signaling via stimulation of the GAP activity (Pan et al., 2010).  
By a candidate approach, we have identified BNIP-2 as a novel regulator of 
BPGAP1 and these two proteins associate through heterophilic interaction of their 
respective BCH domains. Interestingly, BCH domain of BNIP-2 also interacts with 
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the GAP module of BPGAP1, perhaps to stabilize the structure of BPGAP1 for its 
catalytic function. Besides being capable of mediating homophilic or heterophilic 
interactions with BCH domain-containing proteins, bioinformatics analyses and 
subsequent verification by immunoprecipitation studies have also mapped the RhoA 
interaction site to specific region within the BCH domain, suggesting the possibility 
of a consensus RhoA binding sequence within this conserved domain.  
Even though RhoA and BPGAP1 share overlapping interacting sites on BNIP-
2 BCH domain, BNIP-2 is able to associate with BPGAP1 in the presence of RhoA 
and colocalization of these three proteins further suggests that they might associate to 
form a tripartite complex. Consistently, results from RhoA activity assays 
demonstrate that BNIP-2 augments the GAP activity of BPGAP1 and promote RhoA 
inactivation. This reduction in active RhoA amount leads to an increase in the loss of 
stress fibers and GAP-induced cell rounding, as well as an overall decrease in cellular 
proliferation. On the contrary, synergistic effect between BNIP-2 and BPGAP1 was 
no longer evident once the RhoGAP activity of BPGAP1 was abolished as shown 
with the catalytic inactive mutant, further strengthening the positive role of BNIP-2 in 
GAP activity regulation.  
Working on this basis, we hereby propose the model in which BPGAP1 in its 
native confirmation displays minimal RhoGAP activity towards RhoA due to 
autoinhibitory forces and/or sequestration of RhoA, as deduced from studies on 
p50RhoGAP (Moskwa et al., 2005; Zhou et al., 2010). By forming heterophilic 
interaction with BPGAP1 via the BCH domain, BNIP-2 could possibly serve to 
relieve the autoinhibition within BPGAP1 by introducing a conformational change 
that enables the GAP domain to gain access to and inactivate RhoA. In addition, 
BNIP-2 may function as a scaffold to bring BPGAP1 and RhoA in close proximity for 
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more efficient catalysis or simply as a regulator that aids in the displacement of RhoA 
from the Rho binding site on BPGAP1 BCH domain to allow subsequent RhoA 
inactivation by the adjacent GAP domain. Interaction between BCH domain of BNIP-
2 and GAP module of BPGAP1 could on the other hand stabilize the resultant 
structure of BPGAP1. Together, these interactions function in concert to promote 
RhoA inactivation, thereby bringing about the observed downstream effects on stress 
fiber, cell morphology and proliferation. However, there exist several interesting 
aspects that could be further explored for a more in-depth understanding on the 
detailed molecular mechanism and also on other possible physiological effects 
conferred by this BNIP-2-BPGAP1 interaction, some of which are further discussed 
below.  
5.2 Future work 
5.2.1 Validation of molecular mechanism model  
To fully comprehend the fundamental molecular mechanism that underlies the 
physiological outcomes observed for interaction between BNIP-2 and BPGAP1, 
several issues pertaining to the current proposed model remain to be addressed in 
greater details. Firstly, although previous work by colleagues strongly suggests the 
existence of autoinhibition within BPGAP1 (Pan et al., 2010; Shang et al., 2003), 
whether this autoinhibition is mediated by intramolecular interaction requires further 
validation. While the regions that could be essential for intramolecular interaction 
have been identified through immunoprecipiation study with deletion mutants 
(Ravichandran and Low, unpublished), use of fluorescence resonance energy transfer 
(FRET)-based analysis in live cell imaging would not only further validate the 
presence of intramolecular interaction within BPGAP1, but could also provide 
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valuable information on the exact spatial activation of this protein. In essence, both 
ends of the protein-of-interest are differentially tagged with either a cyan fluorescence 
protein (CFP) or a yellow fluorescence protein (YFP) and a basal level of FRET 
signal exists when the protein is in an autoinhibited state due to close proximity of the 
two fluorophores. An abolishment of the FRET activity will occur once these 
fluorophores are at a distance sufficiently far from each other, hence allowing any 
changes in conformation to be monitored.   
Studies on p50RhoGAP have provided evidences that inhibition of the GAP 
activity by its adjacent BCH domain is conferred not only by intramolecular 
interactions but also depends greatly on RhoA sequestration by the BCH domain 
(Moskwa et al., 2005; Zhou et al., 2010). Unlike p50RhoGAP, BPGAP1 utilizes the 
same region within its BCH domain for binding to RhoA (as identified in this study) 
and for establishing intramolecular interaction with the C-terminal region at amino 
acids 389-433, beyond the GAP domain (Ravichandran and Low, unpublished). In 
this case, the use of a BPGAP1 deletion mutant devoid of the RhoA binding region, 
which is important also for intramolecular interaction, when assaying for RhoGAP 
activity could not effectively distinguish whether one or both mechanisms are 
required for autoinhibition within BPGAP1. This can ideally be overcome by using 
another protein, which displays a higher RhoA-binding affinity than BPGAP1 that 
could sequester RhoA away from the RhoA binding region and yet not disturb any 
intramolecular interaction. It would also be of interest to study the binding profiles of 
BCH and GAP domains of BPGAP1 to the nucleotide-free, GDP- or GTPγS-bound 
form of RhoA using in vitro GTP and GDP loading assays, for comparison with the 
binding profiles of the various RhoA mutants. 
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Next, although it has been established in this study that BCH domain of BNIP-
2 could form heterophilic interaction with BPGAP1 BCH domain, whether any 
conformational change is introduced within BPGAP1 upon their association would 
require further validation from structural studies. In addition, to further substantiate 
the role of BNIP-2 as regulator of BPGAP1, siRNA can be designed to transiently 
knockdown this protein. By decreasing the amount of endogenous protein present, 
this abolishes the functional effect brought about by this protein and hence allows the 
manifestation of physiological effects, if any.  
 
5.2.2 Spatiotemporal dynamics of RhoA activity in the presence of BNIP-2 and 
BPGAP1 
 Having shown through a biochemical approach that BNIP-2 and BPGAP1 
function in synergism to perturb global level of active RhoA, it is of great interest 
next to dissect this change by examining the spatiotemporal dynamics of RhoA 
activity in living cells when BNIP-2 and BPGAP1 are introduced. Over the years, 
with the emergence of GFP-based FRET probes, real-time monitoring of 
spatiotemporal activities of Ras and Rho small GTPases has been made possible in 
live cell imaging (Nakamura et al., 2005; Pertz and Hahn, 2004). Continuous 
improvement in the design of these probes has further led to the development of 
single-chain biosensor that not only allows for the activity of RhoA to be monitored 
in terms of GDP/GTP exchange, but also enable subcellular targeting of this molecule 
through the C-terminal CAAX motif, as well as regulation of its membrane 
localization by RhoGDI (Pertz et al., 2006). Each single chain biosensor is composed 
of RBD of effector Rhotekin that recognizes and binds specifically to GTP-RhoA, 
CFP, an unstructured linker of optimized length, YFP and RhoA in tandem. In theory, 
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intramolecular binding of activated RhoA to RBD upon activation by GTP loading re-
orientates the two fluorophores, which subsequently brings them into close proximity 
for increasing FRET (Nakamura et al., 2005; Pertz et al., 2006). Use of this technique 
along with multiple Rho biosensors has successfully demonstrated the dynamics of 
Rho GTPase activities including RhoA, Rac1 and Cdc42 during cell protrusion event 
(Machacek et al., 2009).  
In future studies, we therefore aim to investigate the spatiotemporal regulation 
of RhoA activity by its negative regulator BPGAP1 and when in concert with BNIP-2 
using live cell imaging with RhoA biosensor. This approach overcomes the limitation 
of current immunofluorescence study that enables only the detection of 
subpopulations of colocalized proteins but does not reflect their activity state in 
precise spatial localization and timing within the cells.  
 
5.2.3 Role of BPGAP1 in cellular proliferation 
 While there have been some hints to a role of BPGAP1 in cellular 
proliferation, how this protein governs the process remains largely unknown. 
Although analyses of the proliferation status of cells transiently transfected with 
BPGAP1 have been carried out in this study, the lack of synchronization could 
potentially obscure the effect of this protein. As such, it is imperative that future 
studies should be performed in conjunction with cell synchronization by first 
subjecting the cells to either serum starvation or treatment with nocodazole.  
 Thus far, there have been mixed evidences in suggesting the possible 
involvement of BPGAP1 in different processes of cell proliferation. We therefore 
wish to determine the exact phase in which BPGAP1 participates during proliferation. 
To begin, cells transiently transfected with BPGAP1 could be assayed for DNA 
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content using FACS (fluorescence activated cell sorting) at various time points during 
cell cycle to identify any deviation in the distribution of cell populations from the 
control cells (Morin et al., 2009). Of note, BPGAP1 induces sustained ERK activation 
upon EGF stimulation (Lua and Low, 2005; Pan et al., 2010). It has yet to be 
ascertained if there is any perturbation in ERK activity under non-stimulated 
conditions in the presence of BPGAP1 and whether the change, if any, will affect the 
proliferation process.  
Besides entry into S-phase, it is not known if BPGAP1 as a negative regulator 
of RhoA, is involved in the cytokinesis process. Multinucleation assay and FRET 
analysis in combination with time-lapse imaging as described in the studies conducted 
on p190RhoGAP could be similarly employed to investigate in real-time whether the 
RhoGAP activity of BPGAP1 is required for controlling the level of active RhoA 
during cytokinesis and also to define the phase of cytokinesis involved (Manchinelly 
et al., 2010; Su et al., 2009). Alternatively, it would be interesting to study if 
BPGAP1, through downregulation of RhoA, may alter the proliferation state of cells 
by interfering with the transcription process. 
On a final note, based on the known effect of BPGAP1 on cell migration and 
its biochemical activity towards RhoA (Shang et al., 2003), it may be worthwhile to 
pursue the effect of BNIP-2 and BPGAP1 interaction on other RhoA-mediated 
processes such as migration and cellular transformation. Furthermore, given that 
RhoA and RhoC are selectively immunoprecipitated by BNIP-2 and BPGAP1, and 
both Rho proteins have been shown to perform distinct roles in the same processes 
including migration and invasion by acting through different downstream targets 
(Vega et al., 2011), it would be interesting to investigate if RhoC is similarly 
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  1 MEGVELKEEWQDEDFPIPLPEDDSIEADILAITGPEDQPGSLEVNGNKVRKKLMAPDISL 60 
    ---EEE--------------------------------------------EEEE----EE 
 
 61 TLDPSDGSVLSDDLDESGEIDLDGLDTPSENSNEFEWEDDLPKPKTTEVIRKGSITEYTA 120 
    E------EE--------------------------------------------------H 
 
121 AEEKEDGRRWRMFRIGEQDHRVDMKAIEPYKKVISHGGYYGDGLNAIVVFAVCFMPESSQ 180 
    HHHHH----HHEEE-----------------EEEEE---------EEEEEE--------- 
 
181 PNYRYLMDNLFKYVIGTLELLVAENYMIVYLNGATTRRKMPSLGWLRKCYQQIDRRLRKN 240 
    ----HHHHHHHHHHHHHH-------EEEEEE-----------HHHHHHHHHHH-HHHHHH 
 
241 LKSLIIVHPSWFIRTLLAVTRPFISSKFSQKIRYVFNLAELAELVPMEYVGIPECIKQVD 300 
    HHEEEEE---HHHHHHHHHHH--------EEEEEE--HHHHHHH---------HHHHHHH 
 
301 QELNGKQDEPKNEQ 
    HHHHH--------- 
 
Key: Regions deleted in BNIP-2 mutants: Δ(167-184); Δ(185-211)    
b BPGAP1 
 
  1 MAGQDPALSTSHPFYDVARHGILQVAGDDRFGRRVVTFSCCRMPPSHELDHQRLLEYLKY 60 
    -------------HHHHHH--EEEEEEE-----EEEEEE-----------HHHHHHHHHH 
 
 61 TLDQYVENDYTIVYFHYGLNSRNKPSLGWLQSAYKEFDRKYKKNLKALYVVHPTSFIKVL 120 
    HHHH------EEEEEE----------HHHHHHHHHHHHHHHHHHHHHEEEE--HHHHHHH 
 
121 WNILKPLISHKFGKKVIYFNYLSELHEHLKYDQLVIPPEVLRYDEKLQSLHEGRTPPPTK 180 
    HHHH-----------EE----HHHHHHHH----------------HHHH----------- 
 
181 TPPPRPPLPTQQFGVSLQYLKDKNQGELIPPVLRFTVTYLREKGLRTEGLFRRSASVQTV 240 
    ------------------EE----------HHHHHHHHHHHH-------EEE----HHHH 
 
241 REIQRLYNQGKPVNFDDYGDIHIPAVILKTFLRELPQPLLTFQAYEQILGITCVESSLRV 300 
    HHHHHHH-------------HHHHHHHHHHHHH---------HHHHHHHHH-----HHHH 
 
301 TGCRQILRSLPEHNYVVLRYLMGSLHAVSRESIFNKMNSSNLACVFGLNLIWPSQGVSSL 360 
    HHHHHHHHH--HHHHHHHHHHHHHHHHHH---------HHHHHHHH------------HH 
 
361 SALVPLNMFTELLIEYYEKIFSTPEAPGEHGLAPWEQGSRAAPLQEAVPRTQATGLTKPT 420 
    HHHHHHHHHHHHHHHHH------------------------------------------- 
 
421 LPPSPLMAARRRL 
    ------------- 
 
Key: Regions in BPGAP1 PGAP mutants - PGAP (168-281) (Bright green region); 
PGAP (168-310) (Bright green and green regions) 
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Figure S1 Secondary structure predictions of BNIP-2 and BPGAP1. The 
predicted secondary structures of (a) BNIP-2 (U15173) and (b) BPGAP1 
(AAN40769) were obtained using secondary structure prediction server - Jpred 
(http://www.compbio.dundee.ac.uk/www-jpred/). Letters H and E represent the 
residues predicted as a part of α-helices and β-sheet, respectively. The regions deleted 
in BNIP-2 are highlighted as follow: 167-184 (magenta) and 185-211 (cyan), while 
the regions covered in PGAP truncation mutants are highlighted in either bright green 
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Figure S2 Residues 167-211 within BNIP-2 BCH domain mediate interactions 
with BPGAP1 BCH domain and PGAP module. (a) Schematic diagram of BNIP-2 
and its deletion mutants. Binding abilities of BNIP-2 BCH domain deletion mutants to 
BPGAP1 BCH domain and PGAP module were summarized and as indicated by the 
positive (+) or negative (-) sign. (b) HA-BCH domain (BPGAP1) or (c) PGAP region 
of BPGAP1, along with each of the FLAG-tagged BNIP-2 deletion mutants, were 
introduced into 293T cells as indicated before subjecting the harvested lysates to 
immunoprecipitation with anti-FLAG M2 beads. Co-transfection of HA-tagged BCH 
(BPGAP1) or PGAP module with FLAG-tagged full length BNIP-2, N terminal or 
expression vector was used as controls. To detect the associated proteins, 
immunoprecipitated lysates were separated on SDS-PAGE, blotted and probed with 
anti-HA (first panel), before stripping and re-probing with anti-FLAG antibodies 
(second panel). WCL were also analyzed by Western blot to verify the presence of the 



























Figure S3 RhoA activity assay for endogenous active RhoA level in CHO cells. 
(a) To assay the endogenous active RhoA level, FLAG-BNIP-2, HA-tagged BPGAP1 
or BPGAP1(R232A) were expressed alone or co-expressed as indicated in CHO cells. 
An equivalent amount of correspondingly tagged expression vector control denoted 
by the – sign was transfected to maintain a constant amount of DNA introduced into 
the cells. After 20-24 hours, the lysates were collected and incubated with either GST 
fusion of Rho-binding domain of Rhotekin immobilized on glutathione sepharose 
beads or with GST proteins as controls. Subsequently, active RhoA proteins captured 
on GST-RBD beads and WCL were resolved on SDS-PAGE, blotted and probed with 
anti-RhoA antibody to detect the amount of bound RhoA protein (first panel) and 
endogenous level of total RhoA protein (fifth panel). Similarly, protein expression of 
HA-tagged BPGAP1, BPGAP1(R232A) and FLAG-BNIP-2 were verified by Western 
blot analyses of the WCL using anti-HA (sixth panel) or anti-FLAG antibodies 
(bottom panel). Equal loading of GST fusion proteins and GST proteins were shown 
using amido black staining in the second and fourth panel, respectively. Blots 
separated by the dotted line are from the same blot with same exposure time. PD: 
Pull-down. (b) For quantitative analysis, amount of active RhoA captured by GST-
RBD beads was normalized to the total level of endogenous RhoA proteins in the cell 
lysates and represented as fold of active RhoA relative to the vector-expressing 
control cells (set as 1), as described in Materials and Methods. Data derived from 
three or more independent sets of experiment are expressed as mean + standard error 
mean and the asterisk indicates differences between values that are statistically 
significant at p < 0.05, measured by two-tailed Student’s t-test with unequal variance.  
 
 
 
